Extended skin color modulation compositions and methods

Abstract

The invention described here provides methods comprising administering a dermatologically suitable chromophoric composition comprising a chromophoric comprising dermal / subdermal chromophoric agent(s) (e.g., chromophoric vitamin(s) or minerals), and a chromophoric extension component to provide a coloration effect to the skin for an extended and sustained period (e.g., at least 3, 6, 9, 12, 15, or 18 months). In aspects, the coloration effect comprises a detectable or significant increase in reddening of at least part of the skin of a treated person. The chromophoric component and chromophoric extension component are typically are present in stable association, e.g., by comprising agent(s) that are covalently conjugated. The invention also provides compositions used in such methods and method of making such compositions.

Description

EXTENDED SKIN COLOR MODULATION COMPOSITIONS AND METHODSTransformative Legal Reference No.: BTM23251WOWBZFIELD OF THE INVENTION

[0001] The invention described herein is primarily, but not exclusively, directed to new dermatologically suitable injectable chromophoric compositions producing a long- lasting / sustained visual color change in the skin of recipient(s), optionally in combination with other cosmetic / dermatologic effects, and methods of using such compositions.RELATED APPLICATIONS I PRIORITY

[0002] This patent Application claims priority to U.S. Provisional Patent Application No. 63 / 521,690 filed June 18, 2023, entitled SKIN COLOR MODULATION COMPOSITIONS AND METHODS. This application claims the benefit of priority to the above-referenced application and incorporates its content by reference.BACKGROUND OF THE INVENTION

[0003] Perception of aesthetic appearance has been and remains an essential element among many societal groups. The visual assessment of the human face, and judgment related to its conveyance of health and beauty, play a major role in social interactions and strongly influence conduct between people. The extraordinary global market size for topical cosmetics evidences the common desire of people, across cultures, to maintain a youthful and vibrant appearance as one ages. Indeed, the global cosmetics market size was estimated at USD 295.95 billion in 2023 and is estimated to reach around USD 661.12 billion by 2032. Also, remarkably, according to the Personal Care Products Council, personal care products manufacturers’ R&D spending grew faster than the manufacturing sector as a whole between 2007 and 2016. More specifically, cosmetic products leader, L’Oreal, had annual research and development expenses for 2023 that alone totaled $1,395 billion, a 16.28% increase from 2022. Clearly, there is a significant global interest in and accompanying research directed at developing ways to improve the appearance of the skin.

[0004] While providing a temporary tool for modifying appearance, the most common cosmetic products, specifically topical cosmetics such as lipsticks, dry or liquid blushing products, eyeliners, concealers, and the like, require daily application and, often, even more frequent re- application. While providing flexibility in daily appearance, the short-term, high maintenance nature of such topical cosmetics can make their use inconvenient or unsatisfactory.SUBSTITUTE SHEET (RULE 26)

[0005] As a result, modem cosmetic dermatology also includes aesthetic treatment procedures aimed at maintaining or improving upon healthful appearance for longer periods of time. A few of such solutions are directed to restoration of an original skin color, e.g., returning skin color to a baseline after an intervention. Other technologies / products are alternatively directed to more directly and sustainedly / permanently changing, e.g., by staining, skin feature(s).

[0006] Products and technologies directed to modification of skin appearance can be associated with or directed at addressing events or processes that impact the appearance of the skin in more acute ways. Examples of such events can include surgical modification of the skin, trauma, and undesirable modifications arising from other cosmetic / dermatological procedures. For example, dermal filler products / interventions, which are typically used to fill fine lines and wrinkles in aging faces or hands, often cause unintended changes in the appearance of the skin. One well known example is the so-called Tyndall effect, a negative consequence of certain dermal filling procedures, which can result in a bluish hue of the skin resulting from the scattering of light caused by dermal filler product constituents after injection. Attempts to address or minimize the Tyndall effect are known. For example, US patent number 9,950,092 (“the ’092 patent”) describes dermal filler compositions for fine line treatment. Thie patent specifically describes the Tyndall effect as a major cause of concern among dermal filler patients and attempts to provide a solution via composition(s) and formulation method(s) for optically transparent, hyaluronic acid-based dermal fillers that can be applied without “tyndalling.” The disclosure specifically focuses on the use of vitamin C, e.g., more specifically vitamin C derivatives such as L-ascorbic acid 2-glucoside (AA2G), ascorbyl 3-aminopropyl phosphate (Vitagen), or sodium ascorbyl phosphate (AA2P), in combination with the dermal filler material and possibly other formulation components (e.g., vitamins, anesthetic(s), etc.) to reduce the Tyndal effect. The patent further describes, among other things, the conjugation of the vitamin C to a biocompatible polymer, e.g., crosslinked hyaluronic acid, to extend the duration of the ascorbic acid in reducing the Tyndall effect caused by the presence of the filler. To date products employing this technology have not reached the market and it is, accordingly, unclear how much, if any, of the disclosure of the ‘092 patent reflects an effective solution to these issues.

[0007] United States patent publication number US 2015 / 0320907 to Dr. Rania Agha, an apparent practicing or former dermatologist and aesthetic surgeon (the “’907 publication”) reflects another attempt to maintain a patient’ s baseline or original state (at the time treatment is initiated) following dermal filler treatment. The ’907 publication discloses, among other things, a method for treating wrinkles and firming an area of the skin in a human patient comprisinginjecting an injectable dermal filler composition comprising cross-linked hyaluronic acid, and further comprising a white colorant, preferably comprising a calcium compound, and, optionally, a synthetic organic coloring agent, e.g., a yellow colorant. Two related US patents issued from the patent application corresponding to the ’907 application (US 9,084,842 and US 9,981,065). Additional colorants disclosed in these patent documents include Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 17 (CAS No. 4531- 49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 180 (CAS No. 77804-81-0), Pigment Yellow 183 (CAS No. 65212-77-3), Pigment Yellow 191 (CAS No. 129423-54-7), Pigment Yellow 3 (CAS No. 6486-23-3), Pigment Yellow 34 (CAS No. 1344-37-2), Pigment Yellow 42 (CAS No. 51274-00-1), Pigment Yellow 65 (CAS No. 6528-34-3), Pigment Yellow 74 (CAS No. 6358-31-2), Pigment Yellow 75 (CAS No. 52320-66-8), Pigment Yellow 81 (CAS No. 22094-93-5), and Pigment Yellow 83 (CAS No. 5567-15-7), other yellow colorants including cadmium yellow, ochres, and chrome yellow and white colorants including lead carbonate, titanium dioxide, barium sulfate, zinc oxide, calcium carbonate, calcium oxide, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, and calcium phosphate. The ‘907 publication describes a method for treating wrinkles and firming an area of a skin on a human patient comprising the administration of an injectable dermal filler composition comprising cross-linked hyaluronic acid, a white colorant and yellow colorant, wherein compositions are designed to be administered to (injected into) the skin of the orbital trough of a patient for use in lightening dark areas around the eye which have developed over time and to reduce such darkness exaggerated by the Tyndall effect. As such, the ‘907 publication attempts to provide a solution for restoring skin appearance back to a baseline. The ‘907 publication discloses these compositions as formulations, without any reference to the relationship between compositional constituent(s), e.g., colorant(s) and other component(s) of the compositions. Despite being publicly disclosed more than 8 years ago, being developed by a medical professional with familiarity in clinical development, and actually achieving two issued US patents (as noted above), the technology described in the ’907 publication has not been developed into a product available for public use. Furthermore, both the ’842 and ’065 patents were not maintained, suggesting that the technology of the ’907 publication failed to achieve real effects for patients. No similar patent documents or research papers have followed, adopted, or modified the disclosure in the ’907 publication. All of this suggests that developing an effective combination of a dermal filler and colorant to overcome the Tyndal effect remains challenging.

[0008] Of course, others have attempted to change skin color characteristics away from a baseline state, such as, e.g., by applying long-duration skin staining or dying methods, or as a way to cover up damaged skin or undesirable skin features. In this regard, medical tattooing and permanent make-up treatments have been proposed as possible options for modifying the appearance of skin in a sustained / long-term manner.

[0009] Medical tattooing procedure(s) are often aimed at camouflaging the appearance of unwanted changes to skin or hair which may develop from a variety of causes. See, e.g., the Medical Tattoo & Cosmetic Centers of America website at medicaltattoocenters.com. Medical tattooing utilizes high concentration inks comprising compounds which break down slowly and thus provide an extraordinarily long-lasting if not permanent effect. Pigments used in medical tattooing are typically inorganic pigments, e.g., natural mineral or synthetic compounds, such as, e.g., metal oxides, or organic pigments synthesized from carbon, hydrogen, nitrogen, sulfur, and oxygen. Tattoo pigments are classified by, e.g., color index (“C.I.”) categories and numbers, being identified as, e.g., “Pigment Red 170,” or, e.g., “Pigment Black 7.”

[0010] “Permanent cosmetic,” or “permanent makeup” techniques include micropigmentation or derma-pigmentation, wherein pigments are applied to the dermal layer of the skin. Such techniques can allow for personalized design(s) and aesthetic enhancements replacing product(s) and technique(s) applied daily to achieve an aesthetic effect. Such techniques are often used to address skin irregularities, address eyebrow shape or size, emphasize eye line(s), or enhance lip color. See for example, Wetzel, Christine. (2012). Permanent Cosmetics. Plastic surgical nursing : official journal of the American Society of Plastic and Reconstructive Surgical Nurses. 32. 117-9. 10.1097 / PSN.0b013e31826929c6. Pigments used in such techniques are deposited into the skin in a manner similar to medical tattooing however typically in lower concentrations. Similar pigments can be used. Permanent cosmetic pigments often include use of organic compounds such as, e.g., D&C Red 21, D&C Red 27, and, e.g., D&C Orange 5; inorganic pigments such as, e.g., iron (ferric) oxides and titanium dioxide; and hybrid pigments which blend both inorganic and organic colorants. By staining the skin, a significantly longer- term effect is produced than that achieved by topically applied cosmetic products, yet as “permanent cosmetic” products provide colorant compounds in, e.g., lower concentrations than medical tattooing inks, such products typically last a number of years (e.g., 3-5 years or more) but are not truly considered permanent.

[0011] Despite the incredible focus in cosmetic and dermatological procedures, such technologies that have been developed to provide a skin coloration effect that is sustained / longerlasting than traditional topically applied cosmetic products remain limited in scope and, accordingly, do not address all possible desired sustained skin coloration change effects. This reflects that the development of new, effective, sustained skin coloration change technology, based on the current state of the art, will require the application of inventive ingenuity.SUMMARY OF THE INVENTION

[0012] This document includes a section entitled “CONSTRUCTION PRINCIPLES AND DESCRIPTION OF SELECT TERMS” that readers are encouraged to consult to help properly interpret the disclosure provided in this section and elsewhere here. That section includes a list of acronyms frequently used in this disclosure.

[0013] This “Summary of the Invention” section (“Summary”) briefly describes the elements and characteristics of selected illustrative embodiment(s) of the invention. The brief summaries of such embodiments provided here are primarily intended to illustrate the nature of the invention and, accordingly, the content of this Summary is not intended to he all-inclusive, and the scope of the invention is not limited to, or by, the exemplary aspects of the invention provided in this section. Any of the aspects of the invention described in this section can be combined with any other aspect described in this or any other aspect of this disclosure.

[0014] In one aspect, the disclosure / invention provides new method(s) of producing aesthetic change(s) in the skin of a recipient, e.g., a companion animal, test subject mammal, and typically in a human recipient (sometimes referred to as a user (e.g., composition user) or a patient). In aspects, the aesthetic change(s) brought about by the method(s) comprise(s), mostly comprises, generally consists of, consists essentially of, or consists only of non-structural change(s) in the skin, such as, e.g., a detectable or significant change in skin color, such as, e.g., a reddening, pinking, rosing, or other ruddy enhancement of the skin. In aspects, such a detectable or significant change in skin color provides a detectable or significant enhancement in skin glow or other recognized visual characteristic(s) of health and youthfulness. In certain aspects, detectable or significant change in skin color is a yellowing, whitening, or lightening of the skin. In certain aspects, however, detectable or significant change in skin color is a darkening of the skin tone.

[0015] In aspects, a method of the invention comprises steps that result in (or composition of the disclosure results in when administered under effective conditions) increasing a yellow / whitish hue of one aspect of the skin in one or more first parts of the skin, while also, e.g., concurrently also, comprising increasing the reddish color of the skin in another part (orseveral other parts) of the skin of the applicable treated person. In aspects, either type of area or both type of area also receives a structural / topological change due to the administration of effective amount(s) of structural agent(s) in the method / composition. In aspects, some, most, generally all, essentially all, substantially all, or all of the areas that receive a color change by practice of the method / administration of the composition also receive a DOS structural / topological effect due to the method / composition (e.g., a dermal filling effect, a lip plumping effect, etc.).

[0016] According to aspects, the disclosure provides new composition(s) that provide a long-term color-related aesthetic effect to area(s) of skin to which composition(s) are administered. In aspects, the disclosure provides method(s) of using such composition(s) to achieve a long-term color-related aesthetic effect, e.g., change in skin color, tone, or skin color and tone, to treated skin. In aspects, a long-term color-related aesthetic effect is a non-permanent effect, e.g., an effect lasting at least about 3 months, e.g., at least about 6, 9, or at least about 12 months, but which does not permanently dye or stain the skin. In aspects, the effect comprises, mostly comprises, consists essentially of, or consists of a change (e.g., a significant or detectable change) as compared to the applicable skin color of the treated person at baseline (when the treatment is performed) (e.g., in aspects, the change in the skin associated with the methods / products of this disclosure comprises a change in skin color that somewhat, mostly, generally only, or only is a change to the skin as compared to baseline rather than a baseline skin color retention effect).

[0017] According to aspects, the disclosure provides composition(s) and associated method(s) for producing long-term skin coloring effect(s) facilitated by the presence of chromophoric agent(s) and chromophoric extension agent(s). In aspects, chromophoric extension agent(s) detectably or significantly extend the aesthetic effect of one or more chromophoric agent(s) of inventive composition(s). In aspects, chromophoric extension agent(s) detectably or significantly extend the aesthetic effect of one or more chromophoric agent(s) by detectably or significantly stabilizing such chromophoric agent(s) such that their effect lasts for a detectably or significantly longer period of time than the effect provided by the chromophoric agent absent the presence of the chromophoric extension agent(s). In aspects, the chromophoric agent(s) are stably associated with the chromophoric extension agent(s) resulting in the extended chromophoric effect(s). In aspects, the stable association is a chemical association, e.g., a conjugation, e.g., a covalent bond between the chromophoric agent(s) and the chromophoric extension agent(s). As noted elsewhere, readers will chromophoric extension agent(s) often maybe exemplified as / referred to as structural agent(s) in this disclosure (or aspects may be described as comprising a structural component), as, in aspects, a method / composition comprises agent(s) that may impart a DOS topological / structural effect to the skin of a treated person as well as also or alternatively DOS extending / sustaining the chromophoric effect of one or more chromatophore(s) of the composition / method. As noted, readers should understand any aspect describing a structural agent or structural component, uncontradicted, provides implicit support for a corresponding aspect in which the chromophoric extension component (CEC) is a nonstructural CEC or the chromophoric extension agent(s) (CEA(s)) comprise, mostly comprise, consist essentially of, or consist of nonstructural CEA(s).

[0018] In aspects, the aesthetic change(s) brought about by the composition(s) and method(s) comprise(s) both non-structural change(s) in the skin and structural change(s) in skin, such as, e.g., change(s) in skin color and a reduction in a visually recognizable sign of aging. Still further, in aspects, aesthetic change(s) brought about by the method(s) comprise(s) both change(s) in non-structural and structural change(s), such as, e.g., enlarging one or more facial feature(s), such as, e.g., lip(s).

[0019] In aspects, method(s) disclosed herein comprises internal (non-topical) administration, e.g., non-topical dermal administration of an aesthetically effective amount of dermatologically suitable chromophoric composition(s), e.g., by injection of composition(s) into the dermis of a subject. Herein, “dermal / subdermal” may be used to describe composition(s) or administration of such composition(s) provided in this disclosure, wherein “dermal / subdermal” encompasses, but may not be limited to, non-topical administration, which may typically comprise administration by injection. Dermal / subdermal agent(s) / component(s) also or alternative can be characterized in causing a DOS aesthetic effect (e.g., a coloring effect, a dermal filling effect, or both) when administered to the dermis, sub dermis, or both, as applicable, in effective amount and under effective conditions. Specific agent(s) described as “dermal / subdermal” agent(s) can be interpreted as agent(s) providing an effect to the skin, including when administered sub-dermally (e.g., a dermal / subdermal chromophoric agent may be an agent which, upon administration, yields a detectable or significant coloring effect on / to the skin, including when administered sub-dermally, including, e.g., by injection). In aspects, dermatologically suitable chromophoric composition(s) used in method(s) provide detectable or significant structural effect, such as, e.g., providing a detectable or significant filling effect of, e.g., skin imperfections such as wrinkles, or, e.g., the size-enhancement or plumping of feature(s) identified as being sub-optimally small, thin, or otherwise diminutive. In aspects,dermatologically suitable chromophoric composition(s) herein comprise(s) an effective amount of a structural component comprising one or more structural agents, wherein the effective amount is an amount sufficient to produce a detectable or significant stabilizing effect to chromophoric agent(s), a detectable or significant structural effect to the skin, such as, e.g., plumping, smoothing, or filling effect, or both when administered in effective amount(s) and an effective number of instance(s) / procedure(s).

[0020] In aspects, dermatologically suitable chromophoric composition(s) comprise an effective amount of a dermal / subdermal chromophoric component comprising one or more dermal / subdermal chromophoric agents, wherein the effective amount of the dermal / subdermal chromophoric agent(s) is an amount sufficient to produce a detectable or significant change in skin color (a “skin coloration effect”) (e.g., in most patients, in a significant number of patients in a population such as in a clinical study, in an individual patient, in a typical or average patient / subject, or in a combination thereof).

[0021] In aspects, administration of dermatologically suitable chromophoric composition(s) disclosed herein provides a detectable or significant chromophoric effect for a period of time establishing a chromophoric aesthetic effect period. E.g., in aspects, administration of composition(s) disclosed herein provides a detectable or significant skin coloration effect lasting for a skin coloration effect period (“coloration effect period” also referred to as a “chromophoric aesthetic effect period.”) In certain aspects, the chromophoric aesthetic effect period can correspond to one or more other detectable or significant effects of the composition, such as, e.g., one or more structural effects of the composition(s). In aspects, composition(s) herein provide a detectable or significant structural aesthetic effect for a period of time establishing a structural aesthetic effect period. In aspects, the structural aesthetic effect period can correspond to one or more other non-structural effects of the composition, such as, e.g., a chromophoric effect. In aspects, a chromophoric aesthetic effect period can correspond to a structural aesthetic effect period. In aspects, administration of composition(s) disclosed herein provides both a detectable or significant chromophoric aesthetic (coloration) effect lasting for a chromophoric aesthetic (coloration) effect period and a detectable or significant structural effect lasting for a structural aesthetic effect period. In aspects, a structural aesthetic effect period is at least about 50%, 75%, or at least about 100% that of one or more other effects, e.g., one or more other non-structural aesthetic effect(s) period, e.g., chromophoric aesthetic effect period. In aspects, a skin coloration period is at least about 15%, e.g., at least about 25%, such as > -33%, at least about 50%, at least about 65%, or at least about 80% that of one or more other effects,e.g. one or more other structural aesthetic effect periods, or, e.g., is at least generally the same, substantially the same, essentially the same, or is the same as a structural aesthetic effect period (the meaning of term(s) such as, e.g., “substantially” is / are described elsewhere herein).

[0022] According to certain aspects, composition(s) herein comprise a structural component wherein the structural component provides a detectable or significant stabilization of a chromophoric component (agent(s) thereof), wherein such stabilization is provided alone or in combination with a structural aesthetic skin effect.

[0023] In aspects, chromophoric agent(s) and structural agent(s) are present in composition(s) provided herein in a sufficiently stable association with each other (such as, e.g., association established by chemical bonding, which can comprise, e.g., covalent bonding of chromophoric agent(s) and structural agent(s)). In aspects, the stable association detectably or significantly enhances the skin coloration period compared to any structural agent(s) provided with chromophoric agent(s) present but not stably associated with one another, such as, e.g., lacking detectable or significant chemical binding or bonding of one to the other).

[0024] The disclosure herein also provides dermatologically suitable composition(s) comprising an aesthetically effective amount of a dermatologically suitable chromophoric component (comprising an effective amount of one or more suitable dermal / subdermal chromophoric agents) and further comprising an effective amount of a structural component that comprises one or more dermal / subdermal structural agents providing stabilizing effect for chromophoric agent(s), structural aesthetic effect to the skin, or both. In aspects, dermal / subdermal chromophoric agent(s) can comprise dermal / subdermal chromophoric vitamin(s), dermal / subdermal chromophoric mineral(s), or both. In aspects, dermal / subdermal chromophoric agent(s) in the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce detectable change(s) in skin color. Feature(s) of such composition(s) are described above with respect to methods of the invention and in further detail below, but exemplary features are also described in this paragraph. For example, in aspects, a dermal / subdermal chromophoric component and a dermal / subdermal structural component are in a sufficiently stable association with one another within the composition(s).

[0025] In aspects, in addition to causing a skin coloration effect, composition(s) impart a detectable or significant structural change when administered in effective amount(s) and administered a suitable number of times (such as, e.g., a smoothing, plumping, or filling effect), that persists for a period of time lasting at least about 50% as long as a chromophoric effect, suchas, e.g., >~60%, >~70%, >~80%, >~90%, or >~100% as long as the chromophoric aesthetic effect period of composition (such as, e.g., about 85-110% or more of the structural aesthetic effect period).

[0026] In aspects, composition(s) cause a detectable or significant skin color change, when administered in effective amount(s) and administered a suitable number of times, that persists for a period of time lasting at least about 50% as long as one or more other aesthetic effects of the composition, such as, e.g., a structural effect, such as, e.g., >~55%, >~60%, >~65%, >~70%, or >~75% as long as the structural aesthetic effect period of composition (such as, e.g., about 85-110% of the structural aesthetic effect period). In aspects, the chromophoric component aesthetic effect lasts for at least about 6, >~9, >~12, >~15, >~18, or > ~24 months.

[0027] In aspects, chromophoric agent(s) and structural agent(s) in composition(s) are in a stable association that comprises one or more chemical bonds, e.g., one or more covalent bonds between the agents or one or more other chemical or physical interactions, such as ionic bond relationships. In aspects, the stable association of the structural agent(s) and chromophoric agent(s) of composition(s) or a prolonged chromophoric effect of chromophoric agent(s) also or alternatively can be achieved by formulation of composition(s), structural relationship of the agents, or both.

[0028] In certain aspects, composition(s) herein comprise a dermal / subdermal chromophoric component wherein the dermal / subdermal chromophoric component of such composition(s) comprises an effective amount of one or more chromophoric vitamin(s) covalently conjugated to structural agent(s). In aspects, chromophoric vitamin(s) of composition(s) are vitamin(s) capable of imparting a detectable or significant change in skin color upon administration (e.g., upon administration in suitable amount(s)). In aspects, chromophoric vitamin(s) present in composition(s) can demonstrate an absorbance of light at wavelengths of between about 420 nm and about 430 nm, demonstrate an at least substantial reflection of light at wavelengths between about 570 nm and about 590 nm, or both. In aspects, chromophoric vitamin(s) present in composition(s) can demonstrate an absorbance of light at wavelengths of between about 500 nm and about 520 nm, demonstrate an at least substantial reflection of light at wavelengths between about 620 nm to about 750 nm, or both.

[0029] In aspects, exemplary dermatologically suitable chromophoric composition(s) disclosed herein further comprise a structural component comprising (a) an effective amount of a hyaluronic acid, (b) an effective amount of one or more non-hyaluronic acid structural agent(s), such as, e.g., one or more lipogenic structural agents, (c) other structural agent providingdetectable or significant chromophoric agent stabilizing effect(s), providing detectable or significant smoothing, plumping, or filling effect(s), or (d) any combination thereof. In certain aspects, a structural component of composition(s) herein comprises an effective amount of a hyaluronic acid wherein the hyaluronic acid is crosslinked, crosslinked

[0030] According to aspects, measurement devices such as spectrophotometers, colorimeters, or other color measurement devices in the art may be used in combination with color analysis software, such as, e.g., Skin Analysis Software “CM-SA” by Konica Minolta, etc. to measure skin color, such as before administration of composition(s) provided herein, after one or more administration(s) of composition(s) of this disclosure, or both. In aspects, color change, e.g., skin color change, induced by administration (such as, e.g., by injection) of composition(s) described herein means a detectable or significant change as measured by a Munsell System (e.g., a DOS change in Munsell System hue, value, or chroma). In an aspect, administration of composition(s) of the invention promotes or achieves coloration of a red of medium lightness and moderate / substantial saturation (e.g., a skin color with a Munsell System measure of 5R 5 / 10, wherein 5P corresponds to hue, the color in the middle of the red band on the Munsell Color Wheel, and “5 / 10” corresponds to the value and chroma, wherein 5 is the value and 10 is the chroma).

[0031] According to certain aspects, composition(s) of the invention comprise effective amount(s) of one or more dermatologically suitable excipients, such as, e.g., crosslinking agent(s), anesthetic agent(s), anti-allergic agent(s), buffer(s), pH adjusting agent(s), carrier(s) / lubricant(s), or any combination(s) thereof. In aspects, composition(s) herein comprise a crosslinking component comprising one or more crosslinking agents. In aspects, exemplary or suitable crosslinking agent(s) comprise, e.g., 1, 4-butanediol diglycidyl ether (BDDE), divinyl sulphone, 2, polyethylene glycol (PEG) 7, 8 -diepoxy octane (DEO), 1,2- bis(2,3- epoxypropoxy)ethylene, or l-(2,3-epoxypropyl)-2, 3-epoxy cyclohexane.

[0032] In aspects, composition(s) provided by the invention are stable for a period of at least about 3 months, such as at least about 6, >~9, >~12, >~18, or, e.g., >~24 months when stored under standard storage conditions, wherein a standard storage condition is, e.g., room temperature of between about 20°C and about 25 °C. In aspects, composition(s) are sufficiently stable to comply with accepted regulatory authority standards for regulated injected medical device products, such as US FDA standards, EMA standards, and other recognized (e.g., internationally recognized) health / regulatory authority stability standards (e.g., Health Canada stability standards). In aspects, such stability is determined by retention of at least about 95%, atleast about 97%, or at least about 99% of initial non- structural (e.g., chromophoric) agent(s), structural (e.g., hyaluronic acid) agent(s), or both non-structural and structural agentsZcompound(s)) in one or more composition(s) after a relevant period of storage (e.g., at least about 1 week, >~1 month, >~3 months, >~6 months, >~12 months, >~18 months, or, e.g., >~24 months. In aspects, stability also or alternatively is assessed by the retention of at least about 95%, at least about 97%, or at least about 99% of the efficacy of one or more composition(s) in terms of the ability to cause both a dermal coloration effect and structurechanging effect. In aspects, composition(s) are stored under condition(s) protecting composition(s) from exposure to light, such as, e.g., in light-protected packaging.

[0033] According to certain aspects, composition(s) disclosed herein are provided as a component of a combination product or a “kit,” wherein a kit can further comprise, in aspects, one or more delivery devices designed for the delivery of composition^ ) to a recipient. In aspects, such kit(s) can be used in any method(s) described herein.EXEMPLARY ASPECTS OF THE INVENTION

[0034] Disclosed here are several different but related exemplary aspects (variations) of the invention. The following is a non-limiting list of exemplary aspects of the invention, which illustrates embodiments of the invention in a summary form to aid readers in quickly understanding the overall scope of the invention. Similar to patent claims, listed aspects described in the paragraphs of this section may make reference to (depend on / from) one or more other paragraphs. Readers will understand that such references mean that the features / characteristics or steps of such referenced aspects are incorporated into / combined with the referring aspect. E.g., if an aspect in a paragraph (e.g., a paragraph indicated by text at the end of the paragraph as aspect 2) refers to another aspect by one or more aspect numbers (e.g., aspect 1 or "any one of aspects 1-3"), it will be understood to include the elements, steps, or characteristics of such referenced aspects (e.g., aspect 1) in addition to those of the aspect in which the reference is made (e.g., if aspect 2 refers to aspect 1, it provides a description of a composition, method, system, device, etc., including the features of both aspect 1 and aspect 2).

[0035] Lists of aspects describing specific exemplary embodiments of the invention are sometimes employed for aiding the reader in understanding the invention. Such aspects can, within them, reference other exemplary aspects, either individually or as groups of aspects (e.g., via reference to a range within a list of numbered aspects when such aspects are provided as a numbered list). Reference to ranges of aspects should be interpreted as referencing all suchaspects individually, each as unique embodiments of the invention, and in combination with one another as unique embodiment(s) of the invention, according to the presentation provided of such aspects unless such an aspect within such a referenced range is either contradictory or nonsensical. If contradicted, reference to the contradictory aspect should be excluded.

[0036] It is intended that these listed exemplary aspects begin with the first listed aspect (ASPECT 1) and thereafter be numbered sequentially and incrementally by inclusion of a reference placed near or at the end of the listed aspect (ASPECT 2, ASPECT, 3, etc.). In case of a missing aspect reference or repeated aspect reference, the order of placement of the actual recited aspect in the list that is associated with the repeated aspect reference or missing aspect reference will control (e.g., if there is an unlabeled aspect located between a first aspect labeled ASPECT 1 and a third aspect labeled ASPECT 2, the unlabeled aspect should be treated as ASPECT 2, and the aspect labeled as ASPECT 2 treated as ASPECT 3, etc.), and all numbering in the list (including all references to aspects in the list) be interpreted as accordingly modified (e.g., if the fourth aspect in such list was labeled as ASPECT 3, it should be interpreted as being labeled as ASPECT 4, and if such aspect referred to “any one or both of aspect 1 or aspect 2,” it should be read as referring to “any one or more of aspects 1-3”). Similarly, if an aspect is misnumbered (e.g., by a number in the sequence being skipped or otherwise missing), readers will similarly construe this list of aspects according to the order of placement of the recited aspects, over the numerical references. Further, if one or more of the listed exemplary aspects of the invention in this section fails to reference any other aspects of the invention, such aspect, uncontradicted, should be interpreted as applying to or as capable of being incorporated into, any one or more other exemplary aspect(s) provided in this section.

[0037] In aspects, the disclosure provides a method of producing a long-lasting, chromophoric aesthetic change in the skin of a recipient comprising administering to at least a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents and (2) a second effective amount of a chromophoric extension component comprising one or more chromophoric extension agents (also referred to in the detailed description generally and this list of exemplary aspects as a “structural component” and “structural agents”), wherein (a) the one or more chromophoric agents and the one or more chromophoric extension / structural agents are in a sufficiently stable association with one another, (b) the one or more dermal / subdermal chromophoric agents of the dermal / subdermalchromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color, and (c) the period of time after administration of the chromophoric composition wherein there is a detectable effect of the one or more chromophoric agents of the chromophoric component establishes a chromophoric aesthetic effect period, and further wherein the administration of the dermatologically suitable chromophoric composition provides (d) a structural aesthetic effect which lasts at least about 75% as long as the chromophoric effect period, (e) a chromophoric effect period which lasts at least about 75% as long as the structural aesthetic effect, or both (d) and (e). (ASPECT 1.)

[0038] In aspects, the disclosure provides the method of aspect 1, wherein the method is performed under the supervision of a licensed healthcare professional, and the method further comprises the healthcare professional determining the aesthetically effective amount of the dermatologically suitable chromophoric composition to administer to the recipient. (ASPECT 2.)

[0039] In aspects, the disclosure provides the method of any one or both of aspect 1 and aspect 2, wherein the method comprises a licensed healthcare professional first assessing the skin color of the recipient in one or more potential target areas and (1) determining an effective amount of a dermal / subdermal chromophoric component to include in the dermatologically suitable chromophoric composition to administer to the recipient based upon the skin color in each of the one or more potential target areas, (2) determining which dermal / subdermal chromophoric agents of a dermal / subdermal chromophoric component are appropriate for administration based upon the skin color in the potential target areas, or (3), both (1) and (2). (ASPECT 3.)

[0040] In aspects, the disclosure provides the method of any one or more of aspects 1 - 3, wherein the method further comprises performing a skin tolerance test for (1) at least one of the one or more dermal / subdermal chromophoric agents in the dermal / subdermal chromophoric component, (2) at least one of the one or more structural agents of the structural component, (3) both (1) and (2), or (4) the dermatologically suitable chromophoric composition, prior to administering the dermatologically suitable chromophoric composition to determine if an unacceptable level of one or more side effects may be expected to occur in the recipient upon administration of the dermatologically suitable chromophoric composition. (ASPECT 4.)

[0041] In aspects, the disclosure provides the method of aspect 4, wherein the skin tolerance test comprises administering an evaluation amount of (1) at least one of the one or more dermal / subdermal chromophoric agents in the dermal / subdermal chromophoric component, (2) at least one of the one or more structural agents in the structural component, (3) both (1) and(2), or (4) the dermatologically suitable chromophoric composition, to a part of the body of the recipient that is different from any target area intended to be an aesthetic treatment site.(ASPECT 5.)

[0042] In aspects, the disclosure provides the method of any one or more of aspects 1 - 5, wherein the method comprises performance under the supervision of a licensed healthcare professional and wherein the method further comprises the licensed healthcare professional determining the aesthetically effective amount of the dermatologically suitable chromophoric composition to administer to the recipient and wherein performing the method on an adequately powered population of individuals results in a statistically significant number of licensed healthcare professionals in an adequately powered population of licensed healthcare professionals determining that a visible change in skin color has occurred and has been sustained for a period of at least about 3 months. (ASPECT 6.)

[0043] In aspects, the disclosure provides the method of any one or more of aspects 1 - 6, wherein the method comprises performance under the supervision of a licensed healthcare professional and wherein the method further comprises the licensed healthcare professional determining the aesthetically effective amount of the dermatologically suitable chromophoric composition to administer to the recipient and wherein performing the method on an adequately powered population of individuals results in a statistically significant number of licensed healthcare professionals in an adequately powered population of licensed healthcare professionals determining that a visible change in skin color has occurred and has been sustained for a period of at least about 6 months. (ASPECT 7.)

[0044] In aspects, the disclosure provides the method of any one or more of aspects 1 - 7, wherein the method comprises performance under the supervision of a licensed healthcare professional and wherein the method further comprises the licensed healthcare professional determining the aesthetically effective amount of the dermatologically suitable chromophoric composition to administer to the recipient and wherein performing the method on an adequately powered population of individuals results in a statistically significant number of licensed healthcare professionals in an adequately powered population of licensed healthcare professionals determining that a visible change in skin color has occurred and has been sustained for a period of at least about 9 months. (ASPECT 8.)

[0045] In aspects, the disclosure provides the method of any one or more of aspects 1 - 8, wherein the method comprises performance under the supervision of a licensed healthcare professional and wherein the method further comprises the licensed healthcare professionaldetermining the aesthetically effective amount of the dermatologically suitable chromophoric composition to administer to the recipient and wherein performing the method on an adequately powered population of individuals results in a statistically significant number of licensed healthcare professionals in an adequately powered population of licensed healthcare professionals determining that a visible change in skin color has occurred and has been sustained for a period of at least about 12 months. (ASPECT 9.)

[0046] In aspects, the disclosure provides the method of any one or more of aspects 1 - 9, wherein the method comprises evaluating the skin color of the recipient at one or more time points or within one or more time period(s) after administration of the dermatologically suitable chromophoric composition to determine if the recipient requires an additional amount of the dermatologically suitable chromophoric composition to be administered to achieve a desired (target) skin color change. (ASPECT 10.)

[0047] In aspects, the disclosure provides the method of any one or more of aspects 1 -10, wherein the method comprises a licensed healthcare professional determining the frequency of applications of dermatologically suitable chromophoric composition to be administered to the recipient to achieve a desired (target) skin color result, a desired (target) structural aesthetic skin effect, or both based upon one or more previously conducted clinical trials, a scale, or other suitable standard. (ASPECT 11.)

[0048] hi aspects, the disclosure provides the method of any one or more of aspects 1 -11 , wherein performing the method results in (a) a detectable or statistically significant reduction of the Tyndall effect in a treated area of skin on a human patient, (b) a detectable or statistically significant reddening effect in a treated area of skin on a human patient, (c) a detectable or significant darkening effect in a treated area of skin on a human patient, or any combination thereof, as assessed by a licensed healthcare professional, a suitable skin color assessment technology such as technology(ies) described herein, or any combination thereof. (ASPECT 12.)

[0049] In aspects, the disclosure provides the method of any one or more of aspects 1 -12, wherein an effective amount of the dermatologically suitable chromophoric composition exhibits a wavelength of (e.g., a reflection of light having a wavelength of) between about 570 nm to about 590 nm, about 620 nm to about 750 nm, about 420 nm to about 430 nm, about 620 nm to about 750 nm, or any combination thereof when subjected to a spectrophotometric analysis (e.g., when exposed to visible light). (ASPECT 13.)

[0050] In aspects, the disclosure provides the method of any one or more of aspects 1 -13, wherein the recipient is a candidate for semipermanent make-up or cosmetic tattooing andthe method is applied as an alternative to semipermanent make-up or cosmetic tattooing, has detectable or significant existing scarring, is a candidate for an anti-aging treatment, or any combination of any or all thereof. (ASPECT 14.)

[0051] In aspects, the disclosure provides the method of any one or more of aspects 1 -14, wherein a dermatologically suitable chromophoric composition comprises a structural component comprising (1) an effective amount of a hyaluronic acid, (2) an effective amount of one or more non-hyaluronic acid structural agents, wherein the one or more non-hyaluronic acid structural agents is a lipogenic structural agent, or (3) any combination thereof. (ASPECT 15.)

[0052] In aspects, the disclosure provides the method of any one or more of aspects 1 -15, wherein the chromophoric extension component (or structural component as described above) comprises an effective amount of a hyaluronic acid, wherein the hyaluronic acid is crosslinked, and at least a portion of the dermal / subdermal chromophoric component comprises an effective amount of dermal / subdermal chromophoric vitamin(s) and / or dermal / subdermal chromophoric mineral(s) covalently conjugated to the crosslinked hyaluronic acid, wherein as a result of the covalent conjugation a licensed healthcare professional can identify a visually perceptible color change when viewing the dermatologically suitable chromophoric composition prior to administration to a human patient, further wherein the dermal / subdermal chromophoric vitamin(s) and / or dermal / subdermal chromophoric mineral(s) exhibit a wavelength of (1) about 570 nm to about 590 nm, (2) about 420 nm to about 430 nm, or (3) both (1) and (2), or, e.g., between about (4) about 620 nm to about 750 nm, (5) about 500 nm to about 520 nm, or (6) both (4) and (5) when subjected to spectrophotometric analysis (e.g., using visible light) or modulate the color of the skin such that the wavelength of light reflected from the skin is detectably or significantly more like one or more of the recited wavelengths after an effective treatment by application of the method than prior to or without the treatment. (ASPECT 16.)

[0053] In aspects, the disclosure provides the method of any one or more of aspects 1 -16, wherein the dermal / subdermal chromophoric component is associated with an effective amount of a dermatologically acceptable controlled release component such that the skin colorchanging effect of the dermal / subdermal chromophoric agent(s) is maintained for a period that is statistically significantly longer than that of an equivalent amount of dermal / subdermal chromophoric agent(s) administered without the controlled release component. (ASPECT 17.)

[0054] In aspects, the disclosure provides the method of aspect 17, wherein some, most, generally all, substantially all, essentially all, or all of the dermal / subdermal chromophoric component is associated with a dermatologically acceptable controlled release component thatcan be characterized as a sustained release component, a delayed release component, or a conditional release component. (ASPECT 18.)

[0055] In aspects, the disclosure provides the method of any one or more of aspects 1 - 18, wherein the dermal / subdermal chromophoric component comprises one or more dermal / subdermal chromophoric vitamins and / or one or more dermal / subdermal chromophoric minerals wherein at least one of the dermal / subdermal chromophoric vitamin(s) is a vitamin capable of imparting a detectable or significant change in color to the skin upon administration, further wherein at least one of the dermal / subdermal chromophoric minerals is a mineral capable of imparting a detectable or significant change in color to the skin upon administration, and the spectral analysis of the dermal / subdermal chromophoric vitamin and / or dermal / subdermal chromophoric mineral reveals >~420 nm, >~425 nm, or, e.g., >~430 nm, or, e.g., >~500 nm, >~515 nm, or, e.g., >~520 nm, and an at least substantial reflection of light by the one or more dermal / subdermal chromophoric vitamin(s) having wavelengths about >~570 nm, >~575 nm, >~600 nm, >~625 nm, >~650 nm, >~700 nm, >~725 nm, or, e.g., >~750 nm, or, e.g., >~620 nm, >~650 nm, >~675 nm, >~700 nm, >~725 nm, or, e.g., >~750 nm. (ASPECT 19.)

[0056] In aspects, the disclosure provides the method of aspect 19, wherein at least one or more dermal / subdermal chromophoric vitamin(s) is thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folate, cobalamin, e.g., cyanocobalamin, or a dermatologically suitable derivative thereof, e.g., a cobalamin, e.g., cyanocobalamin, or dermatologically suitable derivative thereof, and / or one or more dermal / subdermal chromophoric agent(s) is a carotenoid, and the method comprises delivering a suitable chromophoric amount of the thiamin, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folate, cobalamin, e.g., cyanocobalamin, or a dermatologically suitable derivative thereof and / or carotenoid to a part of the face of the recipient comprising an upper lip, a lower lip, or both. (ASPECT 20.)

[0057] In aspects, the disclosure provides the method of any one or more of aspects 1 - 18, wherein the dermal / subdermal chromophoric component comprises one or more dermal / subdermal chromophoric vitamins and one or more dermal / subdermal chromophoric minerals wherein at least one of the dermal / subdermal chromophoric vitamins is a vitamin capable of imparting a detectable or significant change in color to the skin upon administration, further wherein at least one of the dermal / subdermal chromophoric minerals is a mineral capable of imparting a detectable or significant change in color to the skin upon administration, and the spectral analysis of the dermal / subdermal chromophoric vitamin(s) and / or dermal / subdermal chromophoric mineral(s) reveals the at least substantial absorbance of light having wavelengthsbetween about 420 nm and about 430 nm and the at least substantial reflection of light having wavelengths between about 570 nm and about 590 nm. (ASPECT 21.)

[0058] In aspects, the disclosure provides the method of aspect 21, wherein (1) at least one of the one or more dermal / subdermal chromophoric vitamin(s) is riboflavin or dermatologically suitable derivative thereof, (2) at least one or more dermal / subdermal chromophoric vitamin(s) is pyridoxine or dermatologically suitable derivative thereof, (3) at least one of the one or more dermal / subdermal chromophoric vitamin(s) is a complex of riboflavin or dermatologically suitable derivative thereof and pyridoxine or dermatologically suitable derivative thereof (riboflavin - pyridoxine complex or complex of derivatives thereof), (4) at least one or more dermal / subdermal chromophoric vitamin(s) is retinol or a dermatologically suitable derivative thereof, or is beta carotene or a dermatologically suitable derivative thereof, (5) at least one or more dermal / subdermal chromophoric agent(s) is urobilin, (6) at least one or more dermal / subdermal chromophoric agent(s) is a B-vitamin derivative, e.g., niacin, or (7) at least one or more dermal / subdermal chromophoric agent(s) is a carotenoid, and wherein the method further comprises administering a suitable chromophoric amount of riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, riboflavin - pyridoxine complex or complex of derivatives thereof, retinol, urobilin, B-vitamin derivative, or carotenoid, or any combination thereof to impart a change in color of the skin in one or more second target area(s) of the skin of the recipient comprising (1) the area of the skin surrounding the orbit, (2) an area including the orbit, or (3) both the areas of skin surrounding and including the orbit. (ASPECT 22.)

[0059] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents and a an effective amount of a chromophoric extension (structural) component that comprises one or more structural agents wherein (1) the one or more dermal / subdermal chromophoric agents in the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color and (2) the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide for the skin color change, e.g., but not limited to, a darkening, reddening, or darkening and reddening of the skin, of the chromophoric component to persist for a period of time which is at least about 65%, such as, e.g., >~70%,>~75%, >~80%, >~85 %, >~90%, >~95%, or >~100% of any aesthetic effect period which may be provided by the chromophoric extension (structural) component. (ASPECT 23.)

[0060] In aspects, the disclosure provides the chromophoric composition of aspect 23, wherein mostly all, generally all, substantially all, or all of the chromophoric agent(s) in the composition are capable of producing a chromophoric effect in at least mostly all, at least generally all, at least substantially all, or all humans when administered in the amount at which they are present in a composition. (ASPECT 24.)

[0061] In aspects, the disclosure provides the chromophoric composition of any one or both of aspect 23 and aspect 24, wherein the composition comprises a dermatologically suitable structural component comprising (1) an effective amount of a hyaluronic acid, (2) an effective amount of one or more non-hyaluronic acid structural agents, or (3) any combination thereof. (ASPECT 25.)

[0062] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 25, wherein the composition comprises a dermal / subdermal chromophoric component comprising a dermally chromophorically effective amount of cobalamin, e.g., cyanocobalamin, or dermatologically suitable derivative thereof. (ASPECT 26.)

[0063] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 26, wherein the composition comprises a dermal / subdermal chromophoric component comprising a dermally chromophorically effective amount of (1) riboflavin or dermatologically suitable derivative thereof, (2) pyridoxine or dermatologically suitable derivative thereof, (3) vitamin complex comprising an effective amount of riboflavin or dermatologically suitable derivative thereof and an effective amount of pyridoxine or dermatologically suitable derivative thereof (riboflavin - pyridoxine complex or complex of derivatives thereof), or (3) any combination thereof. (ASPECT 27.)

[0064] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 27, wherein the structural component comprises a hyaluronic acid, wherein the hyaluronic acid is crosslinked, and at least some, at least most, at least generally all, at least substantially all, or all of the dermal / subdermal chromophoric vitamin(s) and / or dermal / subdermal chromophoric mineral(s) present in the composition is / are covalently conjugated to crosslinked hyaluronic acid (ASPECT 28.)

[0065] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 28, wherein administering the composition in an effective amount, for an effective number of administrations, or both, results in a statistically significant skin colorchange in a significant number of recipients as determined by an adequately powered and appropriately controlled study. (ASPECT 29.)

[0066] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 29, wherein an effective amount of the dermatologically suitable chromophoric composition produces a detectable or significant change in skin color as measured by spectrophotometric analysis of light reflecting one or more wavelength(s) of between about 570 nm to about 590 nm, or, e.g., about 620 nm to about 750 nm. (ASPECT 30.)

[0067] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 30, wherein the composition, when used in any one or more of the method(s) described in aspects 1 - 22, induces a darkening of skin tone, a red toned skin color change, or both a darkening and a red toned skin color change in a recipient, e.g., a human patient, as detected and confirmed by a statistically significant number of licensed healthcare professionals. (ASPECT 31.)

[0068] In aspects, the disclosure provides a container comprising an amount, e.g., a unit amount, of a chromophoric composition according to any one or more of aspects 23 - 30, wherein the container is comprised of a material suitable for protecting the composition from exposure to a detectable or significant amount of light, is suitably packaged to protect the composition from exposure to light, or both, and is capable of stably maintaining the composition for a period of at least about 1 month after manufacturing when stored at a temperature of between about 20 °C and about 25°C. (ASPECT 32.)

[0069] In aspects, the disclosure provides a container comprising an amount, e.g., a unit amount, of a chromophoric composition according to any one or more of aspects 23 - 32, wherein the container is comprised of a material suitable for protecting the composition from exposure to a significant amount of light, is suitably packaged to protect the composition from exposure to light, or both and is capable of stably maintaining the composition for a period of at least about 3 months after manufacturing when stored at a temperature of between about 20 °C and about 25°C. (ASPECT 33.)

[0070] In aspects, the disclosure provides a container comprising an amount, e.g., a unit amount, of a chromophoric composition according to any one or more of aspects 23 - 33, wherein the container is comprised of a material suitable for protecting the composition from exposure to a significant amount of light, is suitably packaged to protect the composition from exposure to light, or both, and is capable of stably maintaining the composition for a period of atleast about 6 months after manufacturing when stored at a temperature of between about 20 °C and about 25°C. (ASPECT 34.)

[0071] In aspects, the disclosure provides a container comprising an amount, e.g., a unit amount, of a chromophoric composition according to any one or more of aspects 23 - 34, wherein the container is comprised of a material suitable for protecting the composition from exposure to a significant amount of light, is suitably packaged to protect the composition from exposure to light, or both, and is capable of stably maintaining the composition in a stable manner for a period of at least about 9 months after manufacturing when stored at a temperature of between about 20 °C and about 25°C. (ASPECT 35.)

[0072] In aspects, the disclosure provides a container comprising an amount, e.g., a unit amount of a composition according to any one or more of aspects 23 - 35, wherein the container is comprised of a material suitable for protecting the composition from exposure to a significant amount of light, is suitably packaged to protect the composition from exposure to light, or both, and is capable of stably maintaining the composition for a period of at least about 12 months after manufacturing when stored at a temperature of between about 20 °C and about 25°C.(ASPECT 36.)

[0073] In aspects, the disclosure provides a kit comprising any one or more of the composition(s) described in any one or more of aspects 23 - 30, any one or more of the containers described in any one or more of aspects 32 - 36, or both. (ASPECT 37.)

[0074] In aspects, the disclosure provides the kit of aspect 37, wherein the kit further comprises one or more delivery devices for delivering the one or more compositions to one or more recipient(s). (ASPECT 38.)

[0075] In aspects, the disclosure provides the kit of aspect 38, wherein the one or more delivery devices comprise(s) a needle and syringe system or a cannula and syringe system. (ASPECT 39.)

[0076] In aspects, the disclosure provides the kit of aspect 39, wherein the needle and syringe system comprises a needle having (1) an outer diameter no greater than about 0.642 mm, such as no greater than about 0.474 mm, (2) an inner diameter no greater than about 0.337 mm, such as no greater than about 0.21 mm, (3) both (1) and (2), (4) a length of no more than about 1 inch, or any combination of (l)-(4). (ASPECT 40.)

[0077] In aspects, the disclosure provides the kit of any one or more of aspects 37-40, wherein the kit is used in any one or more of the methods described in aspects 1 - 22 (ASPECT 41.)

[0078] In aspects, the disclosure provides a dermatologically suitable chromophoric composition, wherein the composition does not comprise any significant amount of vitamin C (ascorbic acid / L-ascorbic acid), vitamin E (tocopherol / alpha- tocopherol), vitamin Bl (thiamin / thiamine), vitamin B3 (niacin / nicotinic acid), vitamin B5 (pantothenic acid), vitamin B8 (inositol / adenosine monophosphate (AMP)), vitamin B9 (folic acid / folate), vitamin BIO (p- aminobenzoic acid), or any combination of any or all thereof. (ASPECT 42.)

[0079] In aspects, the disclosure provides a dermatologically suitable chromophoric composition, wherein the composition does not comprise any significant amount of any one or more salt(s) of amino acids, antioxidant compounds, lidocaine or other anaesthetizing agent(s), or any combination of any or all thereof. (ASPECT 43.)

[0080] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a suitable chromophoric component which is capable of withstanding traditional sterilization techniques, e.g., the chromophoric component is maintained at a level of at least about 80% of an initial value after application of traditional sterilization techniques, such as steam sterilization, filtration, microfiltration, gamma radiation, or a combination of any or all of such sterilization methods typically applied in the art. (ASPECT 44.)

[0081] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 31 and 42 - 44, wherein the structural component comprises (1) between about 85 wt.% (of the total structural component) and about 95 wt.% high molecular weight hyaluronic acid and between about 5 wt.% and about 15 wt.% low molecular weight hyaluronic acid, or (2) about 100 wt.% high molecular weight hyaluronic acid. (ASPECT 45.)

[0082] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 31 and 42 - 45, wherein the structural agent comprises a hyaluronic acid in an amount of between about 10 mg / mL and about 40 mg / mL (ASPECT 46.)

[0083] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 31 and 42 - 46, wherein the dermal / subdermal chromophoric component comprises a dermally chromophorically effective amount of one or more dermal / subdermal chromophoric agent(s), wherein the effective amount is between about 10 mg / mL and about 50 mg / mL. (ASPECT 47.)

[0084] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 23 - 31 and 42 - 47, wherein the chromophoric composition comprises effective amount(s) of one or more dermatologically suitable excipient component(s), each comprisingone or more dermatologically suitable agent(s), wherein the excipient component(s) can comprise one or more crosslinking component(s), anesthetic component(s), anti-allergic component(s), buffer component(s), pH adjusting component(s), carrier / lubricant component(s), or any combination thereof. (ASPECT 48.)

[0085] In aspects, the disclosure provides the chromophoric composition of aspect 48, wherein the dermatologically suitable chromophoric composition comprises an effective amount of a crosslinking component comprising one or more crosslinking agent(s), wherein the one or more crosslinking agent(s) comprise any one of 1, 4-butanediol diglycidyl ether (BDDE), divinyl sulphone, 2, poly ethylene glycol (PEG) 7, 8-diepoxyoctane (DEO), 1,2- bis(2,3- epoxypropoxy)ethylene, l-(2,3-epoxypropyl)-2, 3 -epoxy cyclohexane, or a combination of any or all thereof. (ASPECT 49.)

[0086] In aspects, the disclosure provides the chromophoric composition of aspect 49, wherein the crosslinking agent is 1, 4-butanediol diglycidyl ether (BDDE) or a cross linking agent providing at least substantially the same crosslinking capability according to compounds or molecules linked, at least substantially the same crosslinking capability according to the strength of linkage provided, at least substantially the same crosslinking capability according to the duration of linkage maintained, the size of the crosslinking agent, the molecular weight of the crosslinking agent, or combination(s) thereof. (ASPECT 50.)

[0087] hi aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising (1) an aesthetically effective amount of a dermatologically suitable chromophoric composition / componet comprising mean(s) for changing skin color, skin tone, or both (2) mean(s) for providing detectable or significant chromophoric extension capability (also referred to herein as structural support) to the means for changing skin color, tone or both, detectable or significant structural aesthetic effect to the skin, or both, and (3) mean(s) for maintaining a stable association between the skin color, tone, or both changing mean(s) and chromophoric extension / structural mean(s), wherein the composition, when administered to a subject, provides a skin color, tone, or color and tone changing effect for a skin color / tone change effect (chromophoric aesthetic effect) period, and a structural aesthetic effect for a structural aesthetic effect period, and wherein the skin color / tone change (chromophoric aesthetic effect) period persists for at least about 65%, such as, e.g., >~70%, >~75%, >~80%, >~85%, >~90%, >~95%, or, e.g., at least about 100% of the structural aesthetic effect period. (ASPECT 51.). This aspect and similar aspects can be alternatively characterized as a dermatologically suitable chromophoric composition comprising (1) an aesthetically effective amount of mean(s)for changing skin tone, (2) mean(s) for providing detectable or significant structural support to the means for changing skin tone, detectable or significant structural aesthetic effect to the skin, or both, and (3) mean(s) for maintaining a stable association between the skin color, tone, or both changing mean(s) and chromophoric extension / structural mean(s) (ASPECT 51 - alternative construction).

[0088] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for achieving a coterminous association between one or more dermal / subdermal chromophoric component(s), comprising one or more dermal / subdermal chromophoric agent(s), and one or more chromophoric extension (structural) component(s), comprising one or more structural agent(s), wherein when administered to a subject, e.g., a human patient, provides a chromophoric extension (structural) effect for a chromophoric extension (structural) aesthetic effect period and a skin color changing effect for a skin color change (chromophoric aesthetic) effect period, wherein the one or more dermal / subdermal chromophoric components / agents and the one or more chromophoric extension (structural) components / agents are degraded, resorbed, or degraded and reabsorbed by the body of the subject at a statistically similar rate. (ASPECT 52.)

[0089] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for achieving conjugation between the one or more dermal / subdermal chromophoric component(s), comprising one or more dermal / subdermal chromophoric agent(s), and one or more chromophoric extension (structural) component(s), comprising one or more chromophoric extension (structural) agent(s), wherein when administered to a subject, e.g., a human patient, provides a skin color changing effect for a skin color change (chromophoric aesthetic) effect period and a structural aesthetic effect for a structural aesthetic effect period, wherein the one or more dermal / subdermal chromophoric components / agents and the one or more structural components / agents are degraded and reabsorbed by the body of the subject at a statistically similar rate, or, e.g., provides a skin color changing effect for a skin color change effect period (chromophoric aesthetic effect period) and a structural aesthetic effect for a structural aesthetic effect period, wherein the skin color change period persists for at least about 65%, such as, e.g., >~70%, >~75%, >~80%, >~85%, >~90%, >~95%, or, e.g., at least about 100% of the structural aesthetic effect period, wherein the structural aesthetic effect period persists for at least 65%, such as, e.g., >~70%, >~75%, >~80%,>~85%, >~90%, >~95%, or, e.g., at least about 100% of the skin color change effect period (chromophoric aesthetic effect period), or both. (ASPECT 53.)

[0090] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for crosslinking one or more structural agent(s), e.g., hyaluronic acid. (ASPECT 54.)

[0091] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for achieving an anesthetic effect, means for a pain-relieving effect, or both, when administered to a recipient, e.g., a human patient (ASPECT 55.)

[0092] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric component / composition comprising means for achieving a buffer effect, means for optimizing the pH of the formulation making it suitable for administration into the human body, when administered to a recipient, e.g., a human patient, or both. (ASPECT 56.)

[0093] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for achieving a tonicity effect, e.g., means for optimizing the isotonicity of a product to reduce the pain of injection as appreciated by a statistically significant number of recipients, e.g., human patients. (ASPECT 57.)

[0094] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising means for achieving a preservative effect, including, e.g., means for reducing or eliminating microbial growth, means for detectably or significantly enhancing stability of composition(s), e.g., increasing the stability of the one or more non- structural dermal / subdermal (e.g., chromophoric) component(s) such as vitamin(s), increasing the stability of the one or more structural component(s), e.g., crosslinked hyaluronic acid, increasing the stability of chromophore-structural agent conjugate(s), or any combination of any or all thereof. (ASPECT 58.)

[0095] In aspects (and as noted elsewhere, uncontradicted), the disclosure provides the chromophoric composition of any one or more of aspects directed to chromophoric composition(s) described in this section, wherein a / the chromophoric extension (structural)component comprises a hyaluronic acid, the hyaluronic acid is crosslinked, and at least some, at least most, at least generally all, at least substantially all, or all of a / the dermal / subdermal chromophoric agent(s), e.g., dermal / subdermal chromophoric vitamins and / or dermal / subdermal chromophoric minerals are ionically bonded (bound) to a crosslinked hyaluronic acid. (ASPECT 59.)

[0096] In aspects (and as noted elsewhere, uncontradicted), the disclosure provides the chromophoric composition of any one or more of aspects directed to chromophoric composition(s) described in this section, wherein a / the chromophoric extension (structural) component comprises a hyaluronic acid, and at least some, at least most, at least generally all, at least substantially all, or all of a / the dermal / subdermal chromophoric agent(s), e.g., dermal / subdermal chromophoric vitamins and / or dermal / subdermal chromophoric minerals are present in a host-guest complex within the hyaluronic acid. (ASPECT 60.)

[0097] In aspects, the disclosure provides the chromophoric composition of any one or more of the aspects directed to chromophoric composition(s) described in this section, wherein the chromophoric extension (structural) component comprises a hyaluronic acid, the hyaluronic acid is crosslinked, and at least some, at least most, at least generally all, at least substantially all, or all of the dermal / subdermal chromophoric vitamins and / or dermal / subdermal chromophoric minerals are present in a host-guest complex with crosslinked hyaluronic acid. (ASPECT 61.)

[0098] hi aspects, the disclosure provides the method of producing an aesthetic change in the skin of a recipient of any one or more of aspects 1 -22, wherein an / the analysis to determine an / the amount of the one or more dermal / subdermal chromophoric agent(s) required to achieve a target skin color / tone is achieved by application of computer analysis, artificial intelligence, machine learning, deep learning, image recognition, image comparison, facial landmark recognition, automated image color analysis, or any combination thereof. (ASPECT 62.)

[0099] In aspects, the disclosure provides the method of producing an aesthetic change in the skin of a recipient of any one or more of aspects 1 -22, wherein the analysis to determine a / the amount of the composition(s) provided herein for injection in the dermis of a recipient, e.g., a human patient, to achieve a desired chromophoric effect, e.g., a color change, to the skin of the recipient is achieved by application of computer analysis, artificial intelligence, machine learning, deep learning, image recognition, image comparison, facial landmark recognition, automated image color analysis, or any combination thereof. (ASPECT 63.)

[0100] In aspects, the disclosure provides the method of producing an aesthetic change in the skin of a recipient of any one or more of aspects 1 -22, wherein the analysis to determine therequired amount of the composition(s) provided herein for injection in the dermis of a recipient, e.g., a human patient, to achieve a desired structural aesthetic change effect, e.g., modulation of the tissue, in a recipient is achieved by application of computer analysis, artificial intelligence, machine learning, deep learning, image recognition, image comparison, facial landmark recognition, automated image color analysis, or any combination thereof (ASPECT 64.)

[0101] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects -directed to chromophoric composition(s) in this section, wherein the one or more dermal / subdermal chromophoric agents does not comprise a synthetic organic coloring agent, e.g., a yellow colorant, e.g., Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 180 (CAS No. 77804-81-0), Pigment Yellow 183 (CAS No. 65212-77-3), Pigment Yellow 191 (CAS No. 129423-54-7), Pigment Yellow 3 (CAS No. 6486-23-3), Pigment Yellow 34 (CAS No. 1344-37-2), Pigment Yellow 42 (CAS No. 51274-00- 1), Pigment Yellow 65 (CAS No. 6528-34-3), Pigment Yellow 74 (CAS No. 6358-31-2), Pigment Yellow 75 (CAS No. 52320-66-8), Pigment Yellow 81 (CAS No. 22094-93-5), and Pigment Yellow 83 (CAS No. 5567-15-7). (ASPECT 65).

[0102] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects directed to chromophoric composition(s) in this section, wherein the one or more chromophoric extension (structural) component(s) does / do not comprise poly-L-lactic acid. (ASPECT 66).

[0103] In aspects, the disclosure provides a method of changing the skin color by injection of the dermatologically suitable chromophoric composition of any one or more of the aspects directed to chromophoric composition(s) described in this section, wherein a red hue or tone is imparted to the skin upon injection (ASPECT 67.)

[0104] In aspects, the disclosure provides a method of changing the skin color by injection of the dermatologically suitable chromophoric composition of any one or more of the aspects directed to chromophoric composition(s) described in this section, wherein a yellow hue or tone is imparted to the skin upon injection (ASPECT 68.)

[0105] In aspects, the disclosure provides a method to increase the longevity of the color changing effect of a chromophoric composition according to one or both of aspects 51 or 52, wherein the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide for the skin color change of the chromophoric component to persist for a period of time which is atleast about 65%, such as, e.g., >~70%, >~75%, >~80%, >~85%, >~90%, >~95%, or, e.g., at least about 100% of any aesthetic effect period of the structural component, any structural aesthetic effect to persist for a period of time which is at least about 65%, such as, e.g., >~70%, >~75%, >~80%, >~85%, >~90%, >~95%, or, e.g., at least about 100% of the chromophoric aesthetic effect period, or both. (ASPECT 69.)

[0106] In aspects, the disclosure provides a method of promoting the level of red coloration in one or more parts of the skin of a patient, the darkening of one or more parts of the skin of a patient, or both, such as, e.g., in the lips of a patient, comprising administering an effective amount of a dermatologically suitable red chromophoric agent to the dermis or subdermis of a patient, in aspects where the red chromophoric agent is a reddish skin tonepromoting vitamin, e.g., a cobalamin or, e.g., cyanocobalamin compound, a mineral, or both, and the effective amount is an amount effective to cause a detectable or significant enhancement in the redness, darkness, or both of the skin of the subject, and the skin color changing effect optionally persists for a period of at least about 1 day, >~>~2 days, >~3 days, >~1 week, >~2 weeks, >~1 month, >~3 months, or longer. (ASPECT 70.)

[0107] In aspects, the disclosure provides a method of any one or more of aspects 1 - 22 and 67-69 and uncontradicted any other aspects directed to method(s) described in this section, wherein the skin color change can be appreciated by a statistically significant number of licensed healthcare professionals, or, e.g., can be measured by one or more additional means of quantifying skin color change in a recipient after injection of composition(s) provided for herein such as, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeters), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color. (ASPECT 71.)

[0108] In aspects, the disclosure provides the method of any one or more of aspects 1 - 22, 67 - 69, and 71 and uncontradicted any other aspects directed to method(s) described in this section, wherein the skin color change comprises a red or yellow color change to the skin, wherein the color change can be appreciated by a statistically significant number of licensed healthcare professionals, or, e.g., can be measured by one or more additional means of quantifying skin color change in a recipient after injection of composition(s) provided for herein such as, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeters), ultraviolet light examination, polarized light examination, in vivo confocalscanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color. (ASPECT 72.)

[0109] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a reddening color change to the skin, wherein the resulting, e.g., after injection of composition(s), red color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 2.5R to about 5R, such as, e.g., about 3. OR to about 5R, about 3.5R to about 5R, about 4R to about 5R, about 4.5R to about 5R, or, e.g., the Munsell System hue is in a range of about 2.5R to about 4.5R, or, e.g., about 2.5R to about 4R, about 2.5R to about 3.5R, or, e.g., about 2.5R to about 3R. (ASPECT 73.)

[0110] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a reddening color change to the skin, wherein the resulting, e.g., after injection of composition(s), red color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 5.5R to about 10R, such as, e.g., about 6R to about 10R, about 6.5R to about 10R, about 7R to about 10R, about 7.5R to about 10R, about 8R to about 10R, about 8.5R to about 10R, about 9R to about 10R, about 9.5R to about 10R, or, e.g., the Munsell System hue is in a range of about 5.5R to about 9.5R, or, e.g., about 5.5R to about 9R, about 5.5R to about 8.5R, about 5.5R to about 8R, about 5.5R to about 7.5R, about 5.5R to about 7R, about 5.5R to about 6.5R, or, e.g., about 5.5R to about 6R. (ASPECT 74.)

[0111] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a reddening color change to the skin, wherein the resulting, e.g., after injection of composition(s), red color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 6.5R to about 8R, such as, e.g., about 7R to about 8R, about 7.5R to about 8R, or, e.g., the Munsell System hue is in a range of about 6.5R to about 7.5R, or, e.g., about 6.5R to about 7R. (ASPECT 75.)

[0112] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a reddening color change to the skin, wherein the resulting, e.g., after injection of composition(s), red color change to the skin is measured using the Munsell System, further wherein the Munsell System value is in a range of about 2 to about 9, such as, e.g., about 3 to about 9, about 4 to about 9, about 5 to about 9, about 6 to about 9, about 7 to about 9, about 8 to about 9, or, e.g., about 2 to about 8, about 2to about 7, about 2 to about 6, about 2 to about 5, about 2 to about 4, or, e.g., about 2 to about 3. (ASPECT 76.)

[0113] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a reddening color change to the skin, wherein the resulting, e.g., after injection of composition(s), red color change to the skin is measured using the Munsell System, further wherein chroma is in a range of about 2 to about 16, such as, e.g., about 3 to about 16, about 4 to about 16, about 5 to about 16, about 6 to about 16, about 7 to about 16, about 8 to about 16, about 9 to about 16, about 10 to about 16, about 11 to about 16, about 12 to about 16, about 13 to about 16, about 14 to about 16, about 15 to about 16, or, e.g., the Munsell System chroma is in a range of about 2 to about 15, such as, e.g., about 2 to about 14, about 2 to about 13, about 2 to about 12, about 2 to about 11, about 2 to about 10, about 2 to about 9, about 2 to about 8, about 2 to about 7, about 2 to about 6, about 2 to about 5, about 2 to about 4, or, e.g., about 2 to about 3. (ASPECT 77.)

[0114] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a yellowing color change to the skin, wherein the resulting, e.g., after injection of composition(s), yellow color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 2.5Y to about 5Y, such as, e.g., about 3.0Y to about 5Y, about 3.5Y to about 5Y, about 4Y to about 5Y, about 4.5 Y to about 5Y, or, e.g., the Munsell System hue is in a range of about 2.5Y to about 4.5Y, or, e.g., about 2.5Y to about 4Y, about 2.5Y to about 3.5Y, or, e.g., about 2.5Y to about 3Y. (ASPECT 78.)

[0115] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a yellowing color change to the skin, wherein the resulting, e.g., after injection of composition(s), yellow color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 5.5Y to about 10Y, such as, e.g., about 6Y to about 10Y, about 6.5Y to about 10Y, about 7Y to about 10Y, about 7.5Y to about 10Y, about 8Y to about 10Y, about 8.5Y to about 10Y, about 9Y to about 10Y, about 9.5Y to about 10Y, or, e.g., the Munsell System hue is in a range of about 5.5Y to about 9.5Y, or, e.g., about 5.5Y to about 9Y, about 5.5Y to about 8.5Y, about 5.5Y to about 8Y, about 5.5Y to about 7.5Y, about 5.5Y to about 7Y, about 5.5Y to about 6.5Y, or, e.g., about 5.5Y to about 6Y (ASPECT 79.)

[0116] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the skin color change is a yellowing color changeto the skin, wherein the resulting, e.g., after injection of composition(s), yellow color change to the skin is measured using the Munsell System, further wherein the Munsell System hue is in a range of about 6.5Y to about 8Y, such as, e.g., about 7Y to about 8Y, about 7.5Y to about 8Y, or, e.g., the Munsell System hue is in a range of about 6.5Y to about 7.5Y, or, e.g., about 6.5Y to about 7Y. (ASPECT 80.)

[0117] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the method of creating a skin color change in the skin tone of a recipient (e.g., a human subject) having an initial Munsell System hue range of about 5Y to about 10Y would induce a change in hue in a range of about 2% to 50%, such as, e.g., about 4% to about 50%, about 6% to 50%, about 8% to 50%, about 10% to about 50%, about 15% to about 50%, about 20% to about 50%, about 25% to about 50%, about 30% to about 50%, about 35% to about 50%, about 40% to about 50%, about 45% to about 50%, or, e.g., about 2% to about 45% from the initial Munsell System hue, such as, e.g., about 2% to about 40%, about 2% to about 35%, about 2% to about 30%, about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 2% to about 8%, about 2% to about 6%, or, e.g., about 2% to about 4% from the initial Munsell System hue. (ASPECT 81.)

[0118] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the method of creating a skin color change in the skin tone of a recipient (e.g., a human subject) having an initial Munsell System hue range of about 2.5Y to about 9.5 Y would induce a change in hue in a range of about 2% to 35%, such as, e.g., about 4% to about 35%, about 6% to 35%, about 8% to 35%, about 10% to about 35%, about 15% to about 35%, about 20% to about 35%, about 25% to about 35%, about 30% to about 35%, or, e.g., about 2% to about 30% from the initial Munsell System hue, such as, e.g., about 2% to about 30%, about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 2% to about 8%, about 2% to about 6%, or, e.g., about 2% to about 4% from the initial Munsell System hue. (ASPECT 82.)

[0119] In aspects, the disclosure provides the method of any one or more of the aspects directed to method(s) in this section, wherein the method of creating a skin color change in the skin tone of a recipient (e.g., a human subject) having an initial Munsell System hue range of about 4Y to about 9Y, would induce a change in hue in a range of about 2% to 45%, such as, e.g., about 4% to about 45%, about 6% to 45%, about 8% to 45%, about 10% to about 45%, about 15% to about 45%, about 20% to about 45%, about 25% to about 45%, about 30% to about 45%, about 35% to about 45%, about 35% to about 45%, or, e.g., about 2% to about 40% fromthe initial Munsell System hue, such as, e.g., about 2% to about 35%, about 2% to about 30%, about 2% to about 25%, about 2% to about 20%, about 2% to about 15%, about 2% to about 10%, about 2% to about 8%, about 2% to about 6%, or, e.g., about 2% to about 4% from the initial Munsell System hue. (ASPECT 83.)

[0120] In aspects, the disclosure provides a method comprising analyzing a patient’s skin, determining a desired degree of skin coloration change (e.g., using one or more Munsell System values), and administering an amount of a composition of any one or more of the composition aspect(s) described in this section to the patient one or more times to change the skin of the patient to the desired degree. (ASPECT 84.)

[0121] In aspects, the disclosure provides an automated system for assessing skin color and proposing an intervention to achieve a change in skin color, the system comprising one, some, or all of image capture technology, image analysis technology, data analysis technology, landmark recognition technology, color analysis technology, artificial intelligence technology, machine learning technology, deep learning technology, image comparison technology, and data storage and retrieval technology. (ASPECT 85.)

[0122] In aspects, the disclosure provides the automated system of aspect 85, wherein the automated system comprises instructions for analyzing the amount of one or more composition(s) of the invention to administer to a subject based on the subject’s initial skin color. (ASPECT 86).

[0123] In aspects, the disclosure provides the automated system of one or both of aspect 85 and aspect 86, wherein the automated system is coupled with a sensor that can measure skin coloration of a subject. (ASPECT 87.)

[0124] In aspects, the disclosure provides the automated system of one or more of aspects 85 - 87, wherein the automated system generate(s) one or more interventions to a system user required to achieve one or more target aesthetic effect(s), such as a target chromophoric aesthetic effect, wherein, in aspects, the proposed intervention(s) are optionally accompanied by preview(s) of the anticipated result(s) of the proposed intervention(s) in the formed of morphed image(s). (ASPECT 88.)

[0125] In aspects, the disclosure provides a method of producing a chromophoric aesthetic effect in the skin of a recipient comprising administering to at least a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agentsand (2) a second effective amount of a chromophoric extension component (also referred to herein as a “structural” component) comprising one or more chromophoric extension (structural) agents, wherein the one or more chromophoric agents and the one or more chromophoric extension (structural) agents are in a sufficiently stable association with one another, and further wherein (a) the one or more dermal / subdermal chromophoric agents of the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color, and (b) the period of time after administration of the chromophoric composition wherein there is a detectable effect of the one or more chromophoric agents of the chromophoric component establishes a chromophoric aesthetic effect period which lasts at least about 3 months. (ASPECT 89.)

[0126] In aspects, the disclosure provides a method of producing a darkening, a reddening, or both a darkening and reddening aesthetic effect in the skin of a recipient comprising administering to at least a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents capable of providing a darkening or reddening effect to the skin, wherein the effective amount is an amount sufficient to produce a detectable darkening, reddening, or darkening and reddening of skin color upon an effective number of administrations within an effective time period, and (2) a second effective amount of a chromophoric extension (structural) component comprising one or more chromophoric extension (structural) agents, wherein (a) the one or more chromophoric agents and the one or more chromophoric extension (structural) agents are in a sufficiently stable association with one another such that the chromophoric extension (structural) agent(s) detectably or significantly extend(s) the darkening, reddening, or both darkening and reddening effect of the chromophoric agent(s) compared to such agents provided an unassociated with one or more structural agents, and (b) the period of time after administration of the chromophoric composition wherein there is a detectable effect of the one or more chromophoric agents of the chromophoric component establishes a chromophoric aesthetic effect period, and further wherein the administration of the dermatologically suitable chromophoric composition provides (c) a chromophoric aesthetic effect which lasts at least about 3 months. (ASPECT 90.)

[0127] In aspects, the disclosure provides the method of one or both of aspect 89 and aspect 90, wherein one or more chromophoric extension (structural) agents of the chromophoric extension (structural) component further provides a detectable or significant structural aestheticeffect to the skin such that performance of the method results in both a detectable or significant color change in the skin and a structural aesthetic effect each lasting at least about 3 months. (ASPECT 91.)

[0128] In aspects the disclosure provides the method of any one or more of aspects 89 -91, wherein the method further comprises any one or more of the characteristics described in any one or more of the aspect(s) directed to method(s) described in this section. (ASPECT 92.)

[0129] In aspects, the disclosure provides the method of any one or more of aspects 89 -92, wherein the method comprises use of any one or more of the compositions described in any of the aspects directed to compositions in this section. (ASPECT 93.)

[0130] In aspects, the disclosure provides the method of any one or more of aspects 89 -93, wherein the method comprises use of any one or more of the kits described in any of the aspects directed to kits in this section. (ASPECT 94.)

[0131] In aspects, the disclosure provides a dermatologically suitable chromophoric composition comprising an aesthetically effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents and an effective amount of a chromophoric extension component (structural component) that comprises one or more chromophoric extension (structural) agent(s) wherein (1) the one or more dermal / subdermal chromophoric agent(s) in the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color and (2) the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide for the skin color / tone change, e.g., but not limited to, a darkening, reddening, or darkening and reddening of the skin, of the chromophoric component to persist for a period of at least about 3 months. (ASPECT 95.)

[0132] In aspects, the disclosure provides the chromophoric composition of aspect 95, wherein the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide for the skin color change, e.g., but not limited to, a darkening, reddening, or darkening and reddening of the skin, of the chromophoric component to persist for a period of at least about 6 months. (ASPECT 96.)

[0133] In aspects, the disclosure provides the chromophoric composition of aspect 96, wherein the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide forthe skin color change, e.g., but not limited to, a darkening, reddening, or darkening and reddening of the skin, of the chromophoric component to persist for a period of at least about 9 months. (ASPECT 97.)

[0134] In aspects, the disclosure provides the chromophoric composition of aspect 97, wherein the chromophoric extension (structural) component and the dermal / subdermal chromophoric component are in a sufficiently stable association with one another to provide for the skin color change, e.g., but not limited to, a darkening, reddening, or darkening and reddening of the skin, of the chromophoric component to persist for a period of at least about 12 months. (ASPECT 98.)

[0135] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 95 - 98, wherein the presence of the chromophoric extension (structural) component allows for a darkening, reddening, or darkening or reddening of the skin upon administration of the composition to persist for a period of time which is detectably or significantly longer than the period of time such a color change persists upon the administration of a similar composition comprising the same chromophoric agent(s) without the chromophoric agent and the chromophoric extension (structural) agent being in a sufficiently stable association with one another. (ASPECT 99.)

[0136] In aspects, the disclosure provides the chromophoric composition of aspect 99, wherein the sufficiently stable association is established by the presence of a covalent bond between the chromophoric agent(s) and the chromophoric extension (structural) agent(s). (ASPECT 100.)

[0137] In aspects, the disclosure provides the chromophoric composition of one or both of aspect 99 and aspect 100, wherein the chromophoric agent is a vitamin and the chromophoric extension (structural) agent is hyaluronic acid. (ASPECT 101.)

[0138] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 95 - 101, wherein the composition is used in any one or more of the method(s) described in aspect(s) directed to method(s) described in this section. (ASPECT 102.)

[0139] In aspects, the disclosure provides the chromophoric composition of any one or more of aspects 95 - 101, wherein the composition is present in a kit described in any one or more of the kit(s) described in aspect(s) directed to kit(s) described in this section. (ASPECT 103.)

[0140] According to still further aspects, the disclosure provides a method of producing an aesthetic change in one or more areas of skin of a recipient comprising administering to atleast a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents, and (2) a second effective amount of a chromophoric extension component that comprises one or more chromophoric extension agents, wherein (a) the period of time after administration wherein there is a detectable structural skin effect of the at least one chromophoric extension agent establishes a structural aesthetic effect period; (b) the one or more dermal / subdermal chromophoric agents in the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color of the recipient; (c) at least most of the least one chromophoric extension agent and the dermal / subdermal chromophoric agent in the composition are initially in a stable association and remain in a stable association when administered to the recipient for a period of at least about 6 months; and (d) the skin color change in the recipient is detectable for a period that is at least about 65% as long as the structural aesthetic effect period. (ASPECT 104.)

[0141] In aspects, the disclosure provides the method of aspect 104, wherein the stable association comprises one or more covalent bonds between one or more of the chromophoric extension agents and one or more of the dermal / subdermal chromophoric agents. (ASPECT105,)

[0142] hi aspects, the disclosure provides the method of aspect 105, wherein most of the dermal / subdermal chromophoric agents in the composition are covalently bound to one or more chromophoric extension agents. (ASPECT 106.)

[0143] In aspects, the disclosure provides the method of any one or more of aspects 104-106, wherein at least most of the chromophoric extension agents in the composition are composed of one or more crosslinked hyaluronic acid molecules. (ASPECT 107.)

[0144] In aspects, the disclosure provides the method of any one or more of aspects 104-107, wherein at least one of the one or more dermal / subdermal chromophoric agents consist of a dermal / subdermal chromophoric vitamin. (ASPECT 108.)

[0145] In aspects, the disclosure provides the method of aspect 108, wherein the one or more dermal / subdermal chromophoric vitamins comprise an effective amount of riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, or a complex or combination thereof. (ASPECT 109.)

[0146] In aspects, the disclosure provides the method of any one or more of aspects 104- 109, wherein the one or more chromophoric agents comprise an effective amount of one or moredermal / subdermal chromophoric vitamins, wherein the one or more dermal / subdermal chromophoric vitamins comprises an A vitamin or one or more A vitamin derivative compounds. (ASPECT 110.)

[0147] In aspects, the disclosure provides the method of aspect 110, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of beta carotene. (ASPECT 111.)

[0148] In aspects, the disclosure provides the method of any one or more of aspects 104- 111, wherein the one or more dermal / subdermal chromophoric agents comprise an effective amount of at least one chromophoric B vitamin derivative. (ASPECT 112.)

[0149] In aspects, the disclosure provides the method of aspect 112, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of niacin. (ASPECT 113.)

[0150] In aspects, the disclosure provides the method of any one or more of aspects 104-113, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of urobilin. (ASPECT 114.)

[0151] In aspects, the disclosure provides the method of any one or more of aspects 104-114, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of one or more dermal / subdermal chromophoric minerals. (ASPECT 115.)

[0152] In aspects, the disclosure provides the method of aspect 115, wherein the one or more dermal / subdermal chromophoric minerals comprise an effective amount of zinc oxide, iron oxide, cadmium oxide, or a combination of some or all thereof. (ASPECT 116.)

[0153] In aspects, the disclosure provides the method of any one or more of aspects 104-116, wherein the concentration of the one or more dermal / subdermal chromophoric agents to the one or more chromophoric extension agents in the composition is about 2.5:1 to about 5.5: 1. (ASPECT 117.)

[0154] In aspects, the disclosure provides the method of any one or more of aspects 104-117, wherein the concentration of the chromophoric extension component in the composition is about 1.5% and 3% and the concentration of the dermal / subdermal chromophoric component is about 3% to about 15%. (ASPECT 118.)

[0155] In aspects, the disclosure provides the method of any one or more of aspects 104-118, wherein the concentration of the chromophoric extension component in the composition is about 1.75% to 2.75% and the concentration of the dermal / subdermal chromophoric component is about 4.2% to about 20.6%. (ASPECT 119.)

[0156] In aspects, the disclosure provides the method of any one or more of aspects 104- 119, wherein the ratio of dermal / subdermal chromophoric agents (molecules thereof) in the composition to the number of chromophoric extension agents (molecules thereof) in the composition is at least about 10:1. (ASPECT 120.)

[0157] In aspects, the disclosure provides the method of aspect 120, wherein the ratio of dermal / subdermal chromophoric agents (molecules thereof) in the composition to the number of chromophoric extension agents (molecules thereof) in the composition is at least about 100: 1. (ASPECT 121.)

[0158] The method of aspect 121, wherein the ratio of dermal / subdermal chromophoric agents (molecules thereof) in the composition to the number of chromophoric extension agents (molecules thereof) in the composition is at least about 1000: 1. (ASPECT 122.)

[0159] The method of any one or more of aspects 104-122, wherein the composition comprises an effective amount of dermal / subdermal chromophoric vitamins, dermal / subdermal chromophoric minerals, or both, conjugated to one or more chromophoric extension agents, wherein the chromophoric vitamins, chromophoric minerals, or both, exhibit a wavelength of (1) about 570 nm to about 590 nm, (2) about 595 nm to about 620 nm, or (3) both (1) and (2), or, e.g., between (4) about 620 nm and about 750 nm, (5) about 755 nm and about 780 nm, or (6) both (4) and (5) when subjected to spectrophotometric analysis. (ASPECT 123.)

[0160] The method of any one or more of aspects 104-123, wherein performing the method modulates the color of the skin of the recipient such that the wavelength of light reflected from the skin is detectably or significantly more like one or more of (1) about 570 nm to about 590 nm, (2) about 595 nm to about 620 nm, or (3) both (1) and (2), or, e.g., between (4) about 620 nm and about 750 nm, (5) about 755 nm and about 780 nm, or (6) both (4) and (5) when subjected to light reflection wavelength analysis than the color of the skin of the recipient with the treatment. (ASPECT 124.)

[0161] In aspects, the disclosure provides the method of any one or more of aspects 104- 124, wherein the recipient has an initial Munsell System hue range of about 5Y to about 10Y and performance of the method results in a change in hue of the recipient’s skin in a range of about 2% to 50% in the recipient. (ASPECT 125.)

[0162] In aspects, the disclosure provides the method of aspect 125, wherein performing the method results in a change in hue of the recipient’s skin of about 15% to about 50%. (ASPECT 126.)

[0163] In aspects, the disclosure provides the method of any one or more of aspects 104-126, wherein the composition does not comprise any significant amount of C vitamin, E vitamin, thiamine, niacin, pantothenic acid, inositol, folic acid (folate), p-aminobenzoic acid (PABA), or any combination of any or all thereof. (ASPECT 127.)

[0164] In aspects, the disclosure provides the method of any one or more of aspects 104-127, wherein the composition is free of any one or more of Pigment Yellow 17 (CAS No. 4531- 49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 180 (CAS No. 77804-81-0), Pigment Yellow 183 (CAS No. 65212-77-3), Pigment Yellow 191 (CAS No. 129423-54-7), Pigment Yellow 3 (CAS No. 6486-23-3), Pigment Yellow 34 (CAS No. 1344-37-2), Pigment Yellow 42 (CAS No. 51274-00-1), Pigment Yellow 65 (CAS No. 6528-34-3), Pigment Yellow 74 (CAS No. 6358-31-2), Pigment Yellow 75 (CAS No. 52320-66-8), Pigment Yellow 81 (CAS No. 22094-93-5), and Pigment Yellow 83 (CAS No. 5567-15-7). (ASPECT 128.)

[0165] In aspects, the disclosure provides the method of any one or more of aspects 104-128, wherein the amount of one or more dermal / subdermal chromophoric agents in the composition is between about 10 mg / mL and about 50 mg / mL. (ASPECT 129.)

[0166] In aspects, the disclosure provides the method of any one or more of aspects 104-129, wherein the method comprises administering an effective amount of the composition an effective number of times to the lower lip of the recipient, the upper lip of the recipient, or both. (ASPECT 130.)

[0167] In aspects, the disclosure provides the method of any one or more of aspects 104-130, wherein the method comprises administering an effective amount of the composition an effective number of times to the area of the skin surrounding the orbit, an area including the orbit, or both. (ASPECT 131.)

[0168] In aspects, the disclosure provides a dermatologically suitable composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising an effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agent(s) and an effective amount of a chromophoric extension component that comprises one or more chromophoric extension agent(s) wherein (1) the one or more dermal / subdermal chromophoric agent(s) in the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color and (2) the chromophoric extension component and the dermal / subdermal chromophoric component are in a sufficientlystable association with one another to provide for the skin color change of the chromophoric component to persist for a period of time which is at least about 65%, such as, e.g., at least about 70%, or, e.g., at least about 75% of any aesthetic effect period attributable to the chromophoric extension component. (ASPECT 132.)

[0169] In aspects, the disclosure provides the composition of aspect 132, wherein the stable association comprises one or more covalent bonds between one or more of the chromophoric extension agents and one or more of the dermal / subdermal chromophoric agents. (ASPECT 133.)

[0170] In aspects, the disclosure provides the composition of aspect 133, wherein most of the dermal / subdermal chromophoric agents in the composition are covalently bound to one or more structural agents. (ASPECT 134.)

[0171] In aspects, the disclosure provides the composition of any one or more of aspects 132-134, wherein at least most of the chromophoric extension agents in the composition are composed of one or more crosslinked hyaluronic acid molecules. (ASPECT 135.)

[0172] In aspects, the disclosure provides the composition of any one or more of aspects 132-135, wherein at least one of the one or more dermal / subdermal chromophoric agents consist of a dermal / subdermal chromophoric vitamin. (ASPECT 136.)

[0173] In aspects, the disclosure provides the composition of aspect 136, wherein the one or more dermal / subdermal chromophoric vitamins comprise an effective amount of riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, or a complex or combination thereof. (ASPECT 137.)

[0174] In aspects, the disclosure provides the composition of any one or more of aspects 132-137, wherein the one or more chromophoric agents comprise an effective amount of one or more dermal / subdermal chromophoric vitamins, wherein the one or more dermal / subdermal chromophoric vitamins comprises vitamin A or one or more vitamin A derivative compounds. (ASPECT 138.)

[0175] In aspects, the disclosure provides the composition of aspect 138, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of beta carotene. (ASPECT 139.)

[0176] In aspects, the disclosure provides the composition of any one or more of aspects 132-139, wherein the one or more dermal / subdermal chromophoric agents comprise an effective amount of at least one chromophoric B vitamin derivative. (ASPECT 140.)

[0177] In aspects, the disclosure provides the composition of aspect 140, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of niacin. (ASPECT 141.)

[0178] In aspects, the disclosure provides the composition of any one or more of aspects 132-141, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of urobilin. (ASPECT 142.)

[0179] In aspects, the disclosure provides the composition of any one or more of aspects 132-142, wherein the at least one or more dermal / subdermal chromophoric agents comprises an effective amount of one or more dermal / subdermal chromophoric minerals. (ASPECT 143.)

[0180] In aspects, the disclosure provides the composition of aspect 143, wherein the one or more dermal / subdermal chromophoric minerals comprise an effective amount of zinc oxide, iron oxide, cadmium oxide, or a combination of some or all thereof. (ASPECT 144.)

[0181] In aspects, the disclosure provides the composition of any one or more of aspects 132-144, wherein the concentration of the one or more dermal / subdermal chromophoric agents to the one or more chromophoric extension agents in the composition is about 2.5: 1 to about 5.5: 1. (ASPECT 145.)

[0182] In aspects, the disclosure provides the composition of any one or more of aspects 132-145, wherein the concentration of the chromophoric extension component in the composition is about 1.5% and 3% and the concentration of the dermal / subdermal chromophoric component is about 3% to about 15%. (ASPECT 146.)

[0183] In aspects, the disclosure provides the composition of any one or more of aspects 132-145, wherein the concentration of the chromophoric extension component in the composition is about 1.75% to 2.75% and the concentration of the dermal / subdermal chromophoric component is about 4.2% to about 20.6%. (ASPECT 147.)

[0184] In aspects, the disclosure provides the composition of any one or more of aspects 132-147, wherein the ratio of dermal / subdermal chromophoric agents (e.g., on a molecular basis or molecule number / molecule number basis) in the composition to the number of structural agents (e.g., molecules thereof) in the composition is at least about 10:1. (ASPECT 148.)

[0185] In aspects, the disclosure provides the composition of aspect 148, wherein the ratio of dermal / subdermal chromophoric agents (e.g., molecules thereof / on a molecular basis) in the composition to the number of structural agents (e.g., molecules thereof / on a molecular basis) in the composition is at least about 100:1. (ASPECT 149.)

[0186] In aspects, the disclosure provides the composition of aspect 149, wherein the ratio of dermal / subdermal chromophoric agents in the composition to the number of structural agents in the composition is at least about 1000: 1. (ASPECT 150.)

[0187] In aspects, the disclosure provides the composition of any one or more of aspects 132-150, wherein the composition comprises an effective amount of dermal / subdermal chromophoric vitamins, dermal / subdermal chromophoric minerals, or both, conjugated to one or more chromophoric extension agents, wherein the chromophoric vitamins, chromophoric minerals, or both, exhibit a wavelength of (1) about 570 nm to about 590 nm, (2) about 595 nm to about 620 nm, or (3) both (1) and (2), or, e.g., between (4) about 620 nm and about 750 nm, (5) about 755 nm and about 780 nm, or (6) both (4) and (5) when subjected to spectrophotometric analysis. (ASPECT 151.)

[0188] In aspects, the disclosure provides the composition of any one or more of aspects 132-151, wherein injection of the composition in the skin of a mammalian recipient modulates the color of the skin of the recipient such that the wavelength of light reflected from the skin is detectably or significantly more like one or more of (1) about 570 nm to about 590 nm, (2) about 595 nm to about 620 nm, or (3) both (1) and (2), or, e.g., between (4) about 620 nm and about 750 nm, (5) about 755 nm and about 780 nm, or (6) both (4) and (5) when subjected to light reflection wavelength analysis than the color of the skin of the recipient with the treatment. (ASPECT 152.)

[0189] In aspects, the disclosure provides the composition of any one or more of aspects 132-152, wherein the recipient has an initial Munsell System hue range of about 5Y to about 10Y and performance of the method results in a change in hue of the recipient’s skin in a range of about 2% to 50% in the recipient. (ASPECT 153.)

[0190] In aspects, the disclosure provides the composition of aspect 153, wherein performing the method results in a change in hue of the recipient’s skin of about 15% to about 50%. (ASPECT 154.)

[0191] In aspects, the disclosure provides the composition of any one or more of aspects 132-154, wherein the composition does not comprise any significant amount of C vitamin, E vitamin E, thiamine, niacin, pantothenic acid, inositol, folic acid (folate), p-aminobenzoic acid (PABA), or any combination of any or all thereof. (ASPECT 155.)

[0192] In aspects, the disclosure provides the composition of any one or more of aspects 132-155, wherein the composition is free of any one or more of Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 174 (CAS No. 78952-72-4), Pigment Yellow 180 (CAS No. 77804-81-0), Pigment Yellow 183 (CAS No. 65212-77-3), Pigment Yellow 191 (CAS No. 129423-54-7), Pigment Yellow 3 (CAS No. 6486-23-3), Pigment Yellow 34 (CAS No. 1344-37-2), Pigment Yellow 42 (CAS No. 51274-00-1), Pigment Yellow 65 (CAS No. 6528-34-3), Pigment Yellow 74 (CAS No. 6358-31-2), Pigment Yellow 75 (CAS No. 52320-66-8), Pigment Yellow 81 (CAS No. 22094-93-5), and Pigment Yellow 83 (CAS No. 5567-15-7). (ASPECT 156.)

[0193] In aspects, the disclosure provides the composition of any one or more of aspects 132-156, wherein the amount of one or more dermal / subdermal chromophoric agents in the composition is between about 10 mg / mL and about 50 mg / mL. (ASPECT 157.)

[0194] In aspects, the disclosure provides the composition of any one or more of aspects 132-157, wherein the composition is suitable for injection into the lower lip of the recipient, the upper lip of the recipient, or both. (ASPECT 158.)

[0195] In aspects, the disclosure provides the composition of any one or more of aspects 132-158, wherein the composition is suitable for injection into the area of the skin surrounding the orbit, an area including the orbit, or both. (ASPECT 159.)

[0196] In aspects, the disclosure provides a dermatologically suitable composition comprising an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising an effective amount of a chromophoric extension component that comprises (1) a means for skin coloration change, and (2) a means for stabilizing one or more compounds, a means for structural skin change, or both, wherein the means for stabilizing one or more compounds, the means for structural skin change, or both and the means for skin coloration change are associated by stable association means, and wherein any structural skin aesthetic effect of the means for stabilizing one or more compound(s), means for structural skin change, or both persists for a period of at least about 6 months and the effect of the skin color change associated with the skin color changing means persists for a period of time which is at least about 65%, as long as such period. (ASPECT 160.)

[0197] In aspects, the disclosure provides a dermatologically suitable composition described in any aspect(s) directed to composition(s) in this section, wherein the composition does not detectably or significantly reduce a Tyndall effect. (ASPECT 161.)

[0198] In aspects, the disclosure provides a dermatologically suitable composition described in any aspect(s) directed to composition(s) in this section, wherein the composition provides a skin coloration change lasting at least about 3 months but does not provide a skincoloration change lasting longer than about 2 years, such as longer than about 2.5 years or longer than about 3 years. (ASPECT 162.)DETAILED DESCRIPTION OF THE INVENTION

[0199] For convenience, both combinations of elements / steps and individual elements / steps related to compositions, methods, and other embodiments of the invention are described in this section of this disclosure. Readers should understand that despite the inclusion of passages focused on specific elements / steps, any aspect, facet, embodiment, or other description of particular step(s) or element(s) can be applied to any general description of composition(s) / methods(s) of the invention, or any other recited element(s) / step(s) thereof, which are provided in any part of this disclosure.COMPOSITIONS

[0200] The invention described herein provides, i.a., dermatologically suitable chromophoric composition(s) that can be used for, i.a., modifying the appearance of the skin of subjects for extended period(s) of time, e.g., providing long-term but non-permanent skin coloration effect(s).

[0201] “Dermatologically suitable,” uncontradicted, and similar terms, are used to refer to a composition, agent, method, or step, as applicable, that is generally safe and effective for its intended purpose(s). Generally, uncontradicted, safe agent(s) and method(s) are associated with a likelihood of adverse event(s) / effect(s) that is sufficiently low such that administration of the agent / composition to a recipient, e.g., a human patient, or performance of the method / step would be deemed acceptable to major healthcare product regulatory authorities, e.g., US FDA, EMA, etc. General efficacy means, uncontradicted, causing or promoting intended effect(s) in subjects, e.g., human patients, either at an individual level or a population level (e.g., a statistically significant number of subjects in a sufficiently powered, adequate and well controlled study, as such studies are understood in the art and described elsewhere herein). Uncontradicted, compositions, elements / agents, ingredients, components, and the like, described herein, are dermatologically suitable when used in suitable amounts and numbers of applications. Efficacy can, in aspects, contemplate causing or promoting intended effect(s) upon administration a suitable number of times, which can, e.g., be a single administration or a number of administrations, causing or promoting intended effect(s) over a suitable period of administration, or both.

[0202] In aspects, dermatologically suitable chromophoric composition(s) described herein can demonstrate a detectable or significant skin color change effect, a structural skin aesthetic effect, or both, upon administration to a recipient, such as a mammalian recipient, such as, e.g., a human. In aspects, as is described further elsewhere herein, composition(s) are administered to a target area of a recipient, e.g., a target area of skin of a recipient, so as to impart a detectable or significant skin color change effect (chromophoric aesthetic effect), structural skin aesthetic effect, or both.

[0203] In certain aspects, an advantage of composition(s) described herein is that they are capable of delivering a detectable or significant chromophoric aesthetic effect for an extended period of time (e.g., at least about 3 months, >~ 6 months, or >~ 12 months or more) due to the presence of a stable association between chromophoric agent(s) of the composition(s) and chromophoric extension agent(s) of the composition(s) (e.g., as compared to the period of time a chromophoric aesthetic effect of such chromophoric agent(s) lasts when provided without such a stable association with chromophoric extension agent(s) present, when such chromophoric agent(s) are provided in different amount(s), when the relative amount(s) of such chromophoric agent(s) and such chromophoric extension agent(s) are different from that described herein, or any combination thereof.

[0204] In certain aspects, chromophoric extension agent(s), e.g., belonging to a chromophoric extension component, detectably or significantly stabilize(s) chromophoric agent(s) and thus may be referenced herein as structural agent(s) (e.g., structural agent(s) belonging to a structural component(s). In aspects, chromophoric extension component(s), chromophoric extension agent(s), or both, detectably or significantly extend the chromophoric effect(s) of chromophoric component(s), chromophoric agent(s), or both. In aspect, chromophoric extension component(s) further provide structural skin aesthetic effect(s), such as, e.g., smoothing, plumping, or, e.g., filling. Uncontradicted, reference to a structural effect of a structural component or structural agent should be interpreted to include, e.g., a chromophoric extension effect of a chromophoric extension component or chromophoric extension agent.

[0205] In certain aspects, an advantage of composition(s) described herein is that they are capable of delivering both a detectable or significant skin color change effect (chromophoric aesthetic effect) and a structural skin aesthetic effect (e.g., smoothing, plumping, or filling of skin). In aspect, chromophoric compositions are characterizable as hypodermal compositions. In aspects, chromophoric composition(s) provided herein provide a plumping effect, e.g., adding volume to one or more feature(s), such as, e.g., lip(s). In aspects, chromophoric composition(s)provided herein provide a fat loss substitute in the hypodermis. In aspects, chromophoric composition(s) provided herein provide a fat loos substitute in the hypodermis while providing detectable or significant skin coloration. In aspects, such effect is accompanied by a reduction in Tyndall effect. In aspects, such effect is unaccompanied by a reduction in Tyndall effect. In certain aspects, composition(s) provided herein do not detectably or significantly impact, e.g., reduce or eliminate, Tyndall effect(s) caused by one or more other element(s) present at the site of application (e.g., injection) or, e.g., present in the composition(s).

[0206] In aspects, the dermatologically suitable chromophoric composition(s) comprise at least one component, such as, e.g., two or more components, e.g., three or more components. In aspects, the dermatologically suitable chromophoric composition(s) comprise a structural component, a dermal / subdermal chromophoric component, an excipient component, or combination(s) of any or all thereof.

[0207] In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant chromophoric effect, e.g., color change to one or more areas of the skin, a detectable or significant structural skin aesthetic effect, e.g., modulation of the smoothness or volume of one or more areas of the skin, or, e.g., a detectable or significant extension of a chromophoric aesthetic effect period, in / of a recipient, e.g., a human patient., upon injection of composition(s) of the invention. In such a respect, any known equivalents of such named agent(s) can also be, e.g., are, incorporated into composition(s) or method(s) of this invention. As with other sections similarly described herein, any of the component(s) of the invention can be, where suitable, described as means (e.g., the above-described dermatologically suitable chromophoric composition(s) or component(s) can be described as dermatologically suitable chromophoric composition means (or chromophoric means, structural means, etc.) or means for providing effective, detectable, or significant chromophoric, structural, or chromophoric and structural activity(ies) / characteristic(s) e.g., color change, to one or more areas of the skin of a recipient, e.g., a patient.

[0208] Component(s) and constituent(s) (e.g., agent(s) of composition(s) herein are often described as being provided in an effective amount, or, e.g., an aesthetically effective amount. An effective amount (or aesthetically effective amount) is an amount administered yielding the ascribed effect(s), e.g., the ascribed target effect(s), such as, e.g., a target change in skin color / tone (a target skin color / tone). In aspects, an effective amount is provided in a singleadministration. In aspects, an effective amount is an amount provided via multiple administrations over an administration period.

[0209] In aspects, amount(s) of constituent(s) described herein are effective amount(s), such that when composition(s) are administered in an amount of, e.g., ~0.1 mL, ~0.2 mL, -0.3 mL, -0.4 mL, -0.5 mL, -0.6 mL, -0.7 mL, -0.8 mL, -0.9 mL, -1 mL, -1.2 mL, -1.4 mL, -1.6 mL, -1.8 mL, -2 mL, -2.2 mL, -2.4 mL, -2.6 mL, -2.8 mL, -3 mL, -3.2 mL, -3.4 mL, -3.6 mL, -3.8 mL, -4 mL, -4.2 mL, -4.4 mL, -4.6 mL, -4.8 mL, or, e.g., -5 mL or more, the ascribed effect(s) is achieved.

[0210] In aspects, amount(s) of constituent(s) provided herein describe amount(s) of such constituent(s) within chromophoric composition(s) provided by the invention, and an effective amount of such constituent(s) is a total amount administered when, e.g., e.g., -0.1 mL, -0.2 mL, -0.3 mL, -0.4 mL, -0.5 mL, -0.6 mL, -0.7 mL, -0.8 mL, -0.9 mL, -1 mL, -1.2 mL, -1.4 mL, -1.6 mL, -1.8 mL, -2 mL, -2.2 mL, -2.4 mL, -2.6 mL, -2.8 mL, -3 mL, -3.2 mL, -3.4 mL, -3.6 mL, -3.8 mL, -4 mL, -4.2 mL, -4.4 mL, -4.6 mL, -4.8 mL, or, e.g., -5 mL or more of the chromophoric composition(s) herein are administered one or more times, such as, e.g., -2, -3, -4, -5, -6, -7, -8, -9, or, e.g., -10 (or more, such as -12, -14, -16, -18, -20, -22, or, e.g., -24) times over the course of an administration period, wherein the administration period is a period of about 1 day, -2 days, -3 days, -4 days, -5 days, -6 days, -7 days, -2 weeks, -3 weeks, -4 weeks, -2 months, -3 months, -6 months, -9 months, -12 months, -15 months, -18 months, -21 months, -24 months, -27 months, -30 months, -33 months, or, e.g., about 36 months.Dermal / Subdermal Chromophoric Component

[0211] In aspects, the dermatologically suitable chromophoric composition can comprise one or more dermal / subdermal chromophoric component(s). In aspects, the one or more dermal / subdermal chromophoric component(s) can comprise one or more dermal / subdermal chromophoric agents. In aspects, the one or more dermal / subdermal chromophoric agents can comprise one or more dermal / subdermal chromophoric vitamins, one or more dermal / subdermal chromophoric minerals, one or more dermal / subdermal non- vitamin agents, one or more dermal / subdermal non-mineral agents, or any combination thereof. In aspects, the one or more dermal / subdermal chromophoric agents can comprise one or more dermal / subdermal chromophoric vitamins or one or more dermal / subdermal chromophoric vitamin derivatives. In aspects, the one or more dermal / subdermal chromophoric agents can comprise one or more dermal / subdermal chromophoric minerals or one or more dermal / subdermal chromophoricmineral derivatives. In aspects, the dermal / subdermal chromophoric vitamin(s) or the dermal / subdermal chromophoric mineral(s) can be present in the form of a prodrug.

[0212] According to aspects, chromophoric composition(s) provided herein comprise one or more chromophoric agent(s) suitable for producing, when present in effective amount(s) in chromophoric composition(s), a reddening, pinking, blushing, or otherwise ruddying of the skin when chromophoric composition(s) are administered in effective amount(s) and over effective time period(s). In aspects, such composition(s) can be administered to one or more area(s) of a mammalian body, e.g., a mammalian face, e.g., a human body or face, such as to, e.g., the lips (among other areas), resulting in such an effect. According to certain alternative aspects, composition(s) can be applied to, e.g., area(s) of scarring to produce such effect(s).

[0213] In aspects, chromophoric composition(s) herein impart one or more effect(s) described herein. In aspects, chromophoric composition(s) herein impart one or more effect(s) described herein such as, e.g., a detectable or significant reddening, pinking, blushing, or otherwise ruddying of the skin when chromophoric composition(s) are administered in effective amount(s) and over effective time period(s). According to certain specific embodiments, chromophoric composition(s) having any one or more characteristic(s) described herein impart one or more detectable or significant effect(s) described herein such as, e.g., a detectable or significant reddening, pinking, blushing, or otherwise ruddying of the skin, e.g., of the lip(s) of a human recipient, of a scar (e.g., atrophic or hypopigmented scar(s)) of a human patient, or both, when the chromophoric composition(s) are administered in effective amount(s) and over effective time period(s).

[0214] According to aspects, chromophoric composition(s) provided herein comprise one or more chromophoric agent(s) suitable for producing, when present in effective amount(s) in chromophoric composition(s), a yellowing effect of the skin when chromophoric composition(s) are administered in effective amount(s) and over effective time period(s). In aspects, such composition(s) can be administered to one or more area(s) of a mammalian body, e.g., a mammalian face, e.g., a human body or face, such as to, e.g., the subdermis of the face or, e.g., elsewhere in the body (e.g., the areas around the eye(s) (orbit(s)), elsewhere on the face, among other areas), resulting in such an effect. According to certain alternative aspects, composition(s) can be applied to, e.g., area(s) of scarring to produce such effect(s).

[0215] In aspects, chromophoric composition(s) herein impart one or more effect(s) described herein. In aspects, chromophoric composition(s) herein impart one or more effect(s) described herein such as, e.g., a detectable or significant yellowing of the skin whenchromophoric composition(s) are administered in effective amount(s) and over effective time period(s). According to certain specific embodiments, chromophoric composition(s) having any one or more characteristic(s) described herein impart one or more detectable or significant effect(s) described herein such as, e.g., a detectable or significant yellowing of the skin, e.g., of the orbit(s) or other body parts of a human recipient, of a scar (e.g., atrophic or hypopigmented scar(s)) of a human patient, or both, when the chromophoric composition(s) are administered in effective amount(s) and over effective time period(s). In aspects, chromophoric composition(s) provided herein cover fat defect(s) or fat loss. In aspects, chromophoric composition(s) provided herein detectibly or significantly rectify fat defect(s) or fat loss in the subdermis, e.g., the subdermis in the face or elsewhere on the body.

[0216] In aspects, dermal / subdermal chromophoric component(s) exhibit(s) a readily observable color property or, e.g., delectably or significantly changes the color of a clear solution, e.g., an aqueous solution, when added in effective amount(s). In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is detectable by spectrophotometric analysis of light, wherein the at least substantial reflection of light occurs at wavelengths of at least about 570 nm to about 590 nm, such as, e.g., about 575 nm to about 590 nm, about 580 nm to about 590 nm, about 585nm to about 590 nm, or, e.g., about 570 nm to about 585 nm, about 570 nm to about 580 nm, or, e.g., about 570 nm to about 575 nm.

[0217] hi aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is detectable by spectrophotometric analysis of light, wherein the at least substantial reflection of light occurs at wavelengths of at least about 620 nm to about 750 nm, such as, e.g., about 630 nm to about 750 nm, about 640 nm to about 750nm, about 650 nm to about 750 nm, about 660 nm to about 750nm, about 670 nm to about 750 nm, about 680 nm to about 750 nm, about 690 nm to about 750 nm, about 700 nm to about 750 nm, about 710 nm to about 750 nm, about 720 nm to about 750 nm, about 730 nm to about 750 nm, about 740 nm to about 750 nm, or, e.g., about 620 nm to about 740 nm, about 620 nm to about 730 nm, about 620 nm to about 720 nm, about 620 nm to about 710 nm, about 620 nm to about 700 nm, about 620 nm to about 690 nm, about 620 nm to about 680 nm, about 620 nm to about 670 nm, about 620 nm to about 660 nm, about 620 nm to about 650 nm, about 620 nm to about 640 nm, or, e.g., about 620 nm to about 630 nm.

[0218] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 2.5R to about 5R, such as, e.g., about 3. OR to about5R, about 3.5R to about 5R, about 4R to about 5R, about 4.5R to about 5R, or, e.g., the Munsell System hue is in a range of about 2.5R to about 4.5R, or, e.g., about 2.5R to about 4R, about 2.5R to about 3.5R, or, e.g., about 2.5R to about 3R.

[0219] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 5.5R to about 10R, such as, e.g., about 6R to about 10R, about 6.5R to about 10R, about 7R to about 10R, about 7.5R to about 10R, about 8R to about 10R, about 8.5R to about 10R, about 9R to about 10R, about 9.5R to about 10R, or, e.g., the Munsell System hue is in a range of about 5.5R to about 9.5R, or, e.g., about 5.5R to about 9R, about 5.5R to about 8.5R, about 5.5R to about 8R, about 5.5R to about 7.5R, about 5.5R to about 7R, about 5.5R to about 6.5R, or, e.g., about 5.5R to about 6R.

[0220] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 6.5R to about 8R, such as, e.g., about 7R to about 8R, about 7.5R to about 8R, or, e.g., the Munsell System hue is in a range of about 6.5R to about 7.5R, or, e.g., about 6.5R to about 7R.

[0221] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 2.5Y to about 5Y, such as, e.g., about 3.0Y to about 5Y, about 3.5Y to about 5Y, about 4Y to about 5Y, about 4.5Y to about 5Y, or, e.g., the Munsell System hue is in a range of about 2.5Y to about 4.5Y, or, e.g., about 2.5Y to about 4Y, about 2.5Y to about 3.5Y, or, e.g., about 2.5Y to about 3Y.

[0222] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 5.5Y to about 10Y, such as, e.g., about 6Y to about 10Y, about 6.5Y to about 10Y, about 7Y to about 10Y, about 7.5Y to about 10Y, about 8Y to about 10Y, about 8.5Y to about 10Y, about 9Y to about 10Y, about 9.5Y to about 10Y, or, e.g., the Munsell System hue is in a range of about 5.5Y to about 9.5Y, or, e.g., about 5.5Y to about 9Y, about 5.5Y to about 8.5Y, about 5.5Y to about 8Y, about 5.5Y to about 7.5Y, about 5.5Y to about 7Y, about 5.5Y to about 6.5Y, or, e.g., about 5.5Y to about 6Y.

[0223] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System hue is in a range of about 6.5Y to about 8Y, such as, e.g., about 7Y to about 8Y,about 7.5Y to about 8Y, or, e.g., the Munsell System hue is in a range of about 6.5Y to about 7.5Y, or, e.g., about 6.5Y to about 7Y.

[0224] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein the Munsell System value is in a range of about 2 to about 9, such as, e.g., about 3 to about 9, about 4 to about 9, about 5 to about 9, about 6 to about 9, about 7 to about 9, about 8 to about 9, or, e.g., about 2 to about 8, about 2 to about 7, about 2 to about 6, about 2 to about 5, about 2 to about 4, or, e.g., about 2 to about 3.

[0225] In aspects, the readily observable color property or change in the color of a clear solution, e.g., an aqueous solution, is measurable using the Munsell System, further wherein chroma is in a range of about 2 to about 16, such as, e.g., about 3 to about 16, about 4 to about 16, about 5 to about 16, about 6 to about 16, about 7 to about 16, about 8 to about 16, about 9 to about 16, about 10 to about 16, about 11 to about 16, about 12 to about 16, about 13 to about 16, about 14 to about 16, about 15 to about 16, or, e.g., the Munsell System chroma is in a range of about 2 to about 15, such as, e.g., about 2 to about 14, about 2 to about 13, about 2 to about 12, about 2 to about 11 , about 2 to about 10, about 2 to about 9, about 2 to about 8, about 2 to about 7, about 2 to about 6, about 2 to about 5, about 2 to about 4, or, e.g., about 2 to about 3.In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant chromophoric effect, e.g., color change to one or more areas of the skin of a recipient, e.g., a human patient, upon injection of composition(s) of the invention. In such a respect, any known equivalent(s) of such named agents can also be, e.g., are, incorporated into compositions or methods of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the abovedescribed dermal / subdermal chromophoric component(s) can be described as dermal / subdermal chromophoric component means (or chromophoric component means) or means for providing effective, detectable, or significant chromophoric activity / characteristic(s), e.g., color change, to one or more areas of the skin of a recipient, e.g., a human patient.Dermal / Subdermal Chromophoric Component Amounts

[0226] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric component(s) present in an amount effective to produce a detectable or significant change in the color of the skin when injected into a recipient, e.g., a human patient (e.g., when administered an effective number oftimes, administered over an effective period of time, or both). In aspects, the dermatologically suitable chromophoric composition produces a detectable or significant change in the color of the skin when injected into a recipient, e.g., human patient, which is the result of most of the one or more dermal / subdermal chromophoric component(s), e.g., agent(s) thereof.

[0227] In aspects, a dermal / subdermal chromophoric component is a component comprising one or more dermal / subdermal chromophoric agents (compounds / molecules or other ingredients). Uncontradicted, a dermal / subdermal chromophoric component is a component of a composition that comprises an amount of one or more chromophore agent(s) that are effective for imparting a DOS skin color change when administered to the dermis, sub-dermis, or both. A dermal / subdermal chromophoric agent refers to an agent that when administered in effective amount under effective conditions imparts / provides a DOS skin color change (e.g., in a significant number of recipients, most recipients, generally all treated persons, etc.) when administered to the derrmis / sub-dermis.

[0228] According to aspects, the dermatologically suitable chromophoric composition(s) described herein comprise one or more dermal / subdermal chromophoric component(s) present in any amount effective to produce a detectable or significant, e.g., a targeted, change in the color of the skin when injected into a recipient, e.g., a human patient.

[0229] According to aspects, the dermatologically suitable chromophoric composition(s) described herein comprise one or more dermal / subdermal chromophoric component(s) present in an amount of between about 0.01 wt.% and about 1 wt.% of the composition, such as, e.g., -0.01 wt.% - -0.95 wt.%, -0.01 wt.% - -0.9 wt.%, -0.85 wt.% - -0.8 wt.%, -0.01 wt.% - -0.75 wt.%, -0.01 wt.% - -0.7 wt.%, -0.01 wt.% - -0.65 wt.%, -0.01 wt.% - -0.6 wt.%, -0.01 wt.% - -0.55 wt.%, -0.01 wt.% - -0.5 wt.%, -0.01 wt.% - -0.45 wt.%, -0.01 wt.% - -0.4 wt.%, -0.01 wt.% - -0.35 wt.%, -0.01 wt.% - -0.3 wt.%, -0.01 wt.% - -0.25 wt.%, -0.01 wt.% - -0.2 wt.%, -0.01 wt.% - -0.15 wt.%, -0.01 wt.% - -0.1 wt.%, or, e.g., -0.01 wt.% - -0.05 wt.%.

[0230] According to aspects, the dermatologically suitable chromophoric composition(s) described herein comprise one or more dermal / subdermal chromophoric component(s) present in an amount of between about 0.05 wt.% and about 1 wt.% of the composition, such as, e.g., -0.1 wt.% - -1 wt.%, -0.15 wt.% - -1 wt.%, -0.2 wt.% - -1 wt.%, -0.25 wt.% - -1 wt.%, -0.3 wt.% - -1 wt.%, -0.35 wt.% - -1 wt.%, -0.4 wt.% - -1 wt.%, -0.45 wt.% - -1 wt.%, -0.5 wt.% - -1 wt.%, -0.55 wt.% - -1 wt.%, -0.6 wt.% - -1 wt.%, -0.65 wt.% - -1 wt.%, -0.7 wt.% - -1 wt.%, -0.75 wt.% - -1 wt.%, -0.8 wt.% - -1 wt.%, -0.85 wt.% - -1 wt.%, -0.9 wt.% - -1 wt.%, or -0.95 wt.% - -1 wt.%.

[0231] According to aspects, the dermatologically suitable chromophoric composition(s) described herein comprise one or more dermal / subdermal chromophoric component(s) present in an amount of between about 0.05 wt.% and about 0.95 wt.% of the composition, such as, e.g., ~0.1 wt.% - ~0.9 wt.%, -0.15 wt.% - -0.85 wt.%, -0.2 wt.% - -0.8 wt.%, -0.25 wt.% - -0.75 wt.%, -0.3 wt.% - -0.6 wt.%, -0.35 wt.% - -0.55 wt.%, or, e.g., -0.4 wt.% - -0.5 wt.%.

[0232] In aspects, the dermatologically suitable chromophoric composition comprises one or more dermal / subdermal chromophoric component(s) present in an amount of about 1 wt.% - about 10 wt.% of the composition such as, for e.g., -1 wt.% - -9 wt.%, -1 wt.% - -8 wt.%, -1 wt.% - -7 wt.%, -1 wt.% - -6 wt.%, or, e.g., -1 wt.% - -5 wt.% of the composition such as, for example, -2 wt.% - -10 wt.%, -3 wt.% - -10 wt.%, -4 wt.% - -10 wt.%, or as in e. g., -5 wt.% - -10 wt.%, of the composition such as in, e.g., about 2 wt.% - about 8 wt.%, -2 wt.% - -9 wt.%, -3 wt.% - -7 wt.%, -3 wt.% - -8 wt.%, -4 wt.% - -6 wt.%, -4 wt.% - -7 wt.%, -5 wt.% - -6 wt.%, or, e.g., about 5 wt.% of the composition.

[0233] In aspects, the dermatologically suitable chromophoric composition comprises one or more dermal / subdermal chromophoric component(s) present in an amount of about 11 wt.% - about 30 wt.% of the composition such as, for e.g., about 11 wt.% - about 29 wt.%, about 11 wt.% - about 28 wt.%, about 11 wt.% - about 27 wt.%, about 11 wt.% - about 26 wt.%, or, e.g., about 11 wt.% - about 25 wt. % of the composition such as, for example, about 12 wt.% - about 30 wt.%, about 13 wt.% - about 30 wt.%, about 14 wt.% - about 30 wt.%, or as in e. g., about 15 wt.% - about 30 wt.%, of the composition such as in, e.g., -12 wt.% - -28 wt.%, -12 wt.% - -29 wt.%, 13 wt.% - -27 wt.%, -13 wt.% - -28 wt.%, 14 wt.% - 26 wt.%, -14 wt.% - -27 wt.%, -16 wt.% - -25 wt.%, -10 wt.% - -20 wt.%, -12 wt.% - -25 wt.%, -12 wt.% - -20 wt.%, -11 wt.% - -17 wt.%, or, e.g., about 15 wt.% of the composition.

[0234] In aspects, the dermatologically suitable chromophoric composition comprises one or more dermal / subdermal chromophoric component(s) present in an amount of about 31 wt.% - about 60 wt.% of the composition such as, for e.g., -31 wt.% - -59 wt.%, -31 wt.% - -58 wt.%, -31 wt.% - -57 wt.%, -31 wt.% - -56 wt.%, or, e.g., -31 wt.% - ~55wt % of the composition such as, for example, about 32 wt.% - about 60 wt.%, about 33 wt.% - about 60 wt.%, about 34 wt.% - about 60 wt.%, or as in e. g., about 35 wt.% - about 60 wt.%, of the composition such as in, e.g., about 32 wt.% - about 58 wt.%, about 33 wt.% - about 57 wt.%, about 34 wt.% - about 56 wt.%, -30 wt.% - -50 wt.%, -30 wt.% - -45 wt.%, -30 wt.% - -40 wt.%, or, e.g., about 35 wt.% of the composition.

[0235] According to certain aspects, chromophoric composition(s) disclosed herein comprise one or more dermal / subdermal chromophoric component(s) present in an amount of greater than about 60 wt.% of the composition.Dermal / Subdermal Chromophoric Agents

[0236] In aspects, the one or more dermal / subdermal chromophoric agent(s) present in the one or more dermal / subdermal chromophoric component(s) can comprise any one or more dermatologically suitable dermal / subdermal chromophoric agent(s). In aspects, the one or more dermal / subdermal chromophoric agent(s) can be present in any suitable amount, e.g., an aesthetically effective amount, to impart a desired hue or color to the skin of a recipient as determined by a statistically significant number of licensed healthcare professionals. In aspects, the dermal / subdermal chromophoric component is mostly composed of, generally only composed of, substantially only composed of, essentially only composed of, or is only (entirely) composed of a single dermal / subdermal chromophoric agent. In aspects, the dermal / subdermal chromophoric component comprises at least two, e.g., two or more dermal / subdermal chromophoric agents. In aspects, a suitable chromophoric agent is an agent which provides a temporary coloration to the skin, e.g., an agent which does not permanently dye or stain human skin.

[0237] In aspects, one or more dermal / subdermal chromophoric agent(s) can be bioactive molecules which do not pose any threat upon administration to a recipient, e.g., are safe for use in humans. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric agent(s) present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., a change in color, such as, e.g., yellow, red, blue, etc., to the skin, a lightening or darkening of the skin, or a combination thereof, as appreciated by a statistically significant number of licensed healthcare professionals when injected in the dermis of a recipient, e.g., a human patient,.

[0238] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric vitamin(s). In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) comprise one or more A vitamins or A vitamin derivatives, such as, e.g., beta carotene or derivative(s) thereof. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) comprise one or more B vitamins or B vitaminderivatives, such as, e.g., cyanocobalamin or derivatives thereof, niacin or derivatives thereof, etc. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) comprise one or more of riboflavin, pyridoxine, cyanocobalamin, or any combination thereof. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., a change in color, such as, e.g., yellow, red, etc., to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s), comprising one or more A vitamin derivatives, such as, e.g., beta carotene, present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s), comprising one or more B vitamin derivatives, such as, e.g., niacin, present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s), comprising one or more B vitamin derivatives, such as, e.g., cyanocobalamin, present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., red, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) do not introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) can comprise a combination of two or more dermal / subdermal chromophoric vitamin(s) comprising one or more dermal / subdermal chromophoric vitamin(s) which introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significantnumber of licensed healthcare professionals, and one or more dermal / subdermal chromophoric vitamin(s) which do not produce a hue e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals.

[0239] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric non- vitamin(s). In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric non-vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., a change in color, such as, e.g., yellow, red, etc., to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric non- vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) do not introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, the one or more dermal / subdermal chromophoric vitamin(s) present in the one or more dermal / subdermal chromophoric component(s) can comprise a combination of dermal / subdermal chromophoric non-vitamin(s) comprising one or more dermal / subdermal chromophoric non-vitamin(s) which introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals, and one or more dermal / subdermal chromophoric non-vitamin(s) which do not produce a hue e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. One or more additional means of quantifying skin color change in a recipient after injection of composition(s), comprising one or more dermal / subdermal chromophoric vitamin(s), provided for herein can comprise, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeter(s), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color.

[0240] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric mineral(s). In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermalchromophoric mineral(s) present in the one or more dermal / subdermal chromophoric component(s) comprise, e.g., rose quartz, iron, zinc, copper, or any combination thereof. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric mineral(s) present in the one or more dermal / subdermal chromophoric component(s) comprise, e.g., iron oxide, zinc oxide, copper oxide, or any combination thereof. In aspects, one or more dermal / subdermal chromophoric mineral(s) present in composition(s) herein can comprise mineral(s) in the compound form, e.g., oxide(s), salt(s), etc. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric mineral(s) present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., a change in color, such as, e.g., yellow, red, etc., to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, some, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric mineral(s) present in the one or more dermal / subdermal chromophoric component(s) do not introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, one or more dermal / subdermal chromophoric mineral(s) can comprise, e.g., amaranth, rubia plant, tartrazine, or any other dermatologically suitable mineral(s) in the art which induce a color change. In aspects, one or more dermal / subdermal chromophoric mineral(s) present in the one or more dermal / subdermal chromophoric component(s) can comprise a combination of dermal / subdermal chromophoric mineral(s) comprising one or more dermal / subdermal chromophoric mineral(s) which introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals, and one or more dermal / subdermal chromophoric mineral(s) which do not produce a hue e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. One or more additional means of quantifying skin color change in a recipient after injection of composition(s), comprising one or more dermal / subdermal chromophoric mineral(s), provided for herein can comprise, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeter(s), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color.

[0241] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric non- mineral(s). In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric non-mineral(s) present in the one or more dermal / subdermal chromophoric component(s) introduce a hue, e.g., a change in color, such as, e.g., yellow, red, etc., to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric non- mineral(s) present in the one or more dermal / subdermal chromophoric component(s) do not introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, the one or more dermal / subdermal chromophoric non-mineral(s) present in the one or more dermal / subdermal chromophoric component(s) can comprise a combination of dermal / subdermal chromophoric non-mineral(s) comprising one or more dermal / subdermal chromophoric non-mineral(s) which introduce a hue, e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals, and one or more dermal / subdermal chromophoric non-mineral(s) which do not produce a hue e.g., red, yellow, to the skin when injected in the dermis of a recipient, e.g., a human patient, as appreciated by a statistically significant number of licensed healthcare professionals. One or more additional means of quantifying skin color change in a recipient after injection of composition(s), comprising one or more dermal / subdermal chromophoric non-vitamin(s) or one or more dermal / subdermal chromophoric non-mineral(s), provided for herein can comprise, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeter(s), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color.

[0242] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric natural compound(s), such as, e.g., urobilin, chitin, keratin, etc. In aspects, one or more dermal / subdermal chromophoric natural(s) is extracted or derived from persimmon(s). In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric natural compound(s) present in the one or more dermal / subdermal chromophoriccomponent(s) comprise, e.g., urobilin. In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more dermal / subdermal chromophoric natural compound(s), such as, e.g., carotenoids, such as, e.g., astaxanthin. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric natural compound(s) present in the one or more dermal / subdermal chromophoric component(s) comprise, e.g., urobilin. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal chromophoric natural compound(s) present in the one or more dermal / subdermal chromophoric component(s) comprise, e.g., urobilin, or, e.g., carotenoids, and when injected in the dermis of a recipient, e.g., a human patient, introduce a detectable or significant yellow or red hue to the skin as appreciated by a statistically significant number of licensed healthcare professionals. One or more additional means of quantifying skin color change in a recipient after injection of composition(s), comprising one or more dermal / subdermal chromophoric natural compound(s), provided for herein can comprise, e.g., use of epiluminescence microscopy or dermoscopy, reflectance spectroscopy, colorimeter(s), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color.

[0243] In aspects, one or more dermal / subdermal chromophoric components are one or more dermal / subdermal chromophoric components subjected to chemical modification concurrent with or after injection. In aspects, the modification is an enzymatic modification. In aspects, the enzymatic modification causes a detectable or significant change in the chromophoric effect. In aspects, one or more dermal / subdermal chromophoric components comprise keratin. In aspects, the method of enzymatic modification is associated with delivering an enzyme that detectably or significantly breaks down keratin. In aspects, the enzyme delivery significantly reduces the yellow color of the skin. In aspects, the enzyme delivery significantly reduces the yellow color of the skin which may be present if such an enzyme is not present.

[0244] In aspects, one or more dermal / subdermal chromophoric components comprise one or more proteins. In aspects, one or more dermal / subdermal chromophoric components comprise associated, e.g., bonded / bound, e.g., conjugated compounds, comprising one or more proteins providing a detectable or significant chromophoric effect, one or more proteins not providing a chromophoric effect, or both. In aspects, one or more dermal / subdermal chromophoric components are conjugated hemosiderin or unconjugated hemosiderin. In aspects, one or more dermal / subdermal chromophoric components comprise one or more proteins,wherein the one or more proteins are conjugated or unconjugated. In aspects, one or more dermal / subdermal chromophoric components comprise two or more proteins, wherein the two or more proteins are conjugated, unconjugated, or both.

[0245] In aspects, the dermal / subdermal chromophoric component is mostly, generally, substantially, or entirely composed of one or more adipose component compounds. In aspects, one or more adipose component compounds is / are associated with, e.g., bound to, e.g., conjugated to, one or more hyaluronic acids. In aspects, one or more adipose component compounds is / are conjugated to one or more crosslinked hyaluronic acids. In aspects, one or more adipose components or one or more conjugates are fat soluble. In aspects, one or more conjugates delectably or significantly contributes to the overall uptake or incorporation or localization of the conjugate into adipose tissue. In aspects, one or more conjugate(s) is / are detectably or significantly associated with less water absorption than a non-derivatized HA.

[0246] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric component(s) and one or more structural component(s) wherein the ratio of the molecular weight of the one or more dermal / subdermal chromophoric component(s), comprising one or more dermal / subdermal chromophoric vitamin(s), to the one or more structural component(s) is about 1 :125, e.g., -1:100, -1 :75, -1 :50, -1:25, or, e.g., -1 :5, or, e.g., is about 1:150, -1:175, or, e.g., -1 :200.

[0247] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric component(s) and one or more structural component(s) wherein the ratio of the molecular weight of the one or more dermal / subdermal chromophoric component(s), comprising one or more dermal / subdermal chromophoric mineral(s), to the one or more structural component(s) is about 55:125 (e.g., about 1:2.2), such as, e.g., -30:125 (-1:4), -35:125, -40:125, -45:125, -50: 125, -60:125, -65:125, -70:125, -75:125, -80: 125, -85: 125, or, e.g., -90:125 (-1 : 1.4).

[0248] In aspects, suitable chromophoric agent(s) is / are agent(s) sharing one, some, most, generally all, substantially all, essentially all, or all characteristics of one, some, most, generally all, substantially all, essentially all, or all exemplified agent(s) disclosed herein.

[0249] In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant chromophoric effect, e.g., color change to one or more areas of the skin of a recipient, e.g., a human patient, upon injection of composition(s) of the invention. In such a respect, any known equivalents of such named agents can also be, e.g., are,incorporated into compositions or methods of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the above-described dermal / subdermal chromophoric agent(s) can be described as dermal / subdermal chromophoric agent means (or chromophoric agent means) or means for providing effective, detectable, or significant chromophoric activity / characteristics, e.g., color change, to one or more areas of the skin of a recipient, e.g., a human patient.Dermal / Subdermal Chromophoric Agents Amounts

[0250] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises a larger number of dermal / subdermal chromophoric agent(s) molecules in comparison to the number of structural molecules present in the composition. In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises a larger number of dermal / subdermal chromophoric agent(s) molecules, wherein the dermal / subdermal chromophoric agent(s) are one or more dermal / subdermal chromophoric vitamin(s) (or derivative(s) thereof), compared to the number of structural agent(s) molecules, wherein the structural agent comprises a hyaluronic acid. In aspects, the dermatologically suitable dermal / subdermal chromophoric composition(s) comprise(s) a larger number of dermal / subdermal chromophoric agent(s) molecules, wherein the dermal / subdermal chromophoric agent(s) are one or more dermal / subdermal chromophoric vitamin(s) (or derivative(s) thereof), compared to the number of structural agent(s) molecules, wherein the structural agent(s) comprise(s) a crosslinked hyaluronic acid. In aspects, a dermatologically suitable dermal / subdermal chromophoric composition comprises a larger number of dermal / subdermal chromophoric agent(s) molecules, wherein the dermal / subdermal chromophoric agent(s) are one or more dermal / subdermal chromophoric mineral(s) (or derivative(s) thereof), compared to the number of structural agent(s) molecules, wherein the structural agent comprises hyaluronic acid. In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises a larger number of dermal / subdermal chromophoric agent(s) molecules, wherein the dermal / subdermal chromophoric agent(s) are one or more dermal / subdermal chromophoric mineral(s) (or derivative(s) thereof), compared to the number of structural agent(s) molecules, wherein the structural agent comprises crosslinked hyaluronic acid.

[0251] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises at least one dermal / subdermal chromophoric agent present in an amount of about Iwt % to about 10 wt.% such as, e.g., ~1 wt.% - ~9 wt.%, ~1 wt.% - ~8 wt.%, ~1 wt.% --7 wt.%, -1 wt.% - ~6 wt.%, or, e.g., -1 wt.% - ~5 wt.% of the composition such as, for example, -2 wt.% - -9 wt.%, -3 wt.% - -9 wt.%, -4 wt.% - -9 wt.%, or as in e. g., ~5 wt.% - -9 wt.%, of the composition such as in, e.g., -2 wt.% - ~8 wt.%, ~3 wt.% - -7 wt.%, -4 wt.% - -6 wt.%, or, e.g., ~5 wt.% of the composition.

[0252] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises at least one dermal / subdermal chromophoric agent present in an amount of about 11 wt.% to about 30 wt.% of the composition such as, for e.g., ~11 wt.% - ~29 wt.%, ~11 wt.% - ~28 wt.%, ~11 wt.% - -27 wt.%, ~11 wt.% - ~26 wt.%, or, e.g., ~11 wt.% - ~25 wt.% of the composition such as, for example, -12 wt.% - -29 wt.%, -13 wt.% - -29 wt.%, -14 wt.% - -29 wt.%, or as in e. g., -15 wt.% - -29 wt.%, of the composition such as in, e.g., -12 wt.% - -28 wt.%, -13 wt.% - -27 wt.%, -14 wt.% - -26 wt.%, or, e.g., -15 wt.% of the composition.

[0253] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises at least one dermal / subdermal chromophoric agent present in an amount of about 31 wt.% to about 60 wt.% of the composition such as, for e.g., -31 wt.% - -59 wt.%, - 31 wt.% - -58 wt.%, -31 wt.% - -57 wt.%, -31 wt.% - -56 wt.%, or, e.g., -31 wt.% - -55 wt.% of the composition such as, for example, -32 wt.% - -59 wt.%, -33 wt.% - -59 wt.%, -34 wt.% - -59 wt.%, or as in e. g., -35 wt.% - -59 wt.%, of the composition such as in, e.g., -32 wt.% - -58 wt.%, -33 wt.% - -57 wt.%, -34 wt.% - -56 wt.%, or, e.g., about 35 wt.% of the composition.

[0254] In aspects, the dermatologically suitable chromophoric composition can comprise one or more dermal / subdermal chromophoric component(s), wherein the one or more dermal / subdermal chromophoric component(s) comprise one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s). In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) / vitamin derivative(s), wherein the one or more chromophoric vitamin(s) are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., -20 mg / mL — 48 mg / mL, -20 mg / mL — 46mg / mL, -20 mg / mL - ~44mg / mL, -20 mg / mL - -42 mg / mL, -20 mg / mL - -40 mg / mL, -20 mg / mL — 38 mg / mL, -20 mg / mL — 36 mg / mL, -20 mg / mL — 34 mg / mL, -20 mg / mL - -32 mg / mL, or, e.g., the one or more chromophoric vitamin(s) / vitamin derivative(s) are present in an amount of -20 mg / mL — 30 mg / mL, -20 mg / mL — 28 mg / mL, -20 mg / mL — 26 mg / mL, -20 mg / mL — 24 mg / mL, -20 mg / mL - -22 mg / mL, such as, e.g., -22 mg / mL - -50 mg / mL, -24 mg / mL - -50 mg / mL, -26 mg / mL - -50 mg / mL, -28 mg / mL — 50 mg / mL, 30 mg / mL — 50 mg / mL, -32mg / mL - ~50 mg / mL, ~34 mg / mL - ~50 mg / mL, ~36 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of about 38 mg / mL - about 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL - ~50 mg / mL, ~46 mg / mL - ~50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0255] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is riboflavin or dermatologically suitable derivative thereof, which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL - ~40 mg / mL, ~20 mg / mL - ~38 mg / mL, ~20 mg / mL - ~36 mg / mL, ~20 mg / mL - ~34 mg / mL, ~20 mg / mL - ~32 mg / mL, ~20 mg / mL — 30 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 28 mg / mL, ~20 mg / mL - ~26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL - ~50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, 30 mg / mL - ~50 mg / mL, ~32 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of 34 mg / mL - ~50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0256] hi aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is pyridoxine or dermatologically suitable derivative thereof, which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL - ~46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL - ~42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL - ~38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL - ~50 mg / mL, ~28 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, ~46 mg / mL - ~50 mg / mL, ~48 mg / mL - ~50 mg / mL or, e.g., ~49 mg / mL.

[0257] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is cobalamin or, e.g., cyanocobalamin or a dermatologically suitable derivative thereof, which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL - ~40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL - ~36 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL - ~50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL - ~50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0258] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is one or more B vitamin derivative(s), which are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, e.g., ~20 mg / mL - ~48 mg / mL, ~20 mg / mL - ~46mg / mL, ~20 mg / mL - ~44mg / mL, ~20 mg / mL - ~42 mg / mL, ~20 mg / mL - ~40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL - ~30 mg / mL, ~20 mg / mL - ~28 mg / mL, ~20 mg / mL - ~26 mg / mL, ~20 mg / mL - ~24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL - ~50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL - ~50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL - ~50 mg / mL, ~42 mg / mL - ~50 mg / mL, -44 mg / mL - ~50 mg / mL, ~46 mg / mL - ~50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0259] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) / vitamin derivative(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is one or more A vitamin derivative(s), which are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL - ~48mg / mL, ~20 mg / mL - ~46mg / mL, ~20 mg / mL - ~44mg / mL, ~20 mg / mL - ~42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL — 50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL - ~50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL — 50 mg / mL, ~46 mg / mL - ~50 mg / mL, ~48 mg / mL - ~50 mg / mL or, e.g., ~49 mg / mL.

[0260] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s), wherein the one or more dermal / subdermal chromophoric vitamin(s) is riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, cobalamin or, e.g., cyanocobalamin or dermatologically suitable derivative thereof, one or more other B vitamin derivative(s), one or more other A vitamin derivative(s), or a combination of any thereof, which are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL - ~38 mg / mL, ~20 mg / mL - ~36 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL - ~32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL — 50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL - ~50 mg / mL, ~28 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~30 mg / mL - ~50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0261] According to aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising two or more chromophoric agents, e.g., two or more vitamins, two or more minerals, two or more non-vitamins and non-minerals, a combination of two or more chromophoric agent(s) representing different types of chromophoric agents. In aspects, at least two of the two or more agents are present in amounts which are present in at least mostly the same, at least generally the same, at least substantially the same, at leastessentially the same, essentially the same, or the same amount. In aspects, one or more agent(s) of such two or more agent(s) of chromophoric composition(s) herein are present in detectably or significantly different amounts.

[0262] For example, in aspects, chromophoric composition(s) provided herein can comprise a first chromophoric agent present in a ratio with one or more additional chromophoric agents (as established by mol.%, wt.%, or, e.g., mg / mL) which is less than about 1 :1, such as, e.g., -1: 1000, -1 :800, -1 :600, -1 :400, -1 :300, -1 :200, -1 :100, -1 :80, -1 :60, -1:40, -1 :20, -1:10, -1 :9, -1 :8, -1 :7, -1 :6, -1 :5, -1 :4, -1 :3, or, e.g., -1 :2.

[0263] For example, in aspects, chromophoric composition(s) provided herein can comprise a first chromophoric agent present in a ratio with one or more additional chromophoric agents (as established by mol.%, wt.%, or, e.g., mg / mL) which is greater than about 1: 1, such as, e.g., -1000:1, -800:1, -600:1, -400: 1, -300:1, -200:1, -100: 1, -80: 1, -60:1 , -40:1, -20:1, -10:1, -9:1, -8:1, -7:1, -6:1, -5:1, -4:1, -3:1, or, e.g., -2:1.

[0264] For example, in aspects, chromophoric composition(s) provided herein can comprise a first chromophoric agent providing a first chromophoric aesthetic effect present in a ratio with one or more additional chromophoric agents providing a second chromophoric aesthetic effect (as established by mol.%, wt.%, or, e.g., mg / mL) which is less than about 1 :1, such as, e.g., -1: 1000, -1:800, -1 :600, -1 :400, -1 :300, -1 :200, -1 :100, -1:80, -1:60, -1 :40, -1:20, -1:10, -1:9, -1:8, -1:7, -1:6, -1:5, -1:4, -1:3, or, e.g., -1:2.

[0265] For example, in aspects, chromophoric composition(s) provided herein can comprise a first chromophoric agent providing a first chromophoric aesthetic effect present in a ratio with one or more additional chromophoric agents providing a second chromophoric aesthetic effect (as established by mol.%, wt.%, or, e.g., mg / mL) which is greater than about 1:1, such as, e.g., -1000: 1, -800: 1, -600: 1, -400:1, -300: 1, -200:1, -100:1, -80:1, -60: 1, -40: 1, -20:1, -10: 1, -9: 1, -8: 1, -7: 1, -6: 1, -5: 1, -4: 1, -3: 1, or, e.g., -2:1.

[0266] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s), wherein the ratio of the number of moles of the one or more dermal / subdermal chromophoric vitamin(s) to the number of moles of the one or more structural component(s) or agent(s) thereof is about 37: 1 to about 461 :1, such as about, e.g., -35:1 to -461 :1, -30: 1 to -461:1, -25: 1 to -461 : 1, -20: 1 to -461 :1, -15:1 to -461:1, -10:1 to -461 :1, or, e.g., -37:1 to -461:1, -37:1 to -460:1, -37:1 to -360:1, -37:1 to -260: 1, -37:1 to -160:1, or, e.g., -37:1 to -60:1.

[0267] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s), wherein the ratio of the number of moles of the one or more dermal / subdermal chromophoric vitamin(s) to the one or more structural component(s) or agent(s) thereof is about 30:1 to 150:1, e.g., -50:1 to -125:1, e.g., -75:1 to -110: 1, e.g., -85:1 to -105:1, e.g., -90: 1 such as -92:1.

[0268] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s), wherein the ratio of the number of moles of the one or more dermal / subdermal chromophoric vitamin(s) to the one or more structural component(s) or agent(s) thereof is about 100:1 - about 350:1, e.g., -125:1 to -275:1, such as -135:1 to -225: 1, such as -175:1 to -200:1, e.g., -185:1.

[0269] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s), wherein the ratio of the weight percent of the one or more dermal / subdermal chromophoric vitamin(s) in composition(s) to the weight percent of one or more structural component(s) or agent(s) thereof in composition(s) is about 1 :5 to about 60: 1, such as about, e.g., 1:4 to -60:1, -1 :3 to -60: 1, -1:2 to 60: 1, -1 : 1 to 60: 1, such as about, e.g., 1 :5 to 55:1, -1 :5 to 50:1, -1 :5 to 45:1, -1 :5 to 40:1, -1:5 to 35:1, -1 :5 to 30:1, -1:5 to 25:1, -1:5 to 20:1, -1 :5 to 15:1, -1:5 to 12:1, -1 :5 to 10:1, or, e.g., -1:5 to 5: 1.

[0270] hi aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the ratio of the number of moles of the one or more dermal / subdermal chromophoric mineral(s) to the number of moles of the one or more structural component(s) or agent(s) thereof is about 1,000,000:1 to about 10,000: 1, such as about, e.g., 800,000:1 to about 12,000:1, -20,00: 1, -100,000: 1, or -200,000: 1, -600,000:1 to -12,000: 1, -20,000: 1 or -100,000: 1, -400,000: 1 to -12,000: 1, -20,000: 1, -100,000:1, -200,000:1 to -100,000: 1, -50,000:1, -20,000:1, -10,000:1, -5,000:1 or -1,000: 1, about 100,000:1 to -50,000:1, -25,000:1, -20,000:1, -10,000:1, -5,000:1, -1,000:1, -500:1, -200: 1, or -100:1, or, e.g., between -100,000: 1 and -10,000,000:1, e.g., between -200,000:1 and 10,000,000:1 or between -1,000,000: 1 and 10,000,000: 1, -5,000:1 to -100,000:1, such as -7,000: 1 to -70,000: 1 or -7,000: 1 to -35,000: 1, -10:1 to 10,000: 1 or -100:1 to 5,000: 1 or -1,000:1 to 500,000: 1.

[0271] In still other aspects, the ratio of the number of moles of the one or more dermal / subdermal chromophoric mineral(s) to the number of moles of the one or more structural component(s) or agent(s) thereof is about 1,500,000: 1 to about 9,000,000: 1, e.g., -2,000,000: 1 to-8,000,000:1, e.g., -2,500,00:1 to -7,000,000:1, e.g., -2,250,000:1 to -6,000,000:1 or -5,000,000:1.

[0272] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the ratio of the weight percent of the one or more dermal / subdermal chromophoric mineral(s) in composition(s) to the weight percent of one or more structural component(s) in composition(s) is about 1 :5 to 60: 1, such as about, e.g., aboutl :4 to 60: 1, about 1 :3 to 60: 1, about 1:2 to 60: 1, about 1: 1 to 60: 1, such as about, e.g., about 1 :5 to 55:1, about 1:5 to 50:1, about 1 :5 to 45:1, about 1 :5 to 40:1, about 1 :5 to 35: 1, about 1:5 to 30:1, about 1:5 to 25:1, about 1:5 to 20:1, about 1:5 to 15:1, about 1:5 to 12:1, about 1 :5 to 10: 1, or, e.g., about 1:5 to 5: 1.

[0273] In aspects, dermatologically suitable chromophoric composition(s) can comprise one or more dermal / subdermal chromophoric component(s), wherein the one or more dermal / subdermal chromophoric component(s) comprise one or more dermal / subdermal chromophoric mineral(s). In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral(s) is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., -20 mg / mL — 48 mg / mL, -20 mg / mL — 46mg / mL, -20 mg / mL — 44mg / mL, -20 mg / mL — 42 mg / mL, -20 mg / mL — 40 mg / mL, -20 mg / mL — 38 mg / mL, -20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of -20 mg / mL — 34 mg / mL, -20 mg / mL — 32 mg / mL, -20 mg / mL — 30 mg / mL, -20 mg / mL — 28 mg / mL, -20 mg / mL — 26 mg / mL, -20 mg / mL — 24 mg / mL, -20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, -24 mg / mL — 50 mg / mL, -26 mg / mL — 50 mg / mL, -28 mg / mL - -50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of -30 mg / mL - -50 mg / mL, -32 mg / mL — 50 mg / mL, -34 mg / mL - -50 mg / mL, -36 mg / mL — 50 mg / mL, -38 mg / mL — 50 mg / mL, -40 mg / mL — 50 mg / mL, -42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, -46 mg / mL — 50 mg / mL, -48 mg / mL — 50 mg / mL or, e.g., -49 mg / mL.

[0274] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral(s) is iron, iron oxide, iron salt, or any combination thereof which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., -20 mg / mL — 48 mg / mL, -20 mg / mL - ~46mg / mL, -20 mg / mL - ~44mg / mL, -20 mg / mL - -42 mg / mL, -20 mg / mL — 40 mg / mL, -20 mg / mL — 38 mg / mL, -20 mg / mL — 36 mg / mL, or, e.g., the one ormore chromophoric mineral(s) are present in an amount of ~20 mg / mL - ~34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL - ~26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL — 50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of about 30 mg / mL - ~50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL - ~50 mg / mL, ~36 mg / mL - ~50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL - ~50 mg / mL, -44 mg / mL - ~50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0275] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral(s) is zinc, zinc oxide, zinc salt, or any combination thereof which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., ~20 mg / mL - ~48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~20 mg / mL - ~34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~30 mg / mL - ~50 mg / mL, ~32 mg / mL - ~50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0276] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral is copper, copper oxide, copper salt, or any combination thereof which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL - ~38 mg / mL, ~20 mg / mL - ~36 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL - ~50 mg / mL, ~28 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~30 mg / mL - ~50mg / mL, ~32 mg / mL - ~50 mg / mL, ~34 mg / mL - ~50 mg / mL, ~36 mg / mL - ~50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL - ~50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0277] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral is rose quartz, which is present in an amount of about 20 mg / mL - about 50 mg / mL, such as, e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL - ~46mg / mL, ~20 mg / mL - ~44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~20 mg / mL - ~34 mg / mL, ~20 mg / mL - ~32 mg / mL, ~20 mg / mL - ~30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL - ~50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL - ~50 mg / mL, ~38 mg / mL - ~50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0278] In aspects, composition(s) provided for herein comprise one or more chromophoric mineral(s), wherein the one or more dermal / subdermal chromophoric mineral(s) is iron, iron oxide, iron salt, zinc, zinc oxide, zinc salt, copper, copper oxide, copper salt, or rose quartz, or a combination of any thereof, which are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL - ~44mg / mL, ~20 mg / mL - ~42 mg / mL, ~20 mg / mL - ~40 mg / mL, ~20 mg / mL - ~38 mg / mL, ~20 mg / mL - ~36 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., ~22 mg / mL — 50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric mineral(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL - ~50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL - ~50 mg / mL or, e.g., ~49 mg / mL.

[0279] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric natural compound(s), wherein the one or more dermal / subdermal chromophoric natural compound(s) is urobilin or one or more carotenoid(s), or a combination of any thereof, which are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, e.g., ~20 mg / mL — 48 mg / mL, ~20 mg / mL — 46mg / mL, ~20 mg / mL - ~44mg / mL, ~20 mg / mL - ~42 mg / mL, ~20 mg / mL - ~40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, or, e.g., the one or more chromophoric natural compound(s) are present in an amount of ~20 mg / mL — 34 mg / mL, ~20 mg / mL — 32 mg / mL, ~20 mg / mL — 30 mg / mL, ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL - ~22 mg / mL, such as, e.g., ~22 mg / mL - ~50 mg / mL, ~24 mg / mL - ~50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, or, e.g., the one or more chromophoric natural compound(s) are present in an amount of ~30 mg / mL — 50 mg / mL, ~32 mg / mL — 50 mg / mL, ~34 mg / mL — 50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL - ~50 mg / mL, ~42 mg / mL — 50 mg / mL, ~44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., ~49 mg / mL.

[0280] In aspects, the dermatologically suitable chromophoric composition can comprise one or more dermal / subdermal chromophoric component(s) comprising one or more dermal / subdermal chromophoric vitamin(s) or vitamin derivative(s). In aspects, the one or more dermal / subdermal chromophoric component(s) can be comprised of most, generally all, substantially all, or entirely of riboflavin or dermatologically suitable derivative thereof. In aspects, the one or more dermal / subdermal chromophoric component(s) can be comprised of most, generally all, substantially all, or entirely of pyridoxine or dermatologically suitable derivative thereof. In aspects, the one or more dermal / subdermal chromophoric component(s) can be comprised of most, generally all, substantially all, or entirely of cobalamin or, e.g., cyanocobalamin. In aspects, the one or more dermal / subdermal chromophoric component(s) can be comprised of most, generally all, substantially all, or entirely of riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, and cobalamin or, e.g., cyanocobalamin or dermatologically suitable derivative thereof, or any combination thereof. In one aspect, the one or more dermal / subdermal chromophoric component(s) in composition(s) described herein only comprises riboflavin or dermatologically suitable derivative thereof, pyridoxine or dermatologically suitable derivative thereof, and cobalamin or, e.g., cyanocobalamin or dermatologically suitable derivative thereof.

[0281] In aspects, the one or more dermal / subdermal chromophoric agent(s) present in the one or more dermal / subdermal chromophoric component(s) can be comprised of one or more dermal / subdermal non- vitamin agent(s) which produce a detectable effect, e.g., change in skin color, when injected in the skin. In aspects, the one or more dermal / subdermal non- vitamin agent(s) can include, but are not limited to, dyes, metal oxides, pigments, or any combination thereof. In aspects, most, generally all, substantially all, or all of the chromophoric dermal / subdermal chromophoric component(s) can be composed of dermal / subdermal nonvitamin agent(s), e.g., dyes, metal oxides, pigments, or any combination thereof. In certain aspects, chromophoric composition(s) herein lack one, some, most, generally all, substantially all, essentially all, or all of such non-vitamin agent(s).

[0282] In aspects, the one or more dermal / subdermal non-vitamin agent(s) can comprise metal oxides of iron, e.g., iron oxide (red), iron oxide (yellow), iron oxide (white), titanium dioxide, or any combination thereof. In aspects, the one or more dermal / subdermal non-vitamin agent(s) can comprise metal oxides of iron, which produce a detectable effect on the hue or color of the skin of a recipient, e.g., as determined by a statistically significant number of licensed healthcare professionals. In aspects, most, generally all, substantially all, or all of the one or more dermal / subdermal non-vitamin agent(s) can be composed of iron oxide (red), iron oxide (yellow), iron oxide (white), titanium dioxide, or any combination thereof.

[0283] hi aspects, the chromophoric aesthetic effect period of the one or more dermal / subdermal chromophoric agent(s) is typically the period of time wherein injection of the dermatologically suitable dermal / subdermal chromophoric composition into the dermis of a recipient, e.g., a human patient, imparts a detectable effect in the hue or color to the skin of the recipient. In aspects, the detectable effect in skin color (chromophoric aesthetic effect) is established by at least one or more dermal / subdermal chromophoric agent(s). In aspects, the detectable effect in skin color is identified by a statistically significant number of licensed healthcare professionals. In aspects, the detectable effect in skin color of the at least one or more dermal / subdermal chromophoric agent(s) can last between about 10% and about 100% such as -15% - -95%, -20% - -90%, -25% - -85 %, -30 % - -75 %, -35% - -80 % of the aesthetic effect period provided by a structural component or for example about 75% of the aesthetic effect period of a structural component.

[0284] In certain aspects, the chromophoric aesthetic effect of the at least one or more dermal / subdermal chromophoric agent(s) is at least mostly, at least generally, at leastsubstantially, at least essentially, essentially, or is the same as that of any structural aesthetic effect provided by structural component(s) or agent(s) thereof.

[0285] One or more additional means of quantifying skin color change in a recipient after injection of composition(s), comprising one or more dermal / subdermal chromophoric component(s), provided for herein can comprise, e.g., use of spumescence microscopy or dermoscopy, reflectance spectroscopy, colorimeter(s), ultraviolet light examination, polarized light examination, in vivo confocal scanning laser microscopy, visual assessment, or any other method in the art used for quantifying changes in color, e.g., changes in skin color.Chromophoric Component - Opacity

[0286] According to certain aspects, chromophoric composition(s) provided herein comprise one or more chromophoric component(s) comprising one or more chromophoric agent(s), wherein the presence of the chromophoric component(s) provide a delectably or significantly colored appearance to the chromophoric composition(s). That is, e.g., in aspects, chromophoric composition(s) provided herein are not completely clear (lack color). In aspects, chromophoric composition(s) provided herein are not completely transparent. In aspects, chromophoric composition(s) provided herein are characterizable as opaque. According to aspects, chromophoric composition(s) herein are at least detectably or significantly translucent. According to certain aspects, composition(s) provided herein allow at least about 50%, >~55%, >~60%, >~65 % , >~70%, >~75%, >~80%, >~85 % , >~90%, or >~95% of visible light pass through when exposed to such light, however, allow for less than 100% of visible light to pass.

[0287] In aspects, chromophoric composition(s) provided herein comprise one or more chromophoric component(s) comprising one or more chromophoric agent(s), wherein the presence of the chromophoric component(s) provide a detectable or significant coloration or tint, e.g., a rose, pink, scarlet, or otherwise characterizably red tint to the chromophoric composition(s) which is detectably or significantly visible to the average observer or which is detectable by measurement via a spectrophotometer or a colorimeter.Chromophoric Composition - Duration of Chromophoric Aesthetic Effect

[0288] According to aspects, chromophoric composition(s) provided herein comprise one or more chromophoric component(s) comprising one or more chromophoric agent(s), which, upon administration of the chromophoric composition in effect amount(s) over an effective administration period, provide a detectable or significant chromophoric aesthetic effect for at least about 1 day, such as, e.g., >~2 days, >~3 days, >~1 week, >~2 weeks, >~1 month, >~2 months, >~3 months, >~4 months, >~5 months, >~6 months, >~7 months, >~8 months, >~9months, >~10 months, >~11 months, >~12 months, >~13 months, >~14 months, >~15 months, >~16 months, >~17 months, >~18 months, >~19 months, >~20 months, >~21 months, >~22 months, >~23 months, or >~24 months, such as >~26 months, >~28 months, >~30 months, >~32 months, >~34 months, or, e.g., >~36 months.Chromophoric Extension Component

[0289] In aspects, dermatologically suitable chromophoric composition(s) comprise a chromophoric extension component. In aspects, a chromophoric extension component comprises one or more chromophoric extension agent(s) providing one or more detectable or significant structural effect(s), such as, e.g., those described herein. In aspects, a chromophoric extension component comprises one or more chromophoric extension agent(s) which detectably or significantly extend the longevity of chromophoric agent(s), the longevity of the aesthetic effect(s) of chromophoric agent(s), or both.

[0290] According to aspects, a chromophoric extension component comprises one or more chromophoric extension agent(s) which, when present and in stable association with chromophoric agent(s) of chromophoric component(s), detectably or significantly extend the stability of the associated chromophoric agent(s) (chromophore(s)), detectably or significantly extend the chromophoric aesthetic effect of the chromophoric component(s), the chromophoric composition(s), or both, or any combination thereof, compared to at least substantially similar composition(s) lacking such chromophoric extension component(s) / chromophoric extension agent(s) or lacking such chromophoric extension component(s) / chromophoric extension agent(s) in stable association with such chromophoric agent(s).

[0291] According to further aspects, a chromophoric extension component can, in aspects, provide one or more detectable or significant structural aesthetic effects to chromophoric composition(s) when present in effective amount(s), when administered over an effective administration period, or both. In aspects, such a structural aesthetic effect can be, e.g., a smoothing, plumping, or filling effect.

[0292] In certain aspects, the disclosure provides chromophoric compositions comprising a dual-purpose chromophoric extension component, the dual-purpose chromophoric extension component comprising one or more dual-purpose chromophoric extension agent(s).Uncontradicted, discussion of structural component(s) and structural agent(s) herein, also or alternatively described herein as chromophoric extension component(s) and chromophoric extension agent(s), should be interpreted as including reference to such component(s) and agent(s) as dual-purpose (e.g., reference to a “structural component(s)” and “structural agent(s)”should be interpreted as including reference to “dual-purpose structural component(s)” and “dual-purpose structural agent(s),” “dual-purpose chromophoric extension component(s),” and, e.g., “dual-purpose chromophoric extension agent(s),” as appropriate. In aspects, such a dualpurpose chromophoric extension (structural) component / agent is a component / agent providing at least two detectable or significant effects. In aspects, one detectable or significant effect is a detectable or significant extension of time of a detectable or significant chromophoric effect provided by one or more chromophoric agent(s). In aspects, such an extension is a result of chromophoric extension (structural) agent(s) being associated with, e.g., conjugated to, the chromophoric agent(s). In aspects, another detectable or significant effect is a detectable or significant structural skin effect, e.g., a detectable or significant smoothing, plumping, or filling of skin (e.g., adding volume, reducing wrinkling, and the like.)

[0293] In aspects, structural agent(s) can be, e.g., any pharmaceutically acceptable and dermatologically suitable structural compound(s) capable of detectably or significantly stably associating with one or more chromophoric agents. In aspects, such structural compound(s) are compound(s) which, when stably associated with chromophoric agent(s) are capable of extending the chromophoric aesthetic effect of such chromophoric agent(s) upon administration to human skin. In aspects, such structural compound(s) are capable of being conjugated to chromophoric agent(s). In aspects, such structural compound(s) are capable of being covalently bonded to chromophoric agent(s). In aspects, such structural compound(s) are capable of forming a detectable or significant chemical bond to chromophoric agent(s).

[0294] In aspects, structural agent(s) can be, e.g., pharmaceutically acceptable and dermatologically suitable structural compound(s) capable of demonstrating a structural aesthetic effect in a subject, such as, e.g., in the skin of a subject (demonstrating a structural aesthetic skin effect / structural skin aesthetic effect), to which composition(s) comprising such component(s) and agent(s) are administered. In aspects, chromophoric composition(s) provided herein, comprise a structural component, wherein if the structural component demonstrates a detectable or significant structural aesthetic effect to the skin, the chromophoric composition simultaneously (at least during some, most, generally all, substantially all, essentially all, or the entirety of the period of time after administration during which the structural component is present) provides a chromophoric effect to the skin. In certain aspects, the two effects (chromophoric and structural) effects demonstrate a duration of effect which is at least mostly, at least generally, at least substantially, at least essentially, or is equivalent. In aspects, a structuralcomponent is present in a composition along with one or more additional component(s), such as, e.g., a dermal / subdermal chromophoric component, an excipient component, or both.

[0295] In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant chromophoric agent stabilizing effect, structural aesthetic effect, or both, e.g., detectable or significant extension of chromophoric effect of chromophoric agent(s), detectable or significant modulation of the volume of one or more areas of the skin of a recipient, e.g., a human patient, upon injection of composition(s) of the invention, or combination(s) thereof. In such a respect, any known equivalents of such named agents can also be, e.g., are, incorporated into compositions or methods of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the above-described structural component(s) can be described as structural component means (or structural means) or means for providing effective, detectable, or significant structural activity / characteristics to one or more chromophoric composition component(s) / agent(s), areas of the skin of a recipient, e.g., a human patient, or both.Chromophoric Extension Component Amount

[0296] In aspects, the chromophoric extension (structural) component can be present in any effective amount, e.g., an effectively chromophore-stabilizing amount or, e.g., a structurally aesthetic effective amount. In aspects, the chromophoric extension (structural) component is present in an effective amount, such as, e.g., an effective amount to detectably or significantly stabilize one or more chromophoric agent(s) present in the composition(s), detectably or significantly reduce the appearance of fine lines, wrinkles, or other visually identifiable contour- related skin indications upon administration, detectably or significantly enhance, increase, or otherwise plump or enlarge one or more facial features such as, e.g., lip(s), or combination(s) thereof.

[0297] In aspects, a structural component is present in an amount of between about 0.5 wt.% and about 5 wt.% of a composition, such as, e.g., ~1 wt.% - ~5 wt.%, such as, e.g., ~1.5 wt.% - -5 wt.%, -2 wt.% - -5 wt.%, -2.5 wt.% - -5 wt.%, -3 wt.% - -5 wt.%, -3.5 wt.% - -5 wt.%, -4 wt.% - -5 wt.%, -4.5 wt.% - -5 wt.%, etc., such as, e.g., an amount of between about 0.5 wt.% - -4.5 wt.%, such as, e.g., -0.5% - -4 wt.%, -0.5 wt.%% - -3.5 wt.%, -0.5 wt.% - -3 wt.%, -0.5 wt.% - 2.5 wt.%, -0.5 wt.% - 2 wt.%, -0.5 wt.% - -1.5 wt.%, or as in e.g., - 0.5 wt.% - -1 wt.%.

[0298] In aspects, a structural component is present in an amount of between about 1 wt.% and about 4 wt.% of a composition, such as, e.g., ~1.5 wt.% - -4 wt.%, such as, e.g., -2 wt.% - -4 wt.%, -2.5 wt.% - -4 wt.%, -3 wt.% - -4 wt.%, -3.5 wt.% - -4 wt.%, etc., such as, e.g., an amount of -1 wt.% - -3.5 wt.%, such as, e.g., -1 wt.% - -3 wt.%, -1 wt.% - -2.5 wt.%, -1 wt.% - -2 wt.%, or as in e.g., about 1 wt.% - -1.5 wt.%.

[0299] In aspects, a structural component is present in an amount of between about 2 wt.% and about 3 wt.% of a composition, such as, e.g., -2.25 wt.% - -3 wt.%, such as, e.g., -2.5 wt.% - 3 wt.%, -2.75 wt.% — 3 wt.%, etc., such as, e.g., an amount of between about 2 wt.% - -2.75 wt.%, such as, e.g., -2% - -2.5 wt.%, or as in e.g., about 2 wt.% - about 2.25 wt.%.

[0300] In aspects, a structural component is present in an amount of between about 5.5 wt.% and about 10 wt.% of a composition, such as, e.g., -5 wt.% - -10 wt.%, such as, e.g., -5 wt.% - -10 wt.%, -4.5 wt.% - -10 wt.%, -4 wt.% - -10 wt.%, -3.5 wt.% - -10 wt.%, -2.5 wt.% - -10 wt.%, -2 wt.% - -10 wt.%, -1.5 wt.% - -10 wt.%, -1 wt.% - -10 wt.%, etc., such as, e.g., -5 wt.% - -9.5 wt.%, such as, e.g., -5 wt.% - -9 wt.%, -5 wt.% - 8.5 wt.%, -5 wt.% - -8 wt.%, -5 wt.% - -7.5 wt.%, -5 wt.% - 7.0 wt.%, -5 wt.% - -6.5 wt.%, or, as in e.g., about 5 wt.% - -6 wt.%.

[0301] In aspects, the dermatologically suitable chromophoric composition can comprise one or more structural component(s). In aspects, composition(s) provided for herein comprise one or more structural components wherein the one or more structural components are present in an amount of about 20 mg / mL - about 50 mg / mL, such as, for e.g., -20 mg / mL — 48 mg / mL, -20 mg / mL — 46mg / mL, -20 mg / mL — 44mg / mL, -20 mg / mL — 42 mg / mL, -20 mg / mL - -40 mg / mL, -20 mg / mL — 38 mg / mL, -20 mg / mL — 36 mg / mL, -20 mg / mL — 34 mg / mL, -20 mg / mL - -32 mg / mL, or, e.g., the one or more structural components are present in an amount of -20 mg / mL - -30 mg / mL, -20 mg / mL — 28 mg / mL, -20 mg / mL - -26 mg / mL, -20 mg / mL — 24 mg / mL, -20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, -24 mg / mL — 50 mg / mL, -26 mg / mL — 50 mg / mL, -28 mg / mL — 50 mg / mL, 30 mg / mL — 50 mg / mL, -32 mg / mL — 50 mg / mL, -34 mg / mL — 50 mg / mL, -36 mg / mL — 50 mg / mL, or, e.g., the one or more structural components are present in an amount of about 38 mg / mL - about 50 mg / mL, -40 mg / mL — 50 mg / mL, -42 mg / mL — 50 mg / mL, -44 mg / mL - -50 mg / mL, -46 mg / mL — 50 mg / mL, -48 mg / mL — 50 mg / mL or, e.g., -49 mg / mL.Chromophoric Extension Agents

[0302] In aspects, dermatologically suitable chromophoric composition(s) provided herein can comprise one or more chromophoric extension (structural) component(s) comprisingone or more pharmaceutically acceptable and dermatologically suitable chromophoric (structural) agent(s), e.g., chromophoric extension (structural) compound(s).

[0303] In aspects, a structural agent can be any pharmaceutically acceptable and dermatologically suitable structural compound capable of detectably or significantly stabilizing (e.g., extending the stability of, chromophoric effect of, or both) one or more chromophoric agent(s) present in the composition(s).

[0304] In aspects, a structural agent can be any pharmaceutically acceptable and dermatologically suitable structural compound capable of detectably or significantly reducing the appearance of fine lines, wrinkles, or other visually identifiable contour-related skin indications upon administration, detectably or significantly enhance, increase, or otherwise plump or enlarge one or more facial features such as, e.g., lip(s), or combination(s) thereof.

[0305] In aspects, a structural agent can be any pharmaceutically acceptable and dermatologically suitable structural compound capable of both detectably or significantly stabilizing (e.g., extending the stability of, chromophoric effect of, or both) one or more chromophoric agent(s) present in the composition(s) and demonstrating a structural aesthetic effect in a subject, such as, e.g., in the skin of a subject, to which composition(s) comprising such agent(s) are administered. In aspects, a structural agent is any pharmaceutically acceptable and dermatologically suitable compound which detectably or significantly stabilizes (e.g., extending the stability of, chromophoric effect of, or both) one or more chromophoric agent(s) of composition(s) herein. IN aspects, a structural agent is any compound which detectably or significantly modifies the structure of the skin, e.g., imparts (when administered in a sufficient and effective amount) a change in the shape of the target site into which it is administered, such as, for example, decreasing the depth of a visually identifiable line or wrinkle in the skin or increasing the volume of a target location (e.g., lip(s)).

[0306] In aspects, the one or more structural agent(s) are dermatologically suitable. A dermatologically suitable structural agent is one that is safe for use in most humans as determined by clinical studies or through other determinations acceptable to those of skill in the art. In aspects, the composition of an aspect or used in a method aspect of this disclosure comprises a structural component and dermatological suitability means having an adverse effect / safety profile that is significantly similar to or about the same, if not superior to, that of RESTYLANE, JUVEDERM, or both. Such fillers are known in the art, and are described in, e.g., US Patent Numbers 10,806,821, 8,778,909 and are reviewed by Weinkle et al. 2009.; JCosmet Dermatol.; Goodman GJ. et al., 2011 ; Brandt F et al., 2011; Prager W. et al 2012; Anne C et al., 2016).

[0307] In aspects, the one or more structural agent(s) present in the structural component can be any suitable one or more structural agent(s), which can be present in any aesthetically effective amount(s). In aspects, the structural component is mostly composed of, generally only composed of, substantially only composed of, essentially only composed of, or is only (entirely) composed of a single structural agent (a single type of structural agent or a single class of structural agent, e.g., two or more grades / types of hyaluronic acid). In aspects, the structural component is mostly, generally, substantially, or entirely composed of a hyaluronic acid (“HA”). In aspects, the HA is any suitable HA or HA derivative. In aspects, the HA can be any one HA or any suitable combination of hyaluronic acids.

[0308] In aspects, one or more hyaluronic acid(s) can comprise a HA with any molecular weight, e.g., a high molecular weight HA, a low molecular weight HA, or, e.g., a HA with a midrange molecular weight. In aspects, most, generally all, substantially all, or all of the one or more hyaluronic acid(s) in composition(s) provided for herein comprise high molecular weight hyaluronic acid.

[0309] In aspects, the HA is a high molecular weight HA. In aspects, such HA is a hyaluronic acid having a molecular weight of about 1,000 to about 1,500 kilodaltons, such as, e.g., -1,000 to -1,400 kDa, -1,000 to -1,300 kDa, -1,000 to -1,200 kDa, -1,000 to -1,100 kDa, or, e.g., -1,100 to 1,500 kDa, -1,200 to -1,500 kDa, -1,300 to -1,500 kDa, or, e.g., about -1,400 - -1,500 kDa.

[0310] In aspects, the HA is a low molecular weight HA. In aspects, such HA is a hyaluronic acid having a molecular weight of about 20 to about 300 kilodaltons, such as, e.g., -20 to -280 kDa, -20 to -260 kDa, -20 to -240 kDa, -20 to -220 kDa, -20 to -200 kDa, -20 to -180 kDa, -20 to -160 kDa, -20 to -140 kDa, -20 to -120 kDa, -20 to -100 kDa, -20 to -80 kDa, -20 to -60 kDa, -20 to -40 kDa, or, e.g., -40 to -300 kDa, -60 to -300 kDa, -80 to -300 kDa, -100 to -300 kDa, -120 to -300 kDa, -140 to -300 kDa, -160 to -300 kDa, -180 to -300 kDa, -200 to -300 kDa, -220 to -300 kDa, -240 to -300 kDa, -260 to -300 kDa, or, e.g., about -280 - -300 kDa.

[0311] In aspects, the HA is a midrange molecular weight HA. In aspects, such HA is a hyaluronic acid having a molecular weight of about 400 to about 900 kilodaltons, such as, e.g., -4000 to -850 kDa, -400 to -800 kDa, -400 to -750 kDa, -400 to -700 kDa, -400 to -650 kDa, -400 to -600 kDa, -400 to -550 kDa, -400 to -500 kDa, -400 to -450 kDa, or, e.g., -450to 900 kDa, -500 to -900 kDa, -550 to -900 kDa, -600 to -900 kDa, -650 to -900 kDa, -700 to -900 kDa, -750 to -900 kDa, -800 to -900 kDa or, e.g., -850 - -900 kDa.

[0312] In aspects, most, generally all, substantially all, or all of the HA in a structural component comprises crosslinked HA. In aspects, a “crosslinked HA” is understood to mean an HA in which 90 % of the HA comprises crosslinking with another HA molecule. (See, e.g., US Patent No. 10, 806, 821). Other examples of crosslinked HA are described below.

[0313] In aspects, the percentage of the structural component which comprises a crosslinked HA is between about 0.5% and about 9% of the total amount of the structural component present in the composition, such as, e.g., -1% - 9%, -1.5% - 9%, -2% - 9%, -2.5% - 9%, -3% - 9%, -3.5% - 9%, -3.5% - 9%, -4% - 9%, -4.5% - 9%, -5% - 9%, -5.5% - 9%, -6% - 9%, -6.5% - 9%, -7% - 9%, -7.5% - 9%, -8% - 9%, etc., such as, e.g., an amount of about 0.5% - 8.5%, such as, e.g., -0.5% - 8%, -0.5% - 7.5%, -0.5% - 7%, -0.5% - 6.5%, -0.5% - 6%, -0.5% - 5.5%, -0.5% - 5%, -0.5% - 4.5%, -0.5% - 4%, -0.5% - 3.5%, -0.5% - 3%, -0.5% - 2.5%, -0.5% - 2%, -0.5% - 1.5%, or as in e.g., about 0.5% - about 1%.

[0314] In aspects, the percentage of the structural component which comprises a crosslinked HA is between about 10% and about 95% of the total amount of the structural component present in the composition, such as, e.g., -15% - 95%, -20% - 95%, -25% - 95%, -30% - 95%, -35% - 95%, -40% - 95%, -45% - 95%, -50% - 95%, -55% - 95%, -60% - 95%,-65% - 95%, -70% - 95%, -75% - 95%, -80% - 95%, -85% - 95%, -90% - 95%, etc., such as, e.g., an amount of about 10% - 95%, such as, e.g., -10% - 90%, -10% - 85%, -10% - 80%, -10% - 75%, -10% - 70%, -10% - 65%, -10% - 60%, -10% - 55%, -10% - 50%, -10% - 45%,-10% - 40%, -10% - 35%, -10% - 30%, -10% - 25%, -10% - 20%, or as in e.g., -10% - -15%.

[0315] In aspects, the percentage of the structural component which comprises a crosslinked HA is between about 15% and about 45% of the total amount of the structural component present in the composition, such as, e.g., -20% - 45%, -25% - 45%, -30% - 45%, -35% - 45%, -40% - 45%, etc., such as, e.g., an amount of between about 15% and about 40%, such as, e.g., -15% - 35%, -15% - 30%, -15% - 25%, or as in e.g., about 15% - about 20%.

[0316] In aspects, the percentage of the structural component which comprises a crosslinked HA is between about 25% and about 85% of the total amount of the structural component present in the composition, such as, e.g., -20% - 85%, -15% - 85%, -10% - 85%, -5% - 85%, etc., such as, e.g., an amount of between about 25% and 80%, such as, e.g., -25% - 75%, -25% - 70%, -25% - 65%, -25% - 60%, -25% - 55%, -25% - 50%, -25% - 45%, -25% - 40%, -25% - 35% or as in e.g., about 25% - about 30%.

[0317] In aspects, the one or more structural agent(s) present in the structural component comprises one or more hyaluronic acid(s), wherein the one or more hyaluronic acid(s) comprises one or more crosslinked hyaluronic acid(s). In aspects, the hyaluronic acid is crosslinked by one or more means including, but not limited to, dynamic-chemistry, physical assembly, host-guest interaction, electrostatic interaction, or use of a crosslinker. In aspects, a crosslinker typically comprises one or more small molecule(s) comprising a spacer and at least about two or more functional groups providing the means to bridge hyaluronic acid chains. Exemplary crosslinking molecule(s) are provided elsewhere herein.

[0318] In aspects, structural component(s) provide a stabilizing effect, e.g., extending the stability of, e.g., chromophoric aesthetic effect period, of one or more chromophoric agent(s) of chromophoric composition(s). In aspects, a stabilizing effect of at least mostly all, at least generally all, at least substantially all, at least essentially all, or all of the structural component within the dermatologically suitable chromophoric composition is provided for a period of at least about 3 months - about 12 months, such as, e.g., at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, or longer, e.g., such that a chromophoric aesthetic effect of such chromophoric agent(s) is detectable or significant for such period(s). In aspects, a stabilizing effect, e.g., as indicated by a visible chromophoric aesthetic effect of existing chromophoric agent(s), is sustained for a period of at least 9 months as appreciated by a statistically significant number of licensed healthcare professionals.

[0319] In aspects, structural component(s) provide a structural aesthetic effect, e.g., a structural aesthetic skin effect or structural skin aesthetic effect. In aspects, a structural aesthetic effect of at least mostly all, at least generally all, at least substantially all, at least essentially all, or all of the structural component within the dermatologically suitable chromophoric composition is sustained for a period of at least about 3 months - about 12 months, such as, e.g., at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, or longer. In aspects, an aesthetic effect, e.g., a structural aesthetic effect, is sustained for a period of at least 9 months as appreciated by a statistically significant number of licensed healthcare professionals.

[0320] In aspects, the dermatologically suitable chromophoric composition provided by the invention can comprise crosslinked hyaluronic acid molecules. In aspects, crosslinking is the process of chemically joining two or more molecules by a covalent bond in the presence of a crosslinker. In aspects, the crosslinkers are molecules that contain two or more reactive ends capable of chemically attaching to specific functional groups (primary amines, sulfhydryl, etc.)on other molecules. In aspects, a hyaluronic acid is chemically modified in order to enhance its physical and chemical properties while retaining its natural biocompatibility, biodegradability, and lack of immunogenicity. In aspects, a hyaluronic acid present in composition(s) undergoes functional modification of the hydroxyl groups within a hyaluronic acid, which results in crosslinked HA. In aspects, the dermatologically suitable chromophoric composition comprises hyaluronic acid molecules which are crosslinked to each other with the help of a crosslinker to form a branched chain polymer of crosslinked hyaluronic acid molecules. In aspects, the structural component in the chromophoric composition comprises mostly, generally, substantially, or is entirely composed of crosslinked hyaluronic acid.

[0321] In aspects, the dermatologically suitable chromophoric composition can comprise a crosslinking component which can comprise one or more crosslinking agent(s). In aspects, the one or more crosslinking agent(s) can be used to crosslink one or more hyaluronic acid molecule(s). In aspects, the crosslinking agent may be any agent known to be suitable for crosslinking a hyaluronic acid and hyaluronic acid derivative(s) via hydroxyl groups. In aspects, the one or more crosslinking agents can include but are not limited to 1 , 4-butanediol diglycidyl ether (BDDE), divinyl sulphone, 2, polyethylene glycol (PEG) 7, 8 -diepoxy octane (DEO), 1,2- bis(2,3-epoxypropoxy) ethylene, and l-(2,3-epoxypropyl)-2, 3-epoxycyclohexane. In aspects, the structural component in the dermatologically suitable chromophoric composition comprises mostly, generally, substantially, or is entirely composed of 1, 4-butanediol diglycidyl ether (BDDE) as a crosslinker. In aspects, suitable crosslinking agent(s) is / are agent(s) sharing one, some, most, generally all, substantially all, essentially all, or all characteristics of one, some, most, generally all, substantially all, essentially all, or all exemplified crosslinking agent(s) disclosed herein, such as, e.g., cross linking agent(s) providing at least substantially the same crosslinking capability according to compounds or molecules linked, at least substantially the same crosslinking capability according to the strength of linkage provided, at least substantially the same crosslinking capability according to the duration of linkage maintained, the size of the crosslinking agent, the molecular weight of the crosslinking agent, or combination(s) thereof, of exemplary crosslinking agent(s) provided here.

[0322] In aspects, the crosslinker is present in composition(s) provided for herein in an amount of about 2 mg / mL to about 40 mg / mL, such as, e.g., -4 mg / mL to ~40 mg / mL, ~6 mg / mL to ~40 mg / mL, ~8 mg / mL to -40 mg / mL, -10 mg / mL to -40 mg / mL, -12 mg / mL to -40 mg / mL, -14 mg / mL to -40 mg / mL, -16 mg / mL to -40 mg / mL, -18 mg / mL to -40 mg / mL, -20 mg / mL to -40 mg / mL, or, e.g., the crosslinker is present in composition(s) provided forherein in an amount of -22 mg / mL to ~40 mg / mL, ~24 mg / mL to ~40 mg / mL, ~26 mg / mL to ~40 mg / mL, ~28 mg / mL to ~40 mg / mL, ~30 mg / mL to ~40 mg / mL, ~32 mg / mL to ~40 mg / mL, or, e.g., the crosslinker is present in composition(s) provided for herein in an amount of ~34 mg / mL to ~40 mg / mL, ~36 mg / mL to ~40 mg / mL, ~38 mg / mL to ~40 mg / mL or, e.g., -2 mg / mL to ~38 mg / mL, -2 mg / mL to ~36 mg / mL, -2 mg / mL to ~34 mg / mL, -2 mg / mL to ~32 mg / mL, -2 mg / mL to ~30 mg / mL, -2 mg / mL to ~28 mg / mL, -2 mg / mL to ~26 mg / mL, -2 mg / mL to ~24 mg / mL, -2 mg / mL to -22 mg / mL, or, e.g., the crosslinker is present in composition(s) provided for herein in an amount of -2 mg / mL to ~20 mg / mL, -2 mg / mL to ~18 mg / mL, -2 mg / mL to ~16 mg / mL, -2 mg / mL to -14 mg / mL, -2 mg / mL to -12 mg / mL, -2 mg / mL to -10 mg / mL, -2 mg / mL to -8 mg / mL, -2 mg / mL to -6 mg / mL, or, e.g., -2 mg / mL to -4 mg / mL.

[0323] In aspects, composition(s) provided for herein comprise a ratio of one or more crosslinker agent(s) to one or more structural agent(s) of about 0.5:1 to about 500: 1, such as, e.g., -0.5:1 to -450:1, -0.5:1 to -400:1, -0.5:1 to -350: 1, -0.5:1 to -300: 1, -0.5:1 to -250:1, -0.5:1 to -200: 1, -0.5:1 to -150: 1, -0.5: 1 to -100: 1, -0.5:1 to -80:1, -0.5:1 to -60:1, -0.5:1 to -40: 1, -0.5:1 to -20: 1, or, e.g., -0.5: 1 to -10: 1.

[0324] In aspects, the dermatologically suitable chromophoric composition can comprise an effective amount of at least one non-hyaluronic acid structural agent. In aspects, the structural component can comprise one or more non-hyaluronic acid based structural agent(s). In aspects, the dermatologically suitable chromophoric composition can comprise one or more structural agent(s) that do not contain hyaluronic acid. In aspects, non-hyaluronic acid structural agent(s) that can be in a composition of the disclosure or that is used in a method can include, but are not limited to calcium hydroxylapatite, exemplified in the FDA on market product Radiesse®, poly- L-lactic acid by Sculptra®, Polymethylmethacrylate (PMMA) exemplified in the FDA on market product Bellafill,® and lipogenic fillers. In aspects, the chromophoric composition comprising one or more structural component(s) can comprise one or more lipogenic filler(s). In aspects, the structural component can comprise an effective amount of one or more structural agent(s) comprising an effective amount of a hyaluronic acid and one more non-hyaluronic acid structural agents in any combination thereof.

[0325] In aspects, a structurally aesthetically effective amount is typically an amount that is effective to produce a sustained aesthetic skin shaping effect in most humans (e.g., as determined in one or more well powered and well controlled clinical studies).

[0326] In aspects, a stabilizing effect period is a period of time after administration of a chromophoric composition to a recipient wherein chromophoric agent(s) of composition(s) are sufficiently present (e.g., present in sufficient amount(s)) and sufficiently stable to provide a detectable or significant chromophoric aesthetic effect as appreciated by a statistically significant number of licensed healthcare professionals. In aspects, the structural aesthetic effect period is the period of time after administration of a chromophoric composition to a recipient wherein a detectable effect is established by at least one structural agent as determined by a statistically significant number of licensed healthcare professionals.

[0327] According to aspects, chromophoric composition(s) provided herein comprise one or more structural component(s) comprising one or more structural agent(s), which, upon administration of the chromophoric composition in effect amount(s) over an effective administration period, provide a detectable or significant stabilizing effect, structural aesthetic effect, or both, for at least about 1 day, such as, e.g., >~2 days, >~3 days, >~1 week, >~2 weeks, >~1 month, >~2 months, >~3 months, >~4 months, >~5 months, >~6 months, >~7 months, >~8 months, >~9 months, >~10 months, >~11 months, >~I2 months, >~13 months, >~I4 months, >~15 months, >~16 months, >~17 months, >~18 months, >~19 months, >~20 months, >~21 months, >~22 months, >~23 months, or >~24 months, such as >~26 months, >~28 months, >~30 months, >~32 months, >~34 months, or, e.g., >~36 months.

[0328] hi aspects, the detectable effect of at least one structural agent can last between about 10% and about 100% such as about 15% - about 95%, about 20% - about 90%, about 25% - about 85 %, about 30 % - about 75 %, about 35% - about 80 % of the chromophoric aesthetic effect period, or, e.g., about 75% of the chromophoric aesthetic effect period.

[0329] In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant chromophoric agent(s) stabilizing effect, e.g., allowing for chromophoric agent(s) to demonstrate detectable or significant chromophoric effect, imparting / providing an effective, detectable, or significant structural aesthetic effect, e.g., modulation of the volume of one or more areas of the skin of a recipient, e.g., a human patient, upon injection of composition(s) of the invention, or both. In such a respect, any known equivalents of such named agents can also be, e.g., are, incorporated into compositions or methods of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the abovedescribed structural agent(s) can be described as structural agent means or means for providingeffective, detectable, or significant chromophoric agent stabilizing activity, effective, detectable, or significant structural skin aesthetic activity / characteristics to one or more areas of the skin of a recipient, e.g., a human patient, or both.Possible Association of the Chromophoric Extension Component and the Dermal / Subdermal Chromophoric Component

[0330] In aspects, the one or more chromophoric extension (structural) component(s) are present in association, e.g., coterminous association, with the one or more dermal / subdermal chromophoric agent(s). For example, in aspects, the one or more chromophoric extension (structural) components and the one or more dermal / subdermal chromophoric agents of composition(s) herein are degraded and reabsorbed by the body of the recipient, e.g., a human patient, at a statistically similar rate. In aspects, the chromophoric extension (structural) component(s) are present in stable association with the dermal / subdermal chromophoric agent(s). In aspects, the increased affinity between the chromophoric extension (structural) component(s) and the dermal / subdermal chromophoric agents, e.g., the stable association of the dermal / subdermal chromophoric agent(s) with the chromophoric extension (structural) component(s), can be achieved by any suitable method of association, including, e.g., conjugation, including, but not limited to, covalent bonding, crosslinking, or encapsulation. In aspects, any suitable method of increasing the affinity between the one or more chromophoric extension (structural) component(s) and the one or more dermal / subdermal chromophoric agents may be employed. In aspects, the increased affinity between the chromophoric extension (structural) component(s) and the one or more dermal / subdermal chromophoric agents produces or promotes (detectably or significantly enhances or increases) a detectable change in the color of the dermatologically suitable dermal / subdermal chromophoric composition which is e.g., appreciated by a statistically significant number of licensed healthcare professionals when observing the dermatologically suitable dermal / subdermal chromophoric composition in a container, e.g., needle / cannula syringe system, e.g., prior to injection in a recipient. In aspects, the increased affinity between the one or more chromophoric extension (structural) component(s) and the one or more dermal / subdermal chromophoric agents produces or promotes (detectably or significantly enhances or increases) a detectable change in the color of the dermatologically suitable dermal / subdermal chromophoric composition which is e.g., appreciated by measurement via a spectrophotometer or a colorimeter. In aspects, the stable association between one or more chromophoric extension (structural) component(s) and one or more dermal / subdermal chromophoric component(s) produces or promotes (detectably or significantly enhances orincreases) the longevity of the chromophoric effect (chromophoric aesthetic effect), e.g., skin color change, induced by injection of composition(s) provided for herein, such that the chromophoric effect fades at a statistically similar rate as any structural effect which may be provided by the chromophoric extension (structural) component(s) / agent(s) thereof, as determined by a statistically significant number of licensed healthcare professionals.

[0331] In aspects, conjugation is the method of joining two or more molecules by alternating single or multiple (double or triple) bonds. In aspects, most, generally all, substantially all, or all of the one or more structural agent(s) are conjugated to one or more dermal / subdermal chromophoric agent(s) in the dermatologically suitable chromophoric dermal / subdermal composition. In aspects, conjugation occurs at one or more sites, such as, e.g., carboxylic acid group, hydroxyl group, etc. In aspects, the one or more structural component(s) comprising hyaluronic acid is conjugated to the one or more dermal / subdermal chromophoric agent(s). In aspects, the one or more dermal / subdermal chromophoric agent(s) are mostly, generally, substantially, or entirely conjugated to the one or more structural component(s). In aspects, conjugation of one or more structural component(s) and one or more dermal / subdermal chromophoric component(s) produces or promotes (detectably or significantly enhances or increases) the longevity of the chromophoric effect, e.g., skin color change, induced by injection of composition(s) provided for herein, e.g., as determined by a statistically significant number of licensed healthcare professionals.. In aspects, conjugation of one or more structural component(s) and one or more dermal / subdermal chromophoric component(s) produces or promotes (detectably or significantly enhances or increases) the longevity of the chromophoric effect, e.g., skin color change, induced by injection of composition(s) provided for herein, such that the chromophoric effect fades at a statistically similar rate as a structural effect provided by the structural component(s) / agent(s) thereof, e.g., as determined by a statistically significant number of licensed healthcare professionals.

[0332] According to certain aspects, structural agent(s) and chromophoric agent(s) are not associated using crosslinkers. In certain aspects, structural agent(s) and chromophoric agent(s) are associated using one or more crosslinkers. In aspects, a crosslinker used to associate chromophoric agent(s) with structural agent(s) is any dermatologically suitable element capable of detectably or significantly attaching one or more chromophoric agent(s) to one or more structural agent(s). In aspects, a suitable crosslinker is a crosslinker that covalently conjugates structural agent(s) to chromophoric agent(s). In aspects, in any such scenario wherein structural agent(s) are associated with chromophoric agent(s) via crosslinker(s), the structural agent may bea crosslinked structural agent, e.g., crosslinked hyaluronic acid, wherein such crosslinking is also accomplished using one or more crosslinking elements. In aspects, such crosslinking elements establishing a crosslinked structural agent (e.g., crosslinked hyaluronic acid) and establishing stable chromophoric agent(s)-structural agent(s) association(s) comprise the same crosslinkers (such as, e.g., BDDE). In aspects, such crosslinking elements establishing a crosslinked structural agent (e.g., crosslinked hyaluronic acid) and establishing stable chromophoric agent(s)-structural agent(s) association(s) comprise different crosslinkers.

[0333] According to aspects, suitable crosslinking agents for crosslinking chromophoric agent(s) and structural agent(s) can be but may not be not limited to 1, 4-butanediol diglycidyl ether (BDDE), divinyl sulphone, 2, polyethylene glycol (PEG) 7, 8 -diepoxy octane (DEO), 1,2- bis(2,3-epoxypropoxy) ethylene, and l-(2,3-epoxypropyl)-2, 3 -epoxy cyclohexane. In aspects, the chromophoric agent-structural agent association in the dermatologically suitable chromophoric composition comprises mostly, generally, substantially, or is entirely composed of 1, 4- butanediol diglycidyl ether (BDDE) as a crosslinker.

[0334] In aspects, a crosslinker is present in chromophoric composition(s) provided for herein in an amount of about 4 mg / mL to about 80 mg / mL, such as, e.g., ~8 mg / mL to ~80 mg / mL, ~12 mg / mL to ~80 mg / mL, ~16 mg / mL to ~80 mg / mL, ~20 mg / mL to ~80 mg / mL, ~24 mg / mL to ~80 mg / mL, ~28 mg / mL to ~80 mg / mL, ~32 mg / mL to ~80 mg / mL, ~36 mg / mL to ~80 mg / mL, ~40 mg / mL to ~80 mg / mL, or, e.g., the crosslinker is present in composition(s) provided for herein in an amount of -44 mg / mL to -80 mg / mL, -48 mg / mL to -80 mg / mL, -52 mg / mL to -80 mg / mL, -56 mg / mL to -80 mg / mL, -60 mg / mL to -80 mg / mL, -64 mg / mL to -80 mg / mL, or, e.g., the crosslinker is present in composition(s) provided for herein in an amount of -68 mg / mL to -80 mg / mL, -72 mg / mL to -80 mg / mL, -76 mg / mL to -80 mg / mL or, e.g., -4 mg / mL to -76 mg / mL, -4 mg / mL to -72 mg / mL, -4 mg / mL to -68 mg / mL, -4 mg / mL to -64 mg / mL, -4 mg / mL to -60 mg / mL, -4 mg / mL to -56 mg / mL, -4 mg / mL to -52 mg / mL, -4 mg / mL to -48 mg / mL, -4 mg / mL to -44 mg / mL, or, e.g., the crosslinker is present in composition(s) provided for herein in an amount of -4 mg / mL to -40 mg / mL, -4 mg / mL to -36 mg / mL, -4 mg / mL to -32 mg / mL, -4 mg / mL to -28 mg / mL, -4 mg / mL to -24 mg / mL, -4 mg / mL to -20 mg / mL, -4 mg / mL to -16 mg / mL, -4 mg / mL to -12 mg / mL, or, e.g., -4 mg / mL to -8 mg / mL.

[0335] According to certain aspects, a single chromophoric agent molecule or compound is associated with a single structural component molecule or compound. That is, in aspects, chromophoric agent- structural agent association(s) comprise(s) a chromophoric agent and astructural agent present in a 1 :1 ratio. In aspects, some, most, generally all, substantially all, essentially all, or all chromophoric agent-structural agent associations comprise a chromophoric agent and a structural agent present in a 1: 1 ratio.

[0336] According to other aspects, a two or more chromophoric agent molecules or compounds are associated with a single structural component molecule or compound. That is, in aspects, chromophoric agent- structural agent association(s) comprise(s) a chromophoric agent and a structural agent present in a ratio which is greater than 1:1, such as, e.g., a ratio of 2:1 or, e.g., 3:1. In aspects, some, most, generally all, substantially all, essentially all, or all chromophoric agent- structural agent associations comprise a chromophoric agent and a structural agent present in a ratio which is greater than 1 :1.

[0337] In aspects wherein two or more chromophoric agents are associated with a structural agent, the chromophoric agents are the same, e.g., the same chromophoric vitamin / vitamin derivative. In other aspects, wherein two or more chromophoric agents are associated with a structural agent, at least one chromophoric agent is detectably or significantly different from at least one other chromophoric agent, such as, e.g., representing different vitamins, different types of compounds (e.g., vitamin vs. mineral, vitamin vs. non-vitamin, etc.), or, e.g., representing different chromophoric effect(s), e.g., color-yielding effect(s) such as by having different spectral characteristic(s) (or combinations thereof).

[0338] hi aspects, the dermatologically suitable chromophoric composition comprising one or more structural component(s) can be comprised of crosslinked hyaluronic acid, noncrosslinked hyaluronic acid, or both (in combination). In aspects, the non-crosslinked hyaluronic acid refers to hyaluronic acid molecules present in the free form without any attachment to other HA molecules. In certain aspects, free HA can refer to HA molecules without any attachment to any other molecules in the composition.

[0339] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric structural component(s) (e.g., agent(s) thereof) present in stable association with one or more dermal / subdermal chromophoric agent(s) wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 1 wt.% and about 10 wt.% of the composition such as, for e.g., ~1 wt.% - ~9 wt.%, ~ 1 wt.% - ~8 wt.%, ~1 wt.% - ~7 wt.%, ~1 wt.% - ~6 wt.%, or, e.g., ~1 wt.% - ~5 wt.% of the composition such as, for example, ~2 wt.% - ~9 wt.%, ~3 wt.% - ~9 wt.%, ~4 wt.% - ~9 wt.%, or as in e. g., ~5 wt.% - ~9 wt.%, of thecomposition such as in, e.g., -2 wt.% - ~8 wt.%, ~3 wt.% - -7 wt.%, -4 wt.% - ~6 wt.%, or, e.g., ~5 wt.% of the composition.

[0340] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal structural component(s) (e.g., agent(s) thereof) present in stable association with one or more dermal / subdermal chromophoric agent(s) wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 15 wt.% and about 98 wt.%, such as, e.g., ~20 wt.%- ~98 wt.%, ~40 wt.% - ~98 wt.%, ~60 wt.% - ~98 wt.%, ~80 wt.% - ~98 wt.%, or e.g. ~90 wt.% — 98 wt.% such as, for example, ~20 wt.% - ~96 wt.%, ~40 wt.% - ~94 wt.%, ~60 wt.%- ~92 wt.%, or as in e.g., ~90 wt.% of the composition.

[0341] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric vitamin(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in an amount of between about between about lwt.% and about 10 wt.% of the composition such as, for e.g., -1 wt.% - -9 wt.%, -1 wt.% - ~8 wt.%, -1 wt.% - -7 wt.%, -1 wt.% - -6 wt.%, or, e.g., -1 wt.% - ~5 wt.% of the composition such as, for example, -2 wt.% - -9 wt.%, ~3 wt.% - -9 wt.%, -4 wt.% - -9 wt.%, or as in e. g., ~5 wt.% - -9 wt.%, of the composition such as in, e.g., -2 wt.% - ~8 wt.%, -3 wt.% - -7 wt.%, -4 wt.% - ~6 wt.%, or, e.g., ~5 wt.% of the composition.

[0342] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric vitamin(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 10 wt.% and about 30 wt.% of the composition such as, for e.g., -1 1 wt.% - ~30 wt.% of the composition such as, for e.g., ~11 wt.% - ~29 wt.%, -11 wt.% - -28 wt.%, -11 wt.% - -27 wt.%, -11 wt.% - -26 wt.%, or, e.g., -11 wt.% - -25 wt.% of the composition such as, for example, -12 wt.% - -29 wt.%, -13 wt.% - -29 wt.%, -14 wt.% - -29 wt.%, or as in e. g., -15 wt.% - -29 wt.%, of the composition such asin, e.g., ~12 wt.% - ~28 wt.%, ~13 wt.% - ~27 wt.%, ~14 wt.% - ~26 wt.%, or, e.g., ~15 wt.% of the composition.

[0343] In aspects, the dermatologically suitable chromophoric composition comprises one or more dermal / subdermal chromophoric component(s) wherein the one or more dermal / subdermal chromophoric agent(s) thereof comprises one or more dermal / subdermal chromophoric vitamin(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 31 wt.% and about 60 wt.% of the composition such as, for e.g., ~31 wt.% - ~59 wt.%, ~31 wt.% - ~58 wt.%, ~31 wt.% - ~57 wt.%, ~31 wt.% - ~56 wt.%, or, e.g., ~31 wt.% - ~55wt % of the composition such as, for example, ~32 wt.% - ~59 wt.%, ~33 wt.% - ~59 wt.%, ~34 wt.% - ~59 wt.%, or as in e. g., ~35 wt.% - ~59 wt.%, of the composition such as in, e.g., ~32 wt.% - ~58 wt.%, ~33 wt.% - ~57 wt.%, ~34 wt.% - ~56 wt.%, or, e.g., ~35 wt.% of the composition.

[0344] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric vitamins, present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between 15 wt.% and about 98 wt.%, such as for example ~20 wt.% - ~98 wt.%, ~40 wt.% - ~98 wt.%, ~60 wt.% - ~98 wt.%, ~80 wt.% - ~98 wt.%, or e.g. ~90 wt.% - ~98 wt.% such as, for example, ~20 wt.% - ~96 wt.%, ~40 wt.% - ~94 wt.%, ~60 wt.% - 92 wt.%, or, e.g., ~90 wt.% of the composition.

[0345] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric mineral(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structur l agent(s) entity is present in the composition in an amount of between about l.wt % and about 10 wt.% of the composition such as, for e.g., ~1 wt.% - ~9 wt.%, ~1 wt.% - ~8 wt.%, ~1 wt.% - ~7 wt.%, ~1 wt.% - ~6 wt.%, or, e.g., ~1 wt.% - ~5 wt.% of the composition such as, for example, ~2 wt.% -~9 wt.%, ~3 wt.% - ~9 wt.%, ~4 wt.% - ~9 wt.%, or as in e. g., ~5 wt.% - ~9 wt.%, of the composition such as in, e.g., ~2 wt.% - ~8 wt.%, ~3 wt.% - ~7 wt.%, -4 wt.% - ~6 wt.%, or, e.g., ~5 wt.% of the composition.

[0346] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric mineral(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 11 wt.% and about 30 wt.% of the composition such as, for e.g., ~11 wt.% - ~29 wt.%, ~11 wt.% - ~28 wt.%, ~11 wt.% - ~27 wt.%, ~11 wt.% - ~26 wt.%, or, e.g., -11 wt.% - ~25 wt.% of the composition such as, for example, ~12 wt.% - ~29 wt.%, -13 wt.% - ~29 wt.%, ~14 wt.% - ~29 wt.%, or as in e. g., -15 wt.% - ~29 wt.%, of the composition such as in, e.g., - 12 wt.% - ~28 wt.%, -13 wt.% - -27 wt.%, -14 wt.%- ~26 wt.%, or, e.g., ~15 wt.% of the composition.

[0347] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric mineral(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprise crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition in an amount of between about 31 wt.% and about 60 wt.% of the composition such as, for e.g., -31 wt.% - ~59 wt.%, -31 wt.% - ~58 wt.%, -31 wt.% - -57 wt.%, -31 wt.% - ~56 wt.%, or, e.g., -31 wt.% - ~55 wt.% of the composition such as, for example, ~32 wt.% - ~59 wt.%, -33 wt.% - ~59 wt.%, ~34 wt.% - ~59 wt.%, or as in e. g., ~35 wt.% - ~59 wt.%, of the composition such as in, e.g., ~32 wt.% - ~58 wt.%, -33 wt.% - -57 wt.%, ~34 wt.%- ~56 wt.%, or, e.g., ~35 wt.% of the composition.

[0348] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises one or more dermal / subdermal chromophoric agent(s), wherein the one or more dermal / subdermal chromophoric agent(s) comprises one or more dermal / subdermal chromophoric mineral(s), present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises crosslinked hyaluronic acid, wherein the associated chromophoric agent(s) / structural agent(s) entity ispresent in the composition in an amount of between about 15 wt.% and about 98 wt.%, such as for example ~20 wt.% - ~98 wt.%, ~40 wt.% - ~98 wt.%, ~60 wt.% - ~98 wt.%, ~80 wt.% - ~98 wt.%, or e.g. ~90 wt.% — 98 wt.% such as, for example, ~20 wt.% - ~96 wt.%, ~40 wt.% - ~94 wt.%, ~60 wt.% - 92 wt. %, or as in e.g., ~90 wt.% of the composition.

[0349] In aspects, composition(s) provided for herein comprise one or more dermal / subdermal chromophoric agent(s), e.g., vitamin(s), mineral(s), or a combination thereof, wherein the one or more dermal / subdermal chromophoric agent(s) are present in stable association with one or more structural component(s) (e.g., agent(s) thereof), wherein the one or more structural component(s) comprises, e.g., hyaluronic acid in free, crosslinked, or a combination of free and crosslinked form(s), wherein the associated chromophoric agent(s) / structural agent(s) entity is present in the composition is an amount of between about 20 mg / mL and about 50 mg / mL, such as, for e.g., ~20 mg / mL - ~48 mg / mL, ~20 mg / mL - ~46mg / mL, ~20 mg / mL — 44mg / mL, ~20 mg / mL — 42 mg / mL, ~20 mg / mL — 40 mg / mL, ~20 mg / mL — 38 mg / mL, ~20 mg / mL — 36 mg / mL, ~20 mg / mL — 34 mg / mL, ~20 mg / mL - ~32 mg / mL, ~20 mg / mL — 30 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of ~20 mg / mL — 28 mg / mL, ~20 mg / mL — 26 mg / mL, ~20 mg / mL — 24 mg / mL, ~20 mg / mL — 22 mg / mL, such as, e.g., -22 mg / mL — 50 mg / mL, ~24 mg / mL — 50 mg / mL, ~26 mg / mL — 50 mg / mL, ~28 mg / mL — 50 mg / mL, 30 mg / mL — 50 mg / mL, ~32 mg / mL - ~50 mg / mL, or, e.g., the one or more chromophoric vitamin(s) are present in an amount of 34 mg / mL - ~50 mg / mL, ~36 mg / mL — 50 mg / mL, ~38 mg / mL — 50 mg / mL, ~40 mg / mL — 50 mg / mL, ~42 mg / mL — 50 mg / mL, -44 mg / mL — 50 mg / mL, ~46 mg / mL — 50 mg / mL, ~48 mg / mL — 50 mg / mL or, e.g., 49 mg / mL.

[0350] According to certain aspects, most, some, generally all, substantially all, essentially all, or all structural agent(s) are associated with chromophoric agent(s). In certain aspects, less than about 50%, such as, e.g., <~45%, <~40%, <~35%, <~30%, <~25%, <~20%, <~15%, <~10%, <~5%, <~1%, or <~0.5% of structural agent(s) are unassociated with chromophoric agent(s).

[0351] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises a ratio of molecules of one or more structural component(s) to structural agent(s). In aspects the one or more structural component(s) comprises crosslinked hyaluronic acid, present in stable association with the one or more dermal / subdermal chromophoric agents, wherein the one or more dermal / subdermal chromophoric agents comprises one or more dermal / subdermal chromophoric minerals ). In aspects, the ratio of chromophoric mineral / s) tomolecules of one or more structural component(s) not in stable association with one or more dermal / subdermal chromophoric agents is between about 20: 1 and about 500: 1, such as, e.g., between -18: 1 and -500: 1, between -16:1 and -500: 1, between -14:1 and -500: 1, between -12:1 and -500:1, between -10:1 and -500:1, between -20:1 and -400:1, between -20:1 and -300:1, between -200:1 and -5: 1, or, e.g., between -20:1 and -100:1.

[0352] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is between about 3 mol.% and about 40 mol.%, such as, e.g., -3 mol.% - -39 mol.%, -3 mol.% - -37 mol.%, -3 mol.% - -35 mol.%, -3 mol.% - -33 mol.%, -3 mol.% - -31 mol.%, -3 mol.% - -29 mol.%, -3 mol.% - -27 mol.%, -3 mol.% - -25 mol.%, -3 mol.% - -23 mol.%, -3 mol.% - -21 mol.%, -3 mol.% - -19 mol.%, -3 mol.% - -17 mol.%, -3 mol.% - -15 mol.%, -3 mol.% - -13 mol.%, or, e.g., -3 mol.% - -39 mol.%.

[0353] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is -4 mol.% - -40 mol.%, -6 mol.% - -40 mol.%, -8 mol.% - -40 mol.%, -10 mol.% - -40 mol.%, -12 mol.% - -40 mol.%, -14 mol.% - -40 mol.%, -16 mol.% - -40 mol.%, -18 mol.% - -40 mol.%, -20 mol.% - -40 mol.%, -22 mol.% - -40 mol.%, -24 mol.% - -40 mol.%, -26 mol.% - -40 mol.%, -28 mol.% - -40 mol.%, -30 mol.% - -40 mol.%, -32 mol.% - -40 mol.%, or, e.g., -34 mol.% - -40 mol.%.

[0354] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is -4 mol.% - -38 mol.%, -6 mol.% - -36 mol.%, -8 mol.% - -34 mol.%, -10 mol.% - -32 mol.%, -12 mol.% - -30 mol.%, -14 mol.% - -28 mol.%, -16 mol.% - -26 mol.%, -18 mol.% - -24 mol.%, or -18 mol.% - -22 mol.%.

[0355] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / arestably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is less than about 4 mol.%, such as, e.g., <~3.5 mol.%, <~3 mol.%, <~2.5 mol.%, <~2 mol.%, <~1.5 mol.%, <~1 mol.%, or, e.g., <~0.5 mol.%.

[0356] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation of, e.g., between about 0.5 mol.% and about 3 mol.%, such as, e.g., ~0.5 mol.% - -2.5 mol.%, -0.5 mol.% - -2 mol.%, -0.5 mol.% - -1.5 mol.%, or -0.5 mol.% - -1 mol.%, such as, e.g., -1 mol.% - -3 mol.%, -1.5 mol.% - -3 mol.%, -2 mol.% - -3 mol.%, or -2.5 mol.% - -3 mol.%, as in, e.g., -1 mol.% - -2.5 mol.% or -1 mol.% - -2 mol.%.

[0357] In aspects, ranges of the above paragraph are limited to an amount less than -3 mol.% (e.g., 0.3, 0.5, 0.75, or 1 mol.% to 2, 2.25, 2.5, 2.75 or 3 mol.%).

[0358] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is greater than -40 mol.%, such as, e.g., >~40.5 mol.%, >~41 mol.%, >~41.5 mol.%, >~42 mol.%, >~43 mol.%, >~43.5 mol.%, >~44 mol.%, >~44.5 mol.%, >~45 mol.%, >~45.5 mol.%, >~46 mol.%, >~46.5 mol.%, >~47 mol.%, >~47.5 mol.%, >~48 mol.%, >~48.5 mol.%, >~49 mol.%, >~49.5 mol.%, or >~50 mol.%.

[0359] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is between about 40 mol.% and about 100 mol.%, such as, e.g., -42 mol.% - -100 mol.%, -44 mol.% - -100 mol.%, -46 mol.% - -100 mol.%, -48 mol.% - -100 mol.%, -50 mol.% - -100 mol.%, -52 mol.% - -100 mol.%, -54 mol.% - -100 mol.%, -56 mol.% - -100 mol.%, -58 mol.% - -100 mol.%, -60 mol.% - -100 mol.%, -62 mol.% - -100 mol.%, -64 mol.% - -100 mol.%, -66 mol.% - -100 mol.%, -68 mol.% - -100 mol.%, -70 mol.% - -100 mol.%, -72 mol.% - -100 mol.%, -74 mol.% - -100 mol.%, -76 mol.% - -100 mol.%, -78 mol.% - -100 mol.%, -80 mol.% - -100 mol.%, -82 mol.% - -100mol.%, ~84 mol.% - -100 mol.%, -86 mol.% - -100 mol.%, -88 mol.% - -100 mol.%, or -90 mol.% - -100 mol.%.

[0360] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is between about 40 mol.% and about 98 mol.%, such as, e.g., -40 mol.% - -96 mol.%, -40 mol.% - -94 mol.%, -40 mol.% - -92 mol.%, -40 mol.% - -90 mol.%, -40 mol.% - -88 mol.%, -40 mol.% - -86 mol.%, -40 mol.% - -84 mol.%, -40 mol.% - -82 mol.%, -40 mol.% - -80 mol.%, -40 mol.% - -78 mol.%, -40 mol.% - -76 mol.%, -40 mol.% - -74 mol.%, -40 mol.% - -72 mol.%, -40 mol.% - -70 mol.%, -40 mol.% - -68 mol.%, -40 mol.% - -66 mol.%, -40 mol.% - -64 mol.%, -40 mol.% - -62 mol.%, -40 mol.% - -60 mol.%, -40 mol.% - -58 mol.%, -40 mol.% - -56 mol.%, -40 mol.% - -54 mol.%, -40 mol.% - -52 mol.%, -40 mol.% - -50 mol.%, -40 mol.% - -48 mol.%, -40 mol.% - -46 mol.%, or, e.g., -40 mol.% - -44 mol.% or -40 mol.% - -42 mol.%.

[0361] In aspects, chromophoric composition(s) provided herein comprise a chromophoric component comprising one or more chromophoric agent(s) and a structural component comprising one or more structural agent(s), wherein the chromophoric agent(s) is / are stably associated with the structural agent(s), e.g., by chemical conjugation (e.g., by covalent bond(s)), wherein the degree of conjugation is between about 42 mol.% and about 98 mol.%, such as, e.g., -44 mol.% - -96 mol.%, -46 mol.% - -94 mol.%, -48 mol.% - -92 mol.%, -50 mol.% - -90 mol.%, -52 mol.% - -88 mol.%, -54 mol.% - -86 mol.%, -56 mol.% - -84 mol.%, -58 mol.% - -82 mol.%, -60 mol.% - -80 mol.%, -62 mol.% - -84 mol.%, -64 mol.% - -82 mol.%, -66 mol.% - -80 mol.%, -68 mol.% - -78 mol.%, -70 mol.% - -76 mol.%, or, e.g., -70 mol.% - -74 mol.%.

[0362] In aspects, ranges of the above paragraph(s) are limited to an amount greater than 40 mol.% (e.g., 40-100 mol.%, 40-95 mol.%, 40-90 mol.%, 45-90 mol.%, 50-95 mol.%, etc.).

[0363] In aspects, the disclosure provides method(s) described herein, wherein the dermal / subdermal chromophoric component(s) of chromophoric composition(s) used in the method(s) is / are associated with an effective amount of a dermatologically acceptable controlled release component such that the chromophoric effect, e.g., skin color-changing (chromophoric aesthetic) effect of the chromophoric agent(s) of the chromophoric component(s), e.g., vitamin(s), is maintained for a period that is statistically significantly longer than that of anequivalent amount of chromophoric agent(s), e.g., vitamin(s), administered without a / the controlled release component. In aspects, the disclosure provides method(s) provided herein, wherein the dermal / subdermal chromophoric component(s) of chromophoric composition(s) used in the method(s) is / are associated with an effective amount of a dermatologically acceptable controlled release component such that the chromophoric effect, e.g., skin color-changing effect of the chromophoric agent(s), e.g., vitamin(s), is maintained for a period of at least about 1 month, e.g., at least about 2 months, such as at least about 3 months, >~4 months, >~5 months, >~6 months, >~7 months, >~8 months, >~9 months, >~10 months, >~1 1 months, or >~12 months. In aspects, such effect(s) are maintained for a period of >~12 months, such as, e.g., >~13 months, >~14 months, >~15 months, >~16 months, >~17 months, >~18 months, >~19 months, >~20 months, >~21 months, >~22 months, >~23 months, >~24 months, >~26 months, >~28 months, >~30 months, >~32 months, or, e.g., >~34 months. In aspects, some, most, substantially all, or all of the dermal / subdermal chromophoric component of chromophoric composition(s) provided herein is associated with a controlled release component that can be characterized as a sustained release component, a delayed release component, or a conditional release component.

[0364] In this and any other aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant increase in affinity between the one or more structural agent(s) and the one or more dermal / subdermal chromophoric agent(s) or creation of a stable association between the one or more structural agent(s) and the one or more dermal / subdermal chromophoric agent(s) of composition(s) of the invention. In such a respect, any known equivalents of such named agents can also be, e.g., are, incorporated into compositions or methods of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the abovedescribed agent(s) allowing for increased affinity / stable association, conjugation, or creation of a host-guest complex can be described as increased affinity / stable association means, conjugation means, or host-guest complexing means or means for providing effective, detectable, or significant increased affinity / stable association activity / characteristics, e.g., imparting / providing an effective, detectable, or significant increase in affinity between the one or more structural agent(s) and the one or more dermal / subdermal chromophoric agent(s) or creation of a stable association between the one or more structural agent(s) and the one or more dermal / subdermal chromophoric agent(s) of composition(s) of the invention, conjugation, or creation of a hostguest complexing.Other Constituents / Other Constituents Means

[0365] In aspects, the dermatologically suitable chromophoric composition comprises one or more additional agent(s) including, but not limited to, anesthetic agents, buffers, tonicity adjusters, preservatives, or carriers.

[0366] According to aspects, chromophoric composition(s) provided herein comprise one or more excipient components, e.g., one or more non-chromophoric, non-structural component(s). In aspects, such component(s) can comprise, e.g., among others, an anesthetic component, a buffer component, a tonicity component, and (or), e.g., a preservative component.Anesthetic / Anesthetic Means

[0367] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition(s) herein can comprise one or more anesthetic component(s). In aspects, the one or more anesthetic component(s) can comprise means for a pain-relieving effect. In aspects, the one or more anesthetic component(s) can comprise compounds including, but not limited to, aptocaine, diphenhydramine, epinephrine, lidocaine, benzocaine, dibucaine, proparacaine, oxybuprocaine, prilocaine, tetracaine butamben, or any combination thereof. In aspects, the one or more anesthetic component(s) in the dermatologically suitable dermal / subdermal chromophoric filler composition comprise mostly, generally, substantially, or are entirely composed of lidocaine.

[0368] hi aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises an aesthetically effective amount of the one or more anesthetic component(s) to reduce the pain associated with injection of the dermatologically suitable dermal / subdermal chromophoric composition as appreciated by a statistically significant number of recipients, e.g., human patients receiving such injections. In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises an effective amount of one or more anesthetic component(s) in an amount of at least about 0.05% - about 0.9 % such as for example -0.05 wt.% - -0.8 wt.%, -0.05 wt.% - -0.7 wt.%, -0.05 wt.% - -0.6 wt.%, -0.05 wt.% - -0.5 wt.%, -0.05 wt.% - -0.4 wt.% or, e.g., -0.05 wt.% - -0.3 wt.% of composition such as, for example, -0.06 wt.% - -0.9 wt.%, -0.07 wt.% - -0.9 wt.%, -0.08 wt.% - -0.9 wt.%, -0.09 wt.% - -0.9 wt.%, -0.1 wt.% - -0.9 wt.%, -0.2 wt.% - -0.9 wt.% or, e.g., -0.3 wt.% - -0.9 wt.% such as, e.g., -0.06 wt.% - -0. 7 wt.%, -0.08 wt.% - -0.6 wt.%, -0.09 wt.% - -0.5 wt.%, -0.1 wt.% - -0.4 wt.%, or e.g., -0.3 wt.%.

[0369] According to certain aspects, composition(s) herein do not comprise any detectable or significant anesthetic agent(s), e.g., any compound(s) demonstrating detectable or significant anesthetic effect(s).

[0370] In this and any other ingredient aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant anesthetic effect to one or more constituents of composition(s) of the invention. In such a respect, any known equivalents of such named agent(s) can also be, e.g., are, incorporated into composition(s) or method(s) of the invention. As with other sections similarly described herein, any of the components of the invention can be, where suitable, described as means (e.g., the above-described anesthetic agent(s) / compound(s) or component(s) can be described as anesthetic means or means for providing effective, detectable, or significant anesthetic activity / characteristic(s) to one or more constituents of the composition).Buffers / Buffer Means

[0371] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition is intended for administration, e.g., injection, into the human body. In aspects, the dermatologically suitable dermal / subdermal chromophoric composition comprises a buffer solution to optimize the pH of the formulation making it suitable for administration into the human body. In aspects, one or more buffer solutions is / are used in the formulation of the composition which can include, but may not be limited to, acetate buffers, phosphate buffers, borate buffers, citrate buffers, in suitable amount(s) to adjust, maintain, or adjust and maintain the pH of the formulation. In aspects, the pH of the formulation is typically in the range of about 6 to about 8.5, e.g., ~6 - ~8, ~6 - ~7.5, ~6 - ~7, or ~6 - ~6.5, as in, e.g., ~6.5 - ~8.5, ~7 - —8.5, ~7.5 - ~8.5 or, e.g., ~7 - ~7.5, as in, e.g., ~6.5 - ~8, ~7 - ~7.5. In aspects, the pH of the formulation is typically maintained at >~6 but <~ 8.5 , as in, e.g., < 6.0, < 6.5, < 7.0, < 7.5, < 8, < 8.5, or, e.g., about 7 - about 7.5.

[0372] In this and any other ingredient aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant buffer effect to one or more constituents of composition(s) of the invention. In such a respect, any known equivalent(s) of such named agent(s) can also be, e.g., are, incorporated into composition(s) or method(s) of the invention. As with other sections similarly described herein, any of the component(s) of the invention can be, where suitable, described as means (e.g., the above-described buffer agent(s) / compound(s) or component(s) canbe described as buffer means or means for providing effective, detectable, or significant buffer activity / characteristic(s) to the composition(s).Tonicity Adjusters / Tonicity Adjustment Means

[0373] In aspects, the dermatologically suitable chromophoric composition comprises one or more tonicity adjuster(s). In aspects, the one or more tonicity adjuster(s) comprise compound(s) contributing to the isotonicity of the composition(s) to reduce the pain, irritation, or both of injection as appreciated by a statistically significant number of recipients, e.g., human patients. In aspects, suitable agent(s) that can be used to adjust tonicity can include, but are not limited to, salts, e.g., sodium chloride, glycerin, sodium acetate, potassium chloride, mannitol, glycerin, other pharmaceutically acceptable tonicity adjusting agent(s) known in the art, or combination(s) thereof.

[0374] In this and any other ingredient aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant tonicity effect to one or more constituents of composition(s) of the invention. In such a respect, any known equivalent(s) of such named agent(s) can also be, e.g., are, incorporated into composition(s) or method(s) of the invention. As with other sections similarly described herein, any of the component(s) of the invention can be, where suitable, described as means (e.g., the above-described tonicity agent(s) / compound(s) or component(s) can be described as tonicity means or means for providing effective, detectable, or significant tonicity activity / characteristic(s) to one or more constituent(s) of the composition).Preservatives / Preservative Means

[0375] In aspects, the dermatologically suitable chromophoric composition can comprise one or more pharmaceutically acceptable preservative(s). In aspects, the one or more pharmaceutically acceptable preservative(s) can comprise compound(s) which detectably or significantly enhances stability of composition(s), e.g., increases the stability of one or more dermal / subdermal component(s), e.g., vitamins, one or more structural component(s), e.g., crosslinked hyaluronic acid, or both. In aspects, the one or more pharmaceutically acceptable preservative(s) can comprise a compound which: (1) detectably or significantly reduces the number(s) and / or amount(s) of detectable or significant impurity(ies) over the course of a storage under room temperature or accelerated storage condition(s); (2) detectably or significantly reduces antimicrobial activity (e.g., within the chromophoric composition(s)); or (3) both. In aspects, one or more pharmaceutically acceptable preservative(s) can be present in composition(s) of the invention, wherein the one or more pharmaceutically acceptablepreservatives detectably or significantly enhance stability of composition(s) disclosed herein. In aspects, the one or more pharmaceutically acceptable preservative(s) can include, but are not limited to, benzalkonium chloride, chlorobactene, thimerosal, phenyl mercuric acetate, or any other pharmaceutically acceptable preservative, or any combination thereof.

[0376] In this and any other ingredient aspect of the invention, the invention also can be characterized as comprising a "means" for providing a recited function, here imparting / providing an effective, detectable, or significant preservative effect to one or more constituents of composition(s) of the invention. In such a respect, any known equivalents of such named agent(s) can also be, e.g., are, incorporated into composition(s) or method(s) of the invention. As with other sections similarly described herein, any of the component(s) of the invention can be, where suitable, described as means (e.g., the above-described preservative agent(s) / compound(s) or component(s) can be described as preservative means or means for providing effective, detectable, or significant preservative activity / characteristic(s) to one or more constituent(s) of the composition(s)).Compositions Ma Not Comprise

[0377] According to certain aspects, one, some, most, generally all, substantially all, essentially all, or all constituent(s) of composition(s) disclosed herein may also alternatively be absent or excluded from the composition(s) disclosed herein, or, e.g., excluded from being present in substantial amount(s). In aspects, chromophoric composition(s) provided by this disclosure are characterizable by one or more constituent(s) which are not present in detectable or significant amounts or, e.g., in substantial amount(s), in composition(s) herein.

[0378] In aspects, composition(s) herein do not comprise a detectable or significant amount of lidocaine. In aspects, composition(s) herein do not comprise a detectable or significant amount of any anesthetic compound(s). In aspects, composition(s) herein do not comprise a detectable or significant amount of any pain-relieving compound(s).

[0379] In aspects, composition(s) herein do not comprise a substantial amount of noncrosslinked structural agent(s). In aspects, composition(s) herein do not comprise a substantial amount of chromophoric agent(s) unbound / non-conjugated to structural agent(s). In aspects, composition(s) herein do not comprise a substantial amount of structural agent(s) unbound / non- conjugated to chromophoric agent(s).

[0380] In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more salts of amino acid(s). In aspects, composition(s) herein do not comprisea detectable or significant amount of one or more antioxidant compound(s) (compound(s) demonstrating a detectable or significant amount of antioxidant activity).

[0381] In aspects, composition(s) herein do not comprise a detectable or significant amount of poly-L-lactic acid.

[0382] In aspects, composition(s) herein are not at least essentially transparent.

[0383] In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more of a crosslinking constituent. In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more of 1 , 4-butanediol diglycidyl ether (BDDE), divinyl sulphone, 2, poly ethylene glycol (PEG) 7, 8-diepoxyoctane (DEO), 1,2- bis(2,3-epoxypropoxy)ethylene, l-(2,3-epoxypropyl)-2, 3-epoxycyclohexane, or a combination of any or all thereof.

[0384] In aspects, composition(s) herein do not comprise a detectable or significant amount of agent(s) characterizable as permanent skin dying compound(s). In aspects, composition(s) herein do not comprise a detectable or significant amount of any component that results in tissue staining, e.g., compound(s) used in medical tattooing.

[0385] In aspects, composition(s) herein do not comprise a detectable or significant amount of a dermal / subdermal chromophoric component comprising one or more synthetic coloring agent(s). In aspects, composition(s) herein do not comprise a detectable or significant amount of a dermal / subdermal chromophoric component comprising one or more synthetic organic coloring agent(s).

[0386] In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more synthetic organic coloring agent(s), such as, e.g., a yellow colorant, such as, e.g., not comprising one or more of Pigment Yellow 3 (CAS No. 6486-23-3), Pigment Yellow 17 (CAS No. 4531-49-1), Pigment Yellow 34 (CAS No. 1344-37-2), Pigment Yellow 42 (CAS No. 51274-00-1), Pigment Yellow 65 (CAS No. 6528-34-3), Pigment Yellow 74 (CAS No. 6358-31-2), Pigment Yellow 75 (CAS No. 52320-66-8), Pigment Yellow 81 (CAS No. 22094-93-5), Pigment Yellow 83 (CAS No. 5567-15-7), Pigment Yellow 174 (CAS No. 78952- 72-4), Pigment Yellow 180 (CAS No. 77804-81-0), Pigment Yellow 183 (CAS No. 65212-77- 3), and Pigment Yellow 191 (CAS No. 129423-54-7). In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more yellow colorants such as, e.g., cadmium yellow, ochres, curcuma yellow, chrome yellow, and diazodiarylide.

[0387] In aspects, composition(s) herein do not comprise a detectable or significant amount of one or more of lead carbonate, titanium dioxide, barium sulfate, zinc oxide, calciumcarbonate, calcium oxide, calcium adipate, calcium adipate monohydrate, calcium gluconate, calcium citrate, calcium lactate, and calcium phosphate.

[0388] In aspects, composition(s) do not comprise ascorbic acid or derivative thereof. In aspects, composition(s) do not comprise a chromophoric agent having a spectral wavelength of less than about 400 nm, such as, e.g., less than about 375 nm, less than about 350 nm, less than about 325 nm, less than about 300 nm, or, e.g., less than about 275 nm.EFFICACY COMPARISON ASPECTS

[0389] In aspects, efficacy of composition(s), stability of composition(s), or other characteristic(s) of compositions described herein can also or alternatively be described / characterized in terms of performance characteristic(s) made / provided in relation to one or more reference product(s) (e.g., one of the compositions described in the Background section of this disclosure, a composition comprising skin color changing agents not in stable association with structural agents (such as those also described in the Background section of this disclosure), or both). In aspects, a reference product as used herein, (e.g., as it relates to efficacy, stability, etc.) can be a composition comprising at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same pharmaceutically suitable ingredient(s) delivered by injection. In aspects, a reference product can be a composition comprising at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same pharmaceutically suitable ingredient(s) delivered by injection, present in at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same amount(s). In aspects, a reference product can be a composition sharing one or more excipient(s). In aspects, a reference product can be a composition sharing one or more excipient(s) in the same amount(s). In aspects, a reference product can be a composition comprising (a) at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same pharmaceutically suitable ingredient(s), (b) at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same pharmaceutically suitable ingredient(s) present in at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same amount(s); (c) one or more of the same excipient(s); (d) one or more of the same excipient(s) in at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same amount(s); or (e) anycombination thereof, administered by injection, but comprising at least one injectable component constituent which varies from that of the present composition(s). In aspects, a reference product can be a product comprising at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same pharmaceutically suitable ingredient(s) in at least mostly the same, at least generally the same, at least essentially the same, essentially the same, at least substantially the same, or the same amount(s), delivered by the same method of administration, e.g., injection, utilizing the same type of delivery device, e.g., a needle / cannula syringe system, but wherein the reference product is provided in a different compositional form, such as, e.g., the reference product is provided as a suspension when the present composition(s) is / are provided as a solution.

[0390] In aspects, a reference product can be a product demonstrating bioequivalence to a reference product as described here (such as, e.g., a reference product recognized by an accepted regulatory authority, such as, e.g., the United States Food and Drug Administration (U.S. FDA), wherein such bioequivalence is determined by an appropriately conducted clinical study recognized by an accepted regulatory authority such as, e.g., the U.S. FDA.

[0391]

[0392] In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in coloring associated with dermatological changes associated with aging, such as, e.g., loss of tone in the lips, loss of tone in a scar, or both as reported by patient(s), physician(s), as determined by any one or more assessments or measures of skin tone or coloring known in the art, or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in coloring associated with dermatological changes associated with aging compared to a reference product, as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA.

[0393] In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in skin coloring of the lips or areas of skin surrounding the eye / orbit as reported by patient(s), physician(s), or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in skin coloring of the lips or areas of skin surrounding the eye / orbit as comparedto a reference product, as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA.

[0394] In aspects, administration of an aesthetically effective amount of composition(s) herein comprising one or more dermal / subdermal chromophoric agent(s) provide(s) a detectable or significant improvement in the coloring associated with dermatological changes associated with aging as reported by patient(s), physician(s), as determined by any one or more assessments or measures of the same known in the art, or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount of composition(s) herein comprising one or more dermal / subdermal chromophoric agent(s) provide(s) a detectable or significant improvement in coloring associated with dermatological changes associated with aging compared to a reference composition comprising structural component(s) as reported by patient(s), physician(s), as determined by any one or more assessments or measures of the same known in the art, or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in coloring associated with dermatological changes associated with aging compared to a reference product, as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA.

[0395] In aspects, composition(s) herein demonstrate (a) detectably or significantly improved chromophoric effect stability; (b) detectably or significantly improved chromophoric effect performance; (c) detectably or significantly improved chromophoric effect delivery; (d) detectably or significantly greater formulation (e.g., physical) stability; or (e) any combination of any or all of (a)-(d). In aspects, composition(s) herein demonstrate (a) detectably or significantly improved chromophoric effect stability; (b) detectably or significantly improved chromophoric effect performance; (c) detectably or significantly improved chromophoric effect delivery; (d) detectably or significantly greater formulation (e.g., physical) stability; or (e) any combination of (a) -(d) compared to a reference product as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA.

[0396] In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant reduction in dermatological changes associated with aging, e.g., nasolabial folds, “crow’s feet,” loss of facial volume, fine lines, wrinkles as, e.g., reported by patient(s), physician(s), or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount ofcomposition(s) herein provide(s) a detectable or significant reduction in frequency, severity, or frequency and severity of dermatological changes associated with aging, e.g. reduction of fine lines and wrinkles compared to a reference product, as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA. In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in the appearance of dermatological changes associated with aging, such as, e.g., reduction of wrinkles or fine lines as reported by patient(s), physician(s), as determined by any one or more assessments or measures of dermatological changes known in the art, or, e.g., as determined by an appropriately conducted and powered clinical study. In aspects, administration of an aesthetically effective amount of composition(s) herein provide(s) a detectable or significant improvement in dermatological changes associated with aging compared to a reference product, as determined by an appropriately conducted clinical study or as recognized by an authoritative regulatory body such as, e.g., the U.S. FDA.

[0397] In aspects, the dermatologically suitable dermal / subdermal chromophoric composition can have a structural effect similar to or detectably or significantly superior to the effect that is obtained using one or more reference product(s), e.g., JUVEDERM® or RESTYLANE®, while further providing a detectable or significant chromophoric aesthetic effect. In aspects, the reference product can comprise IUVEDERM®, e.g., the product approved under FDA PMA Number Pl 10033 / P050047. In aspects, the reference product can comprise RESTYLANE®, e.g., the product approved under FDA PMA Number P140029.STABILITY CHARACTERISTICS

[0398] In aspects, the stability of composition(s) provided for in the present invention are characterized by assessing the chemical and physical stability properties of the composition, e.g., homogeneity, color, clarity, pH, or any combination thereof, when stored at about room temperature, e.g., between about 20°C and about 25°C, for a commercially reasonable, e.g., commercially relevant, period of time, such as, e.g., at least about 1 month, such as at least about 2 months, or at least about 3 months or more, e.g. typically for at least about 4, ~5, -6, -7, ~8, -9, -10, -11, —12, —18, -24, -30, or, e.g., -36 months.. In aspects, composition(s) disclosed herein remain stable with regard to homogeneity, color, clarity or opacity, pH, or combination(s) thereof when stored at about room temperature, e.g., between about 20°C and about 25°C, for a commercially reasonable period of time, such as, e.g., at least about 1 month, such as at least about 2 months, or at least about 3 months or more, e.g. typically for at least about 4, -5, -6, -7, -8, -9, -10, -1 1, -12, -18, -24, -30, or, e.g., -36 months. In aspects, composition(s) disclosedherein exhibit sufficient physical and chemical integrity to maintain at least -98% of the amount of any dermal / subdermal chromophoric component and any structural component when stored at about room temperature, e.g., between about 20°C and about 25°C, for a commercially reasonable (commercially relevant) period of time, such as, e.g., at least about 1 month, such as at least about 2 months, or at...

Claims

CLAIMSWhat is claimed is:

1. A method of imparting a non-permanent, long-lasting, color change in the skin of a recipient comprising administering to at least a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents that are capable of providing a detectable or significant reddening effect to the skin, wherein the effective amount is an amount sufficient to produce a detectable or significant reddening of skin color upon an effective number of administrations within an effective time period, and (2) a second effective amount of a chromophoric extension component comprising one or more chromophoric extension agents, wherein (a) the one or more dermal / subdermal chromophoric agents and the one or more chromophoric extension agents are in a sufficiently stable association with one another such that the structural agent detectably or significantly extends the reddening effect of the one or more chromophoric agents, wherein the administration of the dermatologically suitable chromophoric composition provides a chromophoric aesthetic effect which lasts at least about 3 months.

2. The method of claim 1 , wherein the dermal / subdermal chromophoric component comprises one or more dermal / subdermal chromophoric agents that exhibits a wavelength of (1) about 570 nm to about 590 nm, (2) about 420 nm to about 430 nm, or (3) both (1) and (2), (4) between about 620 nm to about 750 nm, (5) about 500 nm to about 520 nm, or (6) both (4) and (5); or (7) both (1) and (6), when subjected to spectrophotometric analysis.

3. The method of claim 2, wherein administration of an effective amount of the composition an effective number of times under effective conditions results in the skin of the recipient having skin exhibiting a reflection of light having a wavelength that is detectably or significantly closer to one or more wavelengths of (i) about 570 nm to about 590 nm, (ii) about 595 nm to about 620 nm, or (iii) both (i) and (ii) when subjected to light reflection wavelength analysis than the color of the skin of the recipient prior to the treatment.

4. The method of claim 3, wherein the chromophoric aesthetic effect comprises a reddening color change to the skin that is measurable under the Munsell System as a Munsell System hue of between about 2.5R and about 10R.

5. The method of claim 3, wherein administration of an effective amount of the composition an effective number of times under effective conditions results in the skin of the recipient having skin exhibiting a reflection of light having a wavelength that is delectably or significantly closer to one or more wavelengths of (i) about 620 nm and about 750 nm, (ii) about 755 nm and about 780 nm, or (iii) both (i) and (ii) when subjected to light reflection wavelength analysis than the color of the skin of the recipient prior to the treatment.

6. The method of claim 3, wherein the stable association between the one or more dermal / subdermal chromophoric agents and the one or more chromophoric extension agents comprises a covalent bond between at least one of the one or more chromophoric agents and at least one of the one or more chromophoric extension agents.

7. The method of claim 3, wherein the one or more dermal / subdermal chromophoric agents comprise riboflavin, pyridoxine, or cyanocobalamin; one or more dermatologically suitable derivatives of riboflavin, pyridoxine, cyanocobalamin; or a combination thereof.

8. The method of claim 7, wherein the stable association between one or more dermal / subdermal chromophoric agents and tone or more chromophoric extension agents comprises a covalent bond.

9. The method of claim 1 , wherein the one or more chromophoric extension agents further provides a detectable or significant structural skin aesthetic effect.

10. The method of claim 8, wherein the one or more chromophoric extension agents further provides a detectable or significant structural skin aesthetic effect.

11. The method of claim 10, wherein the one or more chromophoric extension agents comprises crosslinked hyaluronic acid.

12. A non-permanent, long-lasting chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents capable of imparting a detectable or significant chromophoric effect to the skin to which the composition is administered, wherein the effective amount is an amount sufficient to produce a detectable chromophoric effect upon an effective number of administrations within an effective time period, and (2) a second effective amount of a chromophoric extension component comprising one or more chromophoric extension agents, wherein (a) the one or more dermal / subdermal chromophoric agents and the one or more chromophoric extension agents of the chromophoric composition are in a sufficiently stable association with one another such that the chromophoric extension agents detectably or significantly extend the chromophoric aesthetic effect of the one or more chromophoric agents compared to such agents provided an unassociated with one or more chromophoric extension agents, and (b) wherein an effective amount of the dermatologically suitable chromophoric composition exhibits a wavelength of between about 570 nm to about 590 nm; about 620 nm to about 750 nm; about 620 nm to about 750 nm; or any combination thereof when subjected to a spectrophotometric analysis.

13. The composition of claim 12, wherein an effective amount of the composition administered to skin establishes a skin color of the skin to which it is administered a Munsell System hue of between about 2.5R and about 10R.

14. The composition of claim 12, wherein an effective amount of the composition imparts a detectable or significant change in the color of the skin of the recipient to which the composition is administered such that the wavelength of light reflected from the skin imparted by the composition is detectably or significantly closer to one or more of the wavelengths (i) about 570 nm to about 590 nm, (ii) about 595 nm to about 620 nm, (iii) about 620 nm to about 750 nm; (iv) about 755 nm and about 780 nm, or (v) any combination thereof when subjected ot light reflection wavelength analysis than the color of the skin of the recipient prior to the presence of the composition, and further wherein the composition imparts the chromophoric effect for at least about 3 months after administration.

15. The composition of claim 12, wherein the stable association between one or more dermal / subdermal chromophoric agents and one or more chromophoric extension agents is a covalent bond or an ionic bond.

16. The composition of claim 15, wherein the one or more chromophoric extension agents comprises one or more structural agents and administration of an effective amount of the composition an effective amount of times under effective conditions further provides a detectable or significant structural skin aesthetic effect.

17. The composition of claim 16, wherein the one or more chromophoric extension agents is crosslinked hyaluronic acid.

18. The composition of any one or more of claims 12-17, wherein the one or more dermal / subdermal chromophoric agents comprise riboflavin, pyridoxine, or cyanocobalamin; one or more dermatologically suitable derivatives of riboflavin, pyridoxine, cyanocobalamin; or a combination thereof.

19. A method of producing a non-permanent, long-lasting chromophoric aesthetic effect in the skin of a recipient comprising administering to at least a first target area of the skin of the recipient an aesthetically effective amount of a dermatologically suitable chromophoric composition comprising (1) a first effective amount of a dermal / subdermal chromophoric component that comprises one or more dermal / subdermal chromophoric agents and (2) a second effective amount of a chromophoric extension component comprising one or more chromophoric extension agents, wherein the one or more dermal / subdermal chromophoric agents and the one or more chromophoric extension agents are in a sufficiently stable association with one another, and further wherein (a) the one or more dermal / subdermal chromophoric agents of the dermal / subdermal chromophoric component are individually or in combination present in an amount sufficient to produce a detectable change in skin color, and (b) the period of time after administration of the chromophoric composition wherein there is a detectable effect of the one or more dermal / subdermal chromophoric agents of the dermal / subdermal chromophoric component establishes a chromophoric aesthetic effect period which lasts at least about 3 months.

20. The method of claim 19, wherein the one or more dermal / subdermal chromophoric agents are agents exhibit a wavelength of (1) about 570 nm to about 590 nm, (2) about 420 nm to about 430 nm, or (3) both (1) and (2), between about (4) about 620 nm to about 750 nm, (5) about 500 nm to about 520 nm, or (6) both (4) and (5); or (7) both (1) and (6), when subjected to spectrophotometric analysis.

21. The method of claim 20, wherein the one or more chromophoric extension agents further provides a detectable or significant structural skin aesthetic effect.

22. The method of claim 21, wherein the stable association between one or more dermal / subdermal chromophoric agents and one or more chromophoric extension agents comprises a covalent bond, an ionic bond, or both.

23. The method of claim 19, wherein the number of moles of the one or more dermal / subdermal chromophoric agents to the number of moles of the one or more chromophoric extension agents is between about 37:1 and about 461 : 1.

24. The method of claim 19, wherein the ratio of the weight percent of the one or more derma; / subdermal chromophoric agents to the weight percent of one or more chromophoric extension agents is between about 1 :5 and about 60: 1 .

Images